Clinical Microbiology Reviews A Publication of the American Society for Microbiology
VOLUME 24
●
OCTOBER 2011
●
NUMBER 4
CONTENTS/SUMMARIES
Sporothrix schenckii and Sporotrichosis. Mo ˆnica Bastos de Lima Barros, Rodrigo de Almeida Paes, and Armando Oliveira Schubach . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
633–654
Summary: Sporotrichosis, which is caused by the dimorphic fungus Sporothrix schenckii, is currently distributed throughout the world, especially in tropical and subtropical zones. Infection generally occurs by traumatic inoculation of soil, plants, and organic matter contaminated with the fungus. Certain leisure and occupational activities, such as floriculture, agriculture, mining, and wood exploitation, are traditionally associated with the mycosis. Zoonotic transmission has been described in isolated cases or in small outbreaks. Since the end of the 1990s there has been an epidemic of sporotrichosis associated with transmission by cats in Rio de Janeiro, Brazil. More than 2,000 human cases and 3,000 animal cases have been reported. In humans, the lesions are usually restricted to the skin, subcutaneous cellular tissue, and adjacent lymphatic vessels. In cats, the disease can evolve with severe clinical manifestations and frequent systemic involvement. The gold standard for sporotrichosis diagnosis is culture. However, serological, histopathological, and molecular approaches have been recently adopted as auxiliary tools for the diagnosis of this mycotic infection. The first-choice treatment for both humans and cats is itraconazole.
Trypanosoma cruzi and Chagas’ Disease in the United States. Caryn Bern, Sonia Kjos, Michael J. Yabsley, and Susan P. Montgomery . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
655–681
Summary: Chagas’ disease is caused by the protozoan parasite Trypanosoma cruzi and causes potentially life-threatening disease of the heart and gastrointestinal tract. The southern half of the United States contains enzootic cycles of T. cruzi, involving 11 recognized triatomine vector species. The greatest vector diversity and density occur in the western United States, where woodrats are the most common reservoir; other rodents, raccoons, skunks, and coyotes are also infected with T. cruzi. In the eastern United States, the prevalence of T. cruzi is highest in raccoons, opossums, armadillos, and skunks. A total of 7 autochthonous vector-borne human infections have been reported in Texas, California, Tennessee, and Louisiana; many others are thought to go unrecognized. Nevertheless, most T. cruzi-infected individuals in the United States Continued on following page
Continued from preceding page
are immigrants from areas of endemicity in Latin America. Seven transfusion-associated and 6 organ donor-derived T. cruzi infections have been documented in the United States and Canada. As improved control of vector- and blood-borne T. cruzi transmission decreases the burden in countries where the disease is historically endemic and imported Chagas’ disease is increasingly recognized outside Latin America, the United States can play an important role in addressing the altered epidemiology of Chagas’ disease in the 21st century.
Current Knowledge of Trichosporon spp. and Trichosporonosis. Arnaldo L. Colombo, Ana Carolina B. Padovan, and Guilherme M. Chaves . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
682–700
Summary: Trichosporon spp. are basidiomycetous yeast-like fungi found widely in nature. Clinical isolates are generally related to superficial infections. However, this fungus has been recognized as an opportunistic agent of invasive infections, mostly in cancer patients and those exposed to invasive medical procedures. It is possible that the ability of Trichosporon strains to form biofilms on implanted devices, the presence of glucuronoxylomannan in their cell walls, and the ability to produce proteases and lipases are all factors likely related to the virulence of this genus and therefore may account for the progress of invasive trichosporonosis. Disseminated trichosporonosis has been increasingly reported worldwide and represents a challenge for both diagnosis and species identification. Phenotypic identification methods are useful for Trichosporon sp. screening, but only molecular methods, such as IGS region sequencing, allow the complete identification of Trichosporon isolates at the species level. Methods for the diagnosis of invasive trichosporonosis include PCR-based methods, Luminex xMAP technology, and, more recently, proteomics. Treating patients with trichosporonosis remains a challenge because of limited data on the in vitro and in vivo activities of antifungal drugs against clinically relevant species of the genus. Despite the mentioned limitations, the use of antifungal regimens containing triazoles appears to be the best therapeutic approach.
Clinical Manifestations, Diagnosis, and Treatment of Mycobacterium haemophilum Infections. Jerome A. Lindeboom, Lesla E. S. Bruijnesteijn van Coppenraet, Dick van Soolingen, Jan M. Prins, and Eduard J. Kuijper . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
701–717
Summary: Mycobacterium haemophilum is a slowly growing acid-fast bacillus (AFB) belonging to the group of nontuberculous mycobacteria (NTM) frequently found in environmental habitats, which can colonize and occasionally infect humans and animals. Several findings suggest that water reservoirs are a likely source of M. haemophilum infections. M. haemophilum causes mainly ulcerating skin infections and arthritis in persons who are severely immunocompromised. Disseminated and pulmonary infections occasionally occur. The second at-risk group is otherwise healthy children, who typically develop cervical and perihilar lymphadenitis. A full diagnostic regimen for the optimal detection of M. haemophilum includes acid-fast staining, culturing at two temperatures with iron-supplemented media, and molecular detection. The most preferable molecular assay is a real-time PCR targeting an M. haemophilum-specific internal transcribed spacer (ITS), but another approach is the application of a generic PCR for a mycobacterium-specific fragment with subsequent sequencing to identify M. haemophilum. No standard treatment guidelines are available, but published literature agrees that immunocompromised patients should be treated with multiple antibiotics, tailored to the disease presentation and underlying degree of immune suppression. The outcome of M. haemophilum cervicofacial lymphadenitis in immunocompetent patients favors surgical intervention rather than antibiotic treatment.
Food Animals and Antimicrobials: Impacts on Human Health. Bonnie M. Marshall and Stuart B. Levy. . . . . . . . . . . . . . . . . . . . . . . . . .
718–733
Summary: Antimicrobials are valuable therapeutics whose efficacy is seriously compromised by the emergence and spread of antimicrobial resistance. The provision of antibiotics to food animals encompasses a wide variety of nontherapeutic purposes that include growth promotion. The concern over resistance emergence and spread to people by nontherapeutic use of antimiContinued on following page
Continued from preceding page
crobials has led to conflicted practices and opinions. Considerable evidence supported the removal of nontherapeutic antimicrobials (NTAs) in Europe, based on the “precautionary principle.” Still, concrete scientific evidence of the favorable versus unfavorable consequences of NTAs is not clear to all stakeholders. Substantial data show elevated antibiotic resistance in bacteria associated with animals fed NTAs and their food products. This resistance spreads to other animals and humans—directly by contact and indirectly via the food chain, water, air, and manured and sludge-fertilized soils. Modern genetic techniques are making advances in deciphering the ecological impact of NTAs, but modeling efforts are thwarted by deficits in key knowledge of microbial and antibiotic loads at each stage of the transmission chain. Still, the substantial and expanding volume of evidence reporting animal-to-human spread of resistant bacteria, including that arising from use of NTAs, supports eliminating NTA use in order to reduce the growing environmental load of resistance genes.
Human Metapneumovirus: Lessons Learned over the First Decade. Verena Schildgen, Bernadette van den Hoogen, Ron Fouchier, Ralph A. Tripp, Rene Alvarez, Catherine Manoha, John Williams, and Oliver Schildgen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
734–754
Summary: It has been 10 years since human metapneumovirus (HMPV) was identified as a causative agent of respiratory illness in humans. Since then, numerous studies have contributed to a substantial body of knowledge on many aspects of HMPV. This review summarizes our current knowledge on HMPV, HMPV disease pathogenesis, and disease intervention strategies and identifies a number of areas with key questions to be addressed in the future.
Serratia Infections: from Military Experiments to Current Practice. Steven D. Mahlen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
755–791
Summary: Serratia species, in particular Serratia marcescens, are significant human pathogens. S. marcescens has a long and interesting taxonomic, medical experimentation, military experimentation, and human clinical infection history. The organisms in this genus, particularly S. marcescens, were long thought to be nonpathogenic. Because S. marcescens was thought to be a nonpathogen and is usually red pigmented, the U.S. military conducted experiments that attempted to ascertain the spread of this organism released over large areas. In the process, members of both the public and the military were exposed to S. marcescens, and this was uncovered by the press in the 1970s, leading to U.S. congressional hearings. S. marcescens was found to be a certain human pathogen by the mid-1960s. S. marcescens and S. liquefaciens have been isolated as causative agents of numerous outbreaks and opportunistic infections, and the association of these organisms with point sources such as medical devices and various solutions given to hospitalized patients is striking. Serratia species appear to be common environmental organisms, and this helps to explain the large number of nosocomial infections due to these bacteria. Since many nosocomial infections are caused by multiply antibioticresistant strains of S. marcescens, this increases the danger to hospitalized patients, and hospital personnel should be vigilant in preventing nosocomial outbreaks due to this organism. S. marcescens, and probably other species in the genus, carries several antibiotic resistance determinants and is also capable of acquiring resistance genes. S. marcescens and S. liquefaciens are usually identified well in the clinical laboratory, but the other species are rare enough that laboratory technologists may not recognize them. 16S rRNA gene sequencing may enable better identification of some of the less common Serratia species.
Immunodiagnosis of Tuberculosis: a Dynamic View of Biomarker Discovery. Shajo Kunnath-Velayudhan and Maria Laura Gennaro . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
792–805
Summary: Infection with Mycobacterium tuberculosis causes a variety of clinical conditions ranging from life-long asymptomatic infection to overt disease with increasingly severe tissue damage and a heavy bacillary burden. Immune biomarkers should follow the evolution of infection and disease because the host immune response is at the core of protection against disease and tissue damage in M. tuberculosis infection. Moreover, levels of immune markers are Continued on following page
Continued from preceding page
often affected by the antigen load. We review how the clinical spectrum of M. tuberculosis infection correlates with the evolution of granulomatous lesions and how granuloma structural changes are reflected in the peripheral circulation. We also discuss how antigen-specific, peripheral immune responses change during infection and how these changes are associated with the physiology of the tubercle bacillus. We propose that a dynamic approach to immune biomarker research should overcome the challenges of identifying those asymptomatic and symptomatic stages of infection that require antituberculosis treatment. Implementation of such a view requires longitudinal studies and a systems immunology approach leading to multianalyte assays.
CLINICAL MICROBIOLOGY REVIEWS, Oct. 2011, p. 633–654 0893-8512/11/$12.00 doi:10.1128/CMR.00007-11 Copyright © 2011, American Society for Microbiology. All Rights Reserved.
Vol. 24, No. 4
Sporothrix schenckii and Sporotrichosis Mo ˆnica Bastos de Lima Barros1* Rodrigo de Almeida Paes,2 and Armando Oliveira Schubach2 National School of Public Health1 and Evandro Chagas Clinical Research Institute,2 Fiocruz, Rio de Janeiro, Brazil INTRODUCTION .......................................................................................................................................................633 HISTORY.....................................................................................................................................................................634 TAXONOMIC STUDIES ...........................................................................................................................................634 SPOROTHRIX CELL BIOLOGY...............................................................................................................................635 Morphology ..............................................................................................................................................................635 Cell Wall ..................................................................................................................................................................636 S. SCHENCKII GENETIC MATERIAL ...................................................................................................................636 S. SCHENCKII PHYSIOLOGY .................................................................................................................................636 S. SCHENCKII ECOLOGY........................................................................................................................................637 PUTATIVE S. SCHENCKII VIRULENCE FACTORS ...........................................................................................637 Thermotolerance .....................................................................................................................................................638 Melanin ....................................................................................................................................................................638 Adhesion...................................................................................................................................................................638 Ergosterol Peroxide ................................................................................................................................................639 Proteins Related to Virulence ...............................................................................................................................639 IMMUNE RESPONSE IN SPOROTRICHOSIS ...................................................................................................639 Innate Response ......................................................................................................................................................639 Cellular Response ...................................................................................................................................................639 Humoral Response..................................................................................................................................................640 SPOROTRICHOSIS DIAGNOSIS ...........................................................................................................................640 Direct Examination.................................................................................................................................................640 Histopathological Examination.............................................................................................................................641 Culture......................................................................................................................................................................641 Molecular Detection ...............................................................................................................................................641 Sporotrichin Skin Test ...........................................................................................................................................642 Antibody Detection..................................................................................................................................................642 EPIDEMIOLOGY .......................................................................................................................................................643 Geographic Distribution ........................................................................................................................................643 Distribution by Age and Gender...........................................................................................................................643 Transmission and Sources of Infection ...............................................................................................................643 Zoonotic Transmission...........................................................................................................................................644 PATHOGENESIS AND CLINICAL FORMS .........................................................................................................645 Human Disease .......................................................................................................................................................645 Cutaneous forms .................................................................................................................................................645 Mucosal form.......................................................................................................................................................646 Extracutaneous form ..........................................................................................................................................646 Associated signs and symptoms........................................................................................................................646 Differential diagnosis..........................................................................................................................................646 Feline Disease..........................................................................................................................................................646 TREATMENT..............................................................................................................................................................647 Antifungal Susceptibility Tests .............................................................................................................................647 PREVENTION.............................................................................................................................................................649 ACKNOWLEDGMENTS ...........................................................................................................................................649 REFERENCES ............................................................................................................................................................649 matter contaminated with the fungus. Certain leisure and occupational activities, such as floriculture, agriculture, mining, and wood exploitation, are traditionally associated with the mycosis. Zoonotic transmission has been described in isolated cases or in small outbreaks. At present, veterinarians, technicians, caretakers, and owners of cats with sporotrichosis are regarded as a new risk category for the acquisition of the disease. The lesions are usually restricted to the skin, subcutaneous cellular tissue, and adjacent lymphatic vessels. Eventually, this fungus can disseminate to other organs, and alternatively, on rare occasions, inhalation of conidia may lead to a
INTRODUCTION Sporotrichosis, caused by the dimorphic fungus Sporothrix schenckii, is currently distributed throughout the world, especially in tropical and subtropical zones. Infection generally occurs by traumatic inoculation of soil, plants, and organic
* Corresponding author. Mailing address: Fundac¸˜ao Oswaldo Cruz/ Fiocruz, Av. Brasil, 4365, Manguinhos, Rio de Janeiro CEP 22045-900, Brazil. Phone: 55 21 2598 2518. Fax: 55 21 3415 2086. E-mail:
[email protected]. 633
634
BARROS ET AL.
CLIN. MICROBIOL. REV.
systemic disease. Several factors, such as inoculum load, immune status of the host, virulence of the inoculated strain, and depth of traumatic inoculation, influence the different clinical forms of sporotrichosis. The gold standard for sporotrichosis detection is culture; however, serological, histopathological, and molecular approaches have been recently adopted as auxiliary tools for the diagnosis of this mycotic infection. HISTORY Sporothrix schenckii was isolated for the first time in 1896 by Benjamin Schenck, a medical student at the Johns Hopkins Hospital in Baltimore, MD, from a 36-year-old male patient presenting lesions on the right hand and arm. This isolate, from the patient abscess, was then studied by the mycologist Erwin Smith, who concluded that the fungus belonged to the genus Sporotrichum (217). Previously, Linck in 1809 and Lutz in 1889 referred to some possible sporotrichosis cases, but the isolation of the fungus by these authors for case definitions was not possible (126). The second undeniable sporotrichosis case was described in 1900 by Hektoen and Perkins, also in the United States (Chicago, IL). This was the case of a boy who suffered an injury with a hammer hitting his finger, with the lesion presenting spontaneous regression. These investigators gave the sporotrichosis agent its current denomination, Sporothrix schenckii (95). Later, this fungus was erroneously included in the genus Sporotrichum, which comprises basidiomycetous fungi which are neither dimorphic nor pathogenic for humans or other animals (216). This erroneous nomenclature remained until 1962, when Carmichael recognized differences in the conidiations of members of the genus Sporotrichum and isolates from sporotrichosis cases (37). In 1903, Sabouraud suggested to Beurmann and Gougerot the use of potassium iodine for the treatment of sporotrichosis, which was a common disease in France during the beginning of the 20th century (126). This has hitherto been a satisfactory therapy for sporotrichosis, although no randomized, doubleblind, placebo-controlled trials have ever been conducted (267). The first reported case of natural animal infection was described in 1907 by Lutz and Splendore in rats from Brazil (141). The possibility of human infection by bites from these rats was considered (186). Also in Brazil, in 1908, Splendore reported the detection of asteroid bodies around Sporothrix yeast cells, which offer a very useful tool for sporotrichosis diagnosis in histological examinations (126, 196). TAXONOMIC STUDIES Sporothrix schenckii belongs to the kingdom Fungi and is a eukaryotic organism that is without mobility and heterotrophic and presents chitin on its cell wall. For several years, this fungus was included in division Eumycota, subdivision Deuteromycotina, class Hyphomycetes, order Moniliales, and family Moniliaceae (128). After a substantial fungal taxonomy revision by Guarro and coworkers, this fungus was characterized in division Ascomycota, class Pyrenomycetes, order Ophiostomatales, and family Ophiostomataceae (84).
The sexual form of S. schenckii is as yet unknown. However, there is substantial molecular evidence that this fungus undergoes recombination in nature (163). Nevertheless, some studies imply that S. schenckii in an ascomycete, since it presents a simple septum, with Woronin bodies (237) and three chitin synthase genes (44). Molecular analyses of the 18S region of the ribosomal DNA indicate that the sexual form of S. schenckii could be Ophiostoma stenoceras (22). On the other hand, morphological and physiological studies exhibit consistent differences between these two species. O. stenoceras is unable to produce dematiaceous conidia, as does S. schenckii. Also, S. schenckii does not produce perithecium on malt, rice, or potato media, as is observed for isolates of O. stenoceras (60, 181). Differences are also apparent when these species are inoculated in mice. S. schenckii can be found in several tissues from all infected mice after intravenous inoculation, and O. stenoceras is detected in certain organs from some infected animals (59). These observations lead to the conclusion that the O. stenoceras anamorph and S. schenckii are different species. Meanwhile, other molecular studies (56, 97), together with work by Berbee and Taylor (22), reinforce that the S. schenckii teleomorph is classified in the genus Ophiostoma. Berbee and Taylor highlight that S. schenckii belongs to the pyrenomycete lineage, lacking forcible ascospore discharge (22). Recently, Marimon and coworkers (150), on the basis of phenotypic and genotypic analyses, suggested that S. schenckii should not be considered the only species that causes sporotrichosis, and based on macroscopic characteristics, sucrose and raffinose assimilation, ability to grow at 37°C, and the nuclear calmodulin gene sequence, they described four new species in the Sporothrix complex: (i) S. globosa, a fungus distributed worldwide (145, 180); (ii) S. brasiliensis, the species related to the zoonotic epidemic of sporotrichosis in Rio de Janeiro, Brazil (150, 179); (iii) S. mexicana, limited to Mexico (150); and (iv) S. luriei, formerly S. schenckii var. luriei (151), differing from S. schenckii mainly in the tissue form by the production of large, often septate budding cells unable to assimilate creatinine or creatine (53). On the other hand, other authors support its separation by rRNA internal transcribed spacer (ITS) sequence data (54). Another species, S. cyanescens has been isolated from blood and skin samples from human patients, but pathogenicity studies conclude that, although this fungus can grow at 37°C, it is avirulent (233). Figure 1 presents a key to differentiate species within the S. schenckii complex (151). Recently, de Meyer and collaborators (56) described three other environmental Sporothrix species, S. stylites, S. humicola, and S. lignivora. The first two species differ from S. schenckii by the inability to produce melanized conidia and the consequent nondarkening of colonies with age. S. lignivora has distinctive conidia that do not match in size and shape those of other Sporothrix or Ophiostoma species. It is interesting to note that isolates classified as S. humicola were previously referred to as environmental isolates of S. schenckii. In their study, the authors concluded that -tubulin sequence analysis is strongly recommended for taxonomic studies of Sporothrix species isolated from the environment.
VOL. 24, 2011
SPOROTHRIX SCHENCKII AND SPOROTRICHOSIS
635
FIG. 1. Identification key for Sporothrix species of clinical interest, based on morphological and phenotypic tests described by Marimon and collaborators (152). PDA, potato dextrose agar; CMA, corn meal agar.
SPOROTHRIX CELL BIOLOGY Morphology Sporothrix schenckii is a dimorphic fungus. In its saprophytic stage or when cultured at 25°C, it assumes a filamentous form, composed of hyaline, septate hyphae 1 to 2 m wide, with conidiogenous cells arising from undifferentiated hyphae forming conidia in groups on small, clustered denticles. These onecelled conidia are tear shaped to clavate (53) and do not yield chains (233). Often, hyaline or brown thick-walled conidia arise beside the hyphae. The dark cell walls of the conidia distinguish S. schenckii from other, nonpathogenic Sporothrix species (56, 242). Macroscopically, filamentous colonies in media such as malt extract agar or potato dextrose agar (Fig. 2) are often smooth and wrinkled, white to creamy at first and then turning brown to black after a few days (126, 170, 196). Some strains, however, have the ability to form dark colonies from the beginning of growth (5). The S. schenckii colonies never become cottony or floccose (126). This fungus is evident in both human and animal tissues as budding yeasts. Yeastlike cells can be observed in various sizes and shapes. They may be round to oval, with 2- to 6-m diameters, and usually have elongated, cigar-shaped buds on a narrow base. Macroscopically, yeast colonies (Fig. 2) are smooth, tan, or cream colored (130). Some molecular aspects implicated in proliferation and maintenance of this morphological form of S. schenckii involve calcium/calmodulin-dependent protein kinases (260) and a signaling pathway involving the interaction between a cytosolic phospholipase and protein G. Studies have proven that this pathway is necessary for the reentry of S. schenckii yeast cells into the budding cycle, suggesting its function in the control of dimorphism in this fungus and for the maintenance of the yeast form (259). The transition from mold to yeast form in S. schenckii can be attained by culturing mycelia or conidia on rich culture media such as brain heart infusion agar at 35 to 37°C (170). Some strains, especially those related to the S. globosa species, may
require lower conversion temperatures, since they do not grow well at 37°C (150). Although rich media are required for the mycelium-to-yeast transition, S. schenckii yeast cells can be maintained at 37°C in other media, such as Sabouraud dextrose agar. This transition process also occurs after patients are infected with filamentous S. schenckii. Morphological transformation at the ultrastructural level occurs by direct formation of budlike structures at the tips and along the hyphae together with oidial cell formation after septation of the hyphae, without conspicuous alterations of the cytoplasmic content of parent mycelial cell. There is no direct budding of yeast from conidiospores (77).
FIG. 2. Cultures of pus from lesions of S. schenckii-infected patients. Most strains become visible after 4 days of growth on Sabouraud dextrose agar, presenting no visible dark pigment at this stage (tube at left), whereas others are melanized since the beginning of growth (tube at center). When transferred to brain heart infusion agar and cultured at 37°C, strains undergo dimorphism, presenting creamy white to tan yeast colonies after 7 days of growth (tube at right).
636
BARROS ET AL.
CLIN. MICROBIOL. REV.
The beginning of the yeast-to-mycelium transition in S. schenckii is a process regulated by calcium, which induces both RNA and protein synthesis on the yeast cell (199). A prerequisite for this transition process is a nuclear division; afterwards, a germ tube is originated from the parental yeast cell and a septum is formed at mother cell-germ tube formation (25). It is interesting to note that yeast cells can be maintained at 25°C if cultured in liquid media with glucose and with the pH around 7.2 (195, 260). Cell Wall Like other fungi, S. schenckii has a cell wall surrounding the plasma membrane in both the mycelial and yeast forms. There are characteristic differences in cell wall thickness between conidia, yeast forms, and filaments, as well variations in plasma membrane invaginations among these three morphological forms of the fungus. It has been shown by freeze fracturing studies that in conidia invaginations are short and abundant and in yeast forms they are scarce and longer, while the plasma membrane of the S. schenckii hyphae is smooth, without invaginations (244). The fungal cell wall is rigid as well as complex, and recently it has been shown that S. schenckii produces vesicles that are probably related to the transfer of periplasmic molecules and pigment-like structures from the plasma membrane to the extracellular space, since in contrast to the case for prokaryotic organisms, in eukaryotic cells there is vesicular traffic of molecules to the plasma membrane (3, 197). The chemical structures of fungal cell wall polysaccharides and glycoproteins have been studied basically because of the knowledge of the antigenic structures of human pathogens (193). A peptide-rhamnomannan was isolated from the yeast S. schenckii cell wall, where there were the polysaccharides D-mannose (50%) and L-rhamnose (33%), small amounts of galactose (1%), and about 16% peptides (138). Comparative studies of mycelial and yeast S. schenckii cell walls showed little difference in the glycosidic components. The cell wall composition of the mycelial phase included large amounts of lipids and protein and a lower concentration of mannose (193). The cell wall composition in S. schenckii conidial cells can also be affected by the time of culture, with a decrease in the rhamnose molar ratio and an increase in the mannose molar ratio (67). The yeast cell wall of S. schenckii also contain granules of melanin (250) and proteins involved in adherence (135, 206), which contribute to fungal virulence. Of particular interest is a glycoprotein of 70 kDa isolated from the cell wall of the S. schenckii yeast phase. The purified glycopeptide has a pI of 4.1, and about 5.7% of its molecular mass is composed of N-linked glycans, with no evidence for O-linked oligosaccharides in this molecule. This glycoprotein has a uniform distribution on the fungal cell surface and participates in adhesion to the dermal extracellular matrix (206). S. SCHENCKII GENETIC MATERIAL Little is known about the S. schenckii genomic composition because this fungus is not amenable to genetic analysis based on meiotic segregation (256). Studies on the genomic DNA base composition rendered an average guanine and cytosine
content of about 54.7 mol%, with the DNA showing a low degree of hybridization with O. stenoceras DNA, supporting the supposition that this fungus does not represent the sexual state of S. schenckii. However, 75% hybridization was observed with Ophiostoma minus DNA (159). More recently, Tateishi and coworkers (249), karyotyping eight strains isolated from patients in Japan, concluded that S. schenckii possesses six to eight chromosomes of 460 to 6,200 kb, with a total genome size of approximately 28 Mbp. Another study with strains from a different geographical origin predicted a 45-Mbp genome size for S. schenckii (256). Perhaps these differences are related to either the different species recently described (150) or to underestimations in the methods adopted for genome size determination. Also, it has been reported that S. schenckii is a diploid organism, bearing around 50 fg DNA per cell, in both the filamentous and yeast phases. On the other hand, aneuploidy, a state in which most of the chromosomes are disomic, cannot be excluded (256). It is interesting to note that diploidy is essential for thermal dimorphism in Cryptococcus neoformans, and similarities in life cycle between this fungus and other dimorphic fungi, including S. schenckii, may occur (232). Studies on identification, typing, and epidemiology of sporotrichosis are usually based on mitochondrial DNA (mtDNA) analysis of restriction length polymorphisms (RFLP) with the restriction enzyme HaeIII. Initially, 24 mtDNA types were cited (136), and more recently types 25 to 30 (168) and 31 to 32 (103) were introduced. These analyses have been adopted in several studies with S. schenckii strains from different geographical origins and also environmental isolates (13, 103, 104, 243, 266). S. SCHENCKII PHYSIOLOGY Even though sporotrichosis is a disease distributed worldwide, there are only a few studies regarding the physiological characteristics of its agent. In general, the optimal temperature for S. schenckii growth is around 30 to 37°C, with growth of all strains being impeded at 40°C (79, 150). Although S. schenckii is able to grow at 35 to 37°C, some growth inhibition is observed compared to that at 28°C. Moreover, this inhibition appears to be geographically related (163). Several carbohydrates can be assimilated by S. schenckii, such as glucose, fructose, mannose, and cellobiose (79, 200). However, there is some variability in assimilation of sucrose, arabinose, starch, raffinose, and ribitol (79, 150). Starch assimilation is also affected by fungal preservation under some storage methodologies, such as the Castellani method (160). The carbohydrate concentration available during S. schenckii growth modulates melanin synthesis by this fungus (Fig. 3), enhancing pigment formation in a glucose concentration-dependent manner (5). This fungus is not able to ferment any carbohydrate (53). Some physiological differences between the two different S. schenckii morphologies may be observed. Mycelial-phase S. schenckii can grow well at pHs of around 3.0 to 11.5, but yeast cells can grow only within the pH range of 3.0 to 8.5. The yeast phase is also more osmotolerant (30%) than the mycelial phase (20%), as is true for halophila. The mycelial phase withstands growth in 7% NaCl, but the yeast-phase S. schenckii can grow well in 11% NaCl (79).
VOL. 24, 2011
SPOROTHRIX SCHENCKII AND SPOROTRICHOSIS
FIG. 3. Glucose concentration-dependent increase of melanin synthesis. The concentration of glucose (%, wt/vol) in each culture is indicated by the numbers on the agar plates. S. brasiliensis strain 17307, grown at 22°C (A), and S. schenckii strain 23250, grown at 37°C (B), are representative isolates showing enhancement of melanization with increasing glucose amounts.
S. schenckii is able to split urea (79, 150, 233), perform reductive iron acquisition with secreted extracellular enzymes (270), and tolerate cycloheximide at 0.25% (150). Thiamine is required for fungal growth (60, 101). S. SCHENCKII ECOLOGY S. schenckii often enters the host through traumatic implantation (126, 129, 170, 196). In nature, the fungus has been found to live as a saprophyte on living and decaying vegetation, animal excreta, and soil (118, 126, 156, 162). Organic material in soil is fundamental for mycelium development. The fungus thrives in soil plentiful in cellulose, with a pH range from 3.5 to 9.4 and a temperature of 31°C (177). The relative humidity cannot be below 92% (126). It has been proposed that the armadillo Dasypus septemcinctus may be a reservoir of S. schenckii, since armadillo hunting was reported by several patients with sporotrichosis in Uruguay (143). In fact, this armadillo harbors S. schenckii in neither its intestine nor its epidermis, but the fungus can be found on the dry grass used by these animals for nesting (126). Here we find an apparent incongruity between the organisms needing high humidity for growth (126) yet being found on dry grass of armadillo nests. Probably these differences are geographically related, like growth inhibition at high temperatures (163). Moreover, we cannot discard the hypothesis that different species within the S. schenckii complex (150, 151) have different humidity requirements for growth. There is another armadillo species, Dasypus novemcinctus, which is susceptible to systemic, fatal sporotrichosis (111, 264). Other animals related to S. schenckii transmission are parrots, rodents, cats, dogs, squirrels, horses, and birds (126, 212). Moreover, S. schenckii was also isolated from aquatic animals, primarily fish and dolphins (91, 164), as well as from insects that had been in direct contact with the fungus (126). Some authors have reported sporotrichosis cases due to mosquito bites (129).
637
It has been confirmed that S. schenckii is associated with plants. Sphagnum moss, rose thorns, and hay are especially recognized to harbor this pathogenic fungus (64, 71, 156). However, S. schenckii does not have the potential to be a plant pathogen, probably because extracts from several plants have antifungal activity against S. schenckii (81, 153, 154, 213). In fact, it has been described that when S. schenckii is inoculated in living or dead sphagnum moss, the fungal cell population proliferates in the moist dead plants but not in live moss (271), suggesting that plants have some mechanism to control S. schenckii overgrowth. There has been some reports about S. schenckii isolation from food (1, 117). Nevertheless, this fungus does not appear to have the potential to cause food-borne infection (116). There are some reports on the isolation of S. schenckii from environmental sources. Methods include direct isolation of the fungus by plating the supernatants of samples suspended in water or physiological saline solution with antibiotics in Mycosel agar medium or by inoculation of this suspension in susceptible mice, such as BALB/c, with further culture of spleens, livers, and lungs of the infected animals (60, 162). Direct isolation appears to be more effective to obtain S. schenckii from environmental samples. However, colonies obtained after mouse inoculation have been free of microbial contamination (162). PUTATIVE S. SCHENCKII VIRULENCE FACTORS We can define a virulence factor as a feature of a microorganism that allows or enhances microbial growth in the host. To study and characterize these factors, is necessary compare the microbe-host interactions of an isolate that expresses the suspected factor and a mutant isolate that has lost the ability to express it, which can be attained by induced mutagenesis through molecular strategies. If differences in the infections caused by these different isolates are noted, it is imperative to make the mutant isolate recover the ability to express the studied factor and check whether or not the organism then regains the capacity to cause infection similar to that of the parental wild-type strain (100). Discovery of the origin of microbial virulence has been the main goal of several studies. In general, the most accepted theory is that with microbial interactions with other organisms present in the natural habitat of the pathogen, the microorganisms acquire survival strategies tending to a higher virulence when they accidentally find an animal host. For instance, these microorganisms, in the mammalian host, usually have the ability to form biofilms and mechanisms to acquire iron and produce proteolytic enzymes that will lead to higher virulence (40). Regarding this theory, Steenbergen and coworkers (240) suggested that the origin of virulence in S. schenckii should be related to the intermicrobial interactions in its environment. The authors demonstrated that when ingested by Acanthamoeba castellanii, a soil amoeba, S. schenckii yeast cells are able to survive within the protozoan, kill it, and use it as nutrient. This behavior is not shared by pathogenic fungi that do not have the soil as habitat, such as Candida albicans, or by fungi that are not primarily pathogenic, such as Saccharomyces cerevisiae. On the other hand, other dimorphic fungal patho-
638
BARROS ET AL.
CLIN. MICROBIOL. REV.
FIG. 4. Melanin ghosts of S. schenckii 18782 strain under several culture conditions. (A) Cultures on minimal medium at 25°C yield melanin ghosts only from dematiaceous conidia. (B) When L-DOPA is added to minimal medium, both hyphae and conidia are melanized. (C) Yeast S. schenckii cells can also produce melanin in culture medium free of phenolic compounds or when L-DOPA is added. Bars, 10 m.
gens, such as Histoplasma capsulatum and Blastomyces dermatitidis (240) as well as Cryptococcus gattii, a highly virulent yeast pathogen (148), have the same behavior as S. schenckii when in contact with A. castellanii. Little is known about S. schenckii virulence factors due to the lack of studies in this field, in part because S. schenckii is not responsive to genetic analysis. However, some putative virulence factors have appeared from some investigations. Thermotolerance One of the putative S. schenckii virulence factors, which is also a virulence factor of other pathogenic fungi, is thermotolerance (40). In fact, isolates able to grow at 35°C but not at 37°C are incapable of causing lymphatic sporotrichosis and produce fixed cutaneous lesions instead. The fungi isolated from lymphatic, disseminated and extracutaneous lesions show tolerance and growth at 37°C (126). Results from a more recent study demonstrate that S. schenckii isolates from Colombia, where most patients are affected with fixed cutaneous sporotrichosis, exhibit high growth inhibition at 35 and 37°C, in contrast to isolates from Mexico and Guatemala, where lymphatic sporotrichosis prevails (163). In an in vivo mouse assay, it has been shown that if the mice have their feet warmed in cages with heat on the floor, progression of sporotrichosis is reduced compared to that in control infected mice maintained in regular cages. Isolates from pulmonary lesions, however, replicate regularly in both groups of mice (246). Melanin Both morphological stages of S. schenckii have the ability to synthesize melanin. This is an insoluble compound highly related to virulence in several fungi (106). Melanin production in S. schenckii dematiaceous conidia occurs through the 1,8-dihydroxynaphthalene (DHN) pentaketide pathway (202). Macroscopically, only the mycelial phase of the fungus is melanized. However, melanin production in yeast cells was demonstrated in vitro during infection (171). Recently, it has been demonstrated that S. schenckii can also produce melanin using phenolic compounds such as 3,4-dihydroxy-L-phenylalanine (L-DOPA) as a substrate both in filamentous and yeast forms (5). It is interesting to note that only conidia can be melanized by the DHN pathway, but if L-DOPA is present, hyphae can be melanized as well (Fig. 4). Since S. schenckii is a soil-accommodated fungus that does
not require host parasitism to complete its life cycle, fungal melanization must be also important against unfavorable environmental conditions, since mycelium is the fungal form encountered in nature (171). In vitro studies indicate that melanization in S. schenckii is controlled by several factors, such as temperature, pH, and nutrient conditions (5). Moreover, similar culture media from different suppliers can yield differences in melanization within a single S. schenckii strain (250). It has been shown that conidial melanization enhances S. schenckii resistance to macrophage phagocytosis, allowing the first steps of infection, since these structures usually are the fungal infective particles (202). Corroborating this hypothesis, it has been demonstrated by molecular typing of an S. schenckii strain isolated from a laboratory worker who had handled a pigmented strain and an albino strain of S. schenckii that the isolate from the patient had the same genotypic profile as the dematiaceous strain (48). Melanization also has a role in the pathogenesis of cutaneous sporotrichosis, since pigmented isolates had a greater invasive ability than the albino mutant strain in an experimental rat model of sporotrichosis. The albino strain also was restricted to the core of the granuloma. In addition, the melanized strain promoted the formation of multifocal granulomas (145). Some S. schenckii melanization in vivo has been previously described, such as a weak brown halo on the yeast S. schenckii cell wall when infected sporotrichosis tissues are stained with Fontana-Masson stain, a technique initially developed to demonstrate melanin in C. neoformans (127). This hypothesis has now been confirmed by detection of Sporothrix melanin ghosts in tissues from infected animals as well as by detection of antimelanin antibody in sera from patients with sporotrichosis (5, 171). Since melanization decreases the susceptibilities of H. capsulatum and C. neoformans to amphotericin B and caspofungin (261), melanin pigment in S. schenckii may hamper treatment in some sporotrichosis cases, especially in cases of extracutaneous disease or in patients infected with human immunodeficiency virus (HIV) (171). However, there have been no studies confirming this hypothesis. Adhesion Primary adhesion to endothelial and epithelial cells as well as on extracellular matrix components is essential to an effective invasion of host tissues by pathogens. Both conidia and yeast cells from S. schenckii are able to recognize three impor-
VOL. 24, 2011
SPOROTHRIX SCHENCKII AND SPOROTRICHOSIS
tant glycoproteins from the extracellular matrix: fibronectin, laminin, and type II collagen (134, 135). Some studies have demonstrated that the fungus has integrins or adhesin lectinlike molecules that recognize human fibronectin at several points on the molecule (135). The fibronectin adhesins are located on the surface of yeast cells, and their expression is related to fungal virulence (251). It is also known that these fibronectin receptors are different from laminin receptors (133). These receptors are present on both hyphae and fungal yeasts, although yeasts have a greater ability to bind to the extracellular matrix. The existence of these adhesins would favor adherence to host tissues and fungal dissemination throughout the body (133). Expression of these molecules in S. schenckii is probably related to virulence, since their preferential expression is in the parasitic rather than the saprophytic form of the fungus. Recently a 70-kDa glycoprotein from an S. schenckii isolate was described, and its participation in adhesion to the dermal extracellular matrix was demonstrated (206). This fungal pathogen is also able to interact in vitro with human endothelial cells, which can internalize fungal yeast cells without injury or decreased viability. Moreover, the fungus can also cross the intercellular space. Both processes facilitate fungus bloodstream penetration and consequent hematogenous dissemination (69). Transendothelium migration occurs through a paracellular route involving extracellular matrix proteins, in a process mediated by transforming growth factor 1 (TGF-1) (70). Although the endothelial proteins responsible for this interaction have been characterized, fungal proteins needed for recognition of and adhesion to these cells are unknown, and their part in fungal virulence requires clarification. Ergosterol Peroxide Sgarbi and coworkers, analyzing lipids from S. schenckii through spectroscopic methods, have identified ergosterol peroxide from S. schenckii yeast cells. This compound can be converted to ergosterol when in contact with an enzyme extract from the fungus. The ergosterol peroxide, found in a pathogenic fungus for the first time in S. schenckii, is formed as a protective mechanism to evade reactive oxygen species during phagocytosis and may also represent a virulence factor. Apparently, however, survival of virulent S. schenckii yeast cells after phagocytosis of polymorphonuclear host cells relies on other detoxification strategies besides the one leading to ergosterol peroxide synthesis (32, 231). Proteins Related to Virulence Roles of diverse proteins in the virulence of different fungal pathogens have been described. For instance, the Paracoccidioides brasiliensis immunodominant antigen, a glycoprotein of 43 kDa, is the molecule responsible for laminin and fibronectin recognition and binding, which increase fungal virulence (158, 262). Calcium binding proteins are important in H. capsulatum virulence, enabling acquisition of this ion in environments with calcium limitations (265). A series of virulence-related proteins, such as different adhesins, have been described for Aspergillus fumigatus, including a 30-kDa hemolysin contain-
639
ing several proteases that favor pulmonary colonization and destruction of effective humoral molecules and a 350-kDa catalase needed for phagocytosis survival (131). However, the function of different S. schenckii proteins in virulence is still unclear. It is believed that acid phosphatases act on fungusmacrophage interactions, although no definite evidence to support this theory exists (100). Peptido-rhamnomannans of the fungal cell wall cause depression of immune response until the sixth week of infection and may act as a virulence factor (34). An antigenic preparation from the S. schenckii yeast phase shows proteolytic activity against different human IgG subclasses, suggesting that some secreted proteins may interfere with the immune response of the host (204). Due to the lack of information, characterization of S. schenckii proteins and determination of new virulence factors are imperative for a better understanding of sporotrichosis pathogenesis. IMMUNE RESPONSE IN SPOROTRICHOSIS The virulence of S. schenckii is one of the factors thought to play a role in the development of sporotrichosis (32), but there are discordant results concerning disease evolution in experimental sporotrichosis with S. schenckii clinical isolates from cutaneous and disseminated infection (29, 176), indicating that host immune responses also substantially participate in the progress of sporotrichosis (32). The immunological mechanisms involved in prevention and control of S. schenckii infections are still not very well understood. However, they probably include both humoral and cellular responses (32, 33, 147), which appear to be triggered by distinct antigens. Surface cell antigens, especially some lipids, inhibit the phagocytosis process, while the humoral response is induced by secreted fungal proteins, the exoantigens, which are not involved in the cellular response (35). The innate immune response also plays a role in the pathogenesis of sporotrichosis (32). Innate Response A complement system can be activated by S. schenckii, especially the alternate pathway, although classic complement activation cannot be excluded. Complement activation may support fungal yeast cell phagocytosis by C3b component deposition on the fungal cell wall. The membrane attack complex also contribute to fungal cell lysis (230, 255). Recent studies have emphasized the importance of Toll-like receptor 4 (TLR4) in sporotrichosis. TLR4, also designated CD284, is an important molecule involved in the activation of the innate immune system that, in sporotrichosis, is able to recognize molecules within a lipid extract from the yeast form of the fungus. This interaction leads to the induction of an oxidative burst against the fungus (32). Cellular Response Acquired immunity against the fungus requires the action of activated macrophages. They can be activated during sporotrichosis by CD4 T lymphocytes, which release gamma interferon (IFN-␥), a strong macrophage activator (247), and by other antigen-presenting cells, establishing a link between innate and
640
CLIN. MICROBIOL. REV.
BARROS ET AL.
adaptive immune responses (32). Tumor necrosis factor alpha (TNF-␣), a cytokine that acts on activated macrophages to produce nitric oxide (35), an antioxidant product presenting a high cytotoxic effect against S. schenckii (66), is produced upon incipient and terminal infection, hopefully providing total resolution (147). Although nitric oxide is a fungicidal molecule, this compound may be implicated in immunosuppression in vivo, because high levels of TNF-␣ and NO released after yeast dissemination into the tissues lead to the induction of molecules suppressing T cell responses, such as interleukin10 (IL10), FasL, and CTLA-4. This deleterious effect of NO occurs just upon initial infection, becoming crucial some time after fungal inoculation (68). In fact, TNF-␣ production drastically subsides at 4 to 6 weeks after experimental infection, inducing the fungus to reproduce and infect host tissues. The opposite situation occurs 2 months after infection, when the levels of IL-1 and TNF-␣ increase, favoring fungal elimination (36). After the phagocytosis of S. schenckii conidia and yeast cells, monocytes and macrophages are also strongly induced to produce reactive oxygen species (202). These reactive species, especially superoxide anion and its oxidative reactive metabolites, which are also produced by neutrophils, are involved in fungistatic and fungicidal responses, and their absence is related to a higher lethality in mouse experimental infections (108). Therefore, the Th1 response is of great importance in sporotrichosis pathogenesis, acting as the key factor in controlling fungal infection and with its differential activation leading to varied clinical manifestations of the disease (258). Similar observations on the activation of Th1 cells have led to them being seen as being responsible for different clinical manifestations in other cutaneous infectious diseases, such as leishmaniasis (38).
Humoral Response The humoral immune response is driven by IL-4 produced by Th2 cells. In experimental sporotrichosis, IL-4 release is enhanced at 5 to 6 weeks after infection (147), suggesting the participation of the humoral immune response only in the advanced stages of sporotrichosis (32). Antibodies may have some effect on S. schenckii development, since a monoclonal antibody against a glycolipid antigen is able to hinder S. schenckii growth and differentiation in vitro (254). A monoclonal antibody against the 70-kDa adhesin is also protective in murine model of sporotrichosis (174). Nonetheless, little is known about antibodies elicited during the course of sporotrichosis. It has been described that mice infected with S. schenckii are able to produce specific IgG1 and IgG3 antibodies against a 70-kDa fungal protein during experimental infection, with these antibodies perhaps being related to fungal elimination in these organisms (173). During human sporotrichosis, our group has demonstrated the production of IgG, IgM, and IgA antibodies against mycelial-phase S. schenckii exoantigens. Nevertheless, since patients with different clinical forms of sporotrichosis produce similar amounts of these antibodies, we believe that the humoral immune response against proteins secreted by S. schenckii does not play a role in sporotrichosis pathogenesis (6).
FIG. 5. Direct examination of clinical specimens for diagnosis of sporotrichosis. (A) KOH mount of a tissue fragment from a cat with sporotrichosis, showing cigar-shaped (arrow) and budding (dashed arrow) S. schenckii yeast cells. Note the high fungal burden in the specimen. (B) Direct examination (10% KOH) of the pus from a lesion of a human patient with sporotrichosis, showing nonspecific budding yeast cells. Bars, 10 m. (Courtesy of Rosani Santos Reis.)
SPOROTRICHOSIS DIAGNOSIS Sporotrichosis can be diagnosed through a correlation of clinical, epidemiological, and laboratory data. Laboratory analysis for the determination of sporotrichosis includes direct examination of specimens such as tissue biopsy specimens or pus from lesions. In case of disseminated infections, other specimens, such as sputum, urine, blood, and cerebrospinal and synovial fluids, can be analyzed, depending on the affected organs. Direct Examination Direct examination of specimens is usually conducted with 10% potassium hydroxide in order to observe parasitic budding yeast cells. These yeasts are small (2 to 6 m in diameter) and scarce and consequently are difficult to detect upon direct examination of specimens collected from humans. However, when the same test is performed with samples collected from infected cats, due to the high fungal burden in these animals, yeast cells can be easily found, even at a magnification of ⫻400 (Fig. 5). Fluorescent-antibody staining can help in the observation of yeast forms of S. schenckii; however, this is not a technique that is readily available in most laboratories (130), especially in underdeveloped countries. When the Gram stain is used on the clinical material, yeast cells appear positively stained, sometimes within giant cells or polymorphonuclear lymphocytes (129). For the detection of S. schenckii, some authors recommend Giemsa stain after 10 to 15 dilutions of
VOL. 24, 2011
SPOROTHRIX SCHENCKII AND SPOROTRICHOSIS
pus in physiological solution (12, 129). These staining procedures also lack sensitivity. Observation of yeast cells through direct examination, however, is not conclusive for sporotrichosis diagnosis. The characteristic “cigar-shaped” buds (2 by 3 to 3 by 10 m) are not always witnessed. Moreover, yeast cells of H. capsulatum and Candida glabrata may be misidentified as S. schenckii (130). Direct examination of pus obtained from lesions of patients with sporotrichosis, without potassium hydroxide, also permits the detection of asteroid bodies. These structures were confirmed in 43.75% of patients, and the sensitivity of the examination can be enhanced (up to 93.75%) if the initial pus is discarded and new samples are collected more deeply. This can help to initiate specific treatment before the results of the culture examinations are available (78).
641
tive of a localized immunological host response to antigens of diverse infectious organisms, including fungi, bacteria, and other parasites. It appears as radiating homogenous, refractile, eosinophilic clublike material surrounding a central eosinophilic focus (130). There are several reports concerning asteroid bodies, the Splendore-Hoeppli reaction in sporotrichosis, in histopathological tissue sections from sporotrichosis patients, ranging in positivity from 20 to 66% (78). Other authors, however, report an absence of this structure in analyzed samples (187). Yeast cells remain viable inside the asteroid bodies, which present IgG and IgM from the host on the spikes of the radiated crowns, suggesting that asteroid bodies are resistance structures which use immune molecules of the host to advantage the yeasts (203). Culture
Histopathological Examination Although S. schenckii may be seen in tissue with the routinely used hematoxylin and eosin (H&E) stain, other special stains such as Gomori methenamine silver (GMS) or periodic acid-Schiff (PAS) stain can be employed to enhance fungal detection (130, 170). Fontana-Masson staining is negative (54). Atypical S. schenckii cells can appear spherical and surrounded by a PAS-positive capsule, resembling Cryptococcus cells (126). Once again, parasitic cells of S. schenckii are difficult to visualize due to the paucity of yeasts in lesions from humans (170) or other animals such as dogs (57). Tissue reaction must be also evaluated in histopathological examinations from patients with sporotrichosis. S. schenckii usually causes a mixed suppurative and granulomatous inflammatory reaction in the dermis and subcutaneous tissue, frequently accompanied by microabscess and fibrosis. Cutaneous infections may also exhibit hyperkeratosis, parakeratosis, and pseudoepitheliomatous hyperplasia (130). Foreign bodies of vegetal origin related to the traumatic inoculation of the agent may also be encountered (182). Besides intact polymorphonuclear cells, granulomas in sporotrichosis usually contain cellular debris, caseous material, giant and epithelioid cell lymphocytes, plasmocytes, and fibroblasts as well as S. schenckii yeast cells within phagocytic cells or in the extracellular medium (129). Miranda and collaborators (167) reported that in dogs with sporotrichosis, lesions present well-formed granulomata, with marked neutrophil infiltration. The peripheral infiltrate often is devoid of lymphocytes and macrophages. Taken together, this information enables the differentiation of sporotrichosis and leishmaniasis in these animals. Some histopathological alterations, such as presence or predominance of epithelioid granulomas, presence of foreign body granulomas, predominance of lymphocytes, presence or predominance of caseous necrosis, and predominance of fibrinoid necrosis and fibrosis, are related to the lack of observation of the fungus in tissue sections from human patients. When the fungus is not in evidence, suppurative granulomas, neutrophils, and liquefaction necrosis are uncommon (187). Splendore in 1908 described a radiate eosinophilic substance in human tissues from patients with sporotrichosis, and Hoeppli in 1932 reported an eosinophilic material around schistosome larvae (126). The Splendore-Hoeppli reaction is indica-
Definitive sporotrichosis diagnosis is based on the isolation and identification of the etiological agent in culture (126). Isolation of S. schenckii is easily obtained after spreading of the clinical specimens on Sabouraud agar with chloramphenicol and on media with cycloheximide, such as mycobiotic agar. After 5 to 7 days of incubation at 25°C, filamentous hyaline colonies start to grow, and after some time, they may develop a dark color, usually in the centers of the colonies (170). To identify an isolate as S. schenckii, one must demonstrate that it undergoes dimorphism by subculturing the fungus on enriched media such as brain heart infusion agar, chocolate agar, and blood agar at 35 to 37°C for 5 to 7 days. Occasional isolates can be difficult to convert and may require multiple subcultures and extended incubation (216). After S. schenckii conversion to the yeast phase, colonies acquire a creamy aspect and a yellow to tan color (170). Environmental Sporothrix strains may also form the yeast phase when grown on appropriate media at 37°C. For this reason, observation of dematiaceous conidia in colonies maintained at 25°C is mandatory (54, 60, 216). For this purpose, slide culture preparations with potato dextrose agar or cornmeal agar are ideal to study S. schenckii conidiogenesis (54). Positive cultures provide the strongest evidence for sporotrichosis, allowing diagnosis of almost all cases of cutaneous disease. Nevertheless, culture diagnosis has significant limitations, mainly in some manifestations of the disease such as S. schenckii induced arthritis, where the collection of material for culture is difficult. Molecular Detection Nonculture methods have been developed to improve the rate and speed of mycological diagnosis (194, 241). Molecular detection of S. schenckii is useful for a rapid diagnosis of sporotrichosis and also valuable in cases of negative cultures due to low fungal burden or secondary infections. Up to now, there has been a scarcity of molecular methods for the detection of S. schenckii DNA from clinical specimens. Sandhu and collaborators (211) reported the development of 21 specific nucleotide probes targeting the large-subunit rRNA genes from several fungi, including S. schenckii. The authors adopted a protocol for DNA extraction from clinical specimens that consists of boiling the specimens in an alkaline
642
BARROS ET AL.
guanidine-phenol-Tris reagent, followed by amplification of a variable region of the 28S rRNA gene with universal primers and amplicon identification using the specific probes. The results displayed a high level of specificity for this test. Some methodologies to identify S. schenckii colonies from pure cultures have been described. Specific probes for fungi with yeast-like morphology in vivo, including all dimorphic fungal pathogens, were developed for the detection of PCR amplicons in an enzyme immunoassay format. S. schenckii DNA was able to hybridize to the probe to detect all dimorphic fungi as well as to its specific probe (137). Specific oligonucleotide primers based on the chitin synthase gene were also developed. This primer was able to detect 10 pg of genomic S. schenckii DNA (110). Primers to distinguish S. schenckii from related species such as Ceratocystis stenoceras, based on the DNA topoisomerase II genes, permitted the amplification of fragments of 663 to 817 bp from S. schenckii and a 660-bp fragment from S. schenckii var. lurei. Another set of primers allowed the amplification of a specific 305-bp fragment from S. schenckii var. lurei (109). These detection systems may be useful as diagnostic tools for the detection of human and animal sporotrichosis. In fact, a PCR assay based on the internal transcriber space in the rRNA gene has been used for the identification of an S. schenckii strain from an atypical case of sporotrichosis (75). Sporotrichin Skin Test The cutaneous sporotrichin skin test detects delayed hypersensitivity, i.e., the cellular immune response, and can be a useful diagnostic tool, but its major usefulness is in epidemiological investigations. This reaction is usually positive in about 90% of confirmed sporotrichosis cases but can also indicate previous infection with the fungus (105). The sporotrichin skin test has been successfully applied to confirm the diagnosis of bulbar conjunctival sporotrichosis after the pathological examination revealed yeast-like cells (113). Epidemiological studies usually involve the sporotrichin skin testing of individuals living or working in a determinate area together with attempts to isolate the fungus from the soil in that area. For instance, this test gave 6.25% positivity in a Mexican state where virulent strains of S. schenckii were isolated from soil (210). On the other hand, 13.67% positivity was found among healthy mine workers from Brazil, although the fungus was not isolated from soil samples from the mines investigated (198). Despite the current use of the sporotrichin skin test in several studies throughout the world, the antigen adopted in these tests lacks standardization. Several studies on sporotrichin in Brazil were performed with a 5 McFarland standard suspension of heat-killed yeast cells (129). A retrospective 10-year study in Mexico used extracted mycelial antigens at a 1:2,000 dilution (28), while another Mexican study diluted yeast-phase antigens at 1:4,000 (210). These variations in antigen production may lead to differences in results. Antibody Detection Several methodologies have been described for the immunological diagnosis of sporotrichosis based on antibody detec-
CLIN. MICROBIOL. REV.
tion in sera from infected patients. Precipitation and agglutination techniques were first adopted. Double immunodiffusion for sporotrichosis does not usually show cross-reactions with sera from patients with chromoblastomycosis or leishmaniasis, infectious diseases with similar clinical manifestations. Immunoelectrophoresis has also been employed, with an anodic arc, called S arc, being observed in all positive cases (2). Tube agglutination and latex agglutination have been utilized for sporotrichosis serodiagnosis since the 1970s, and very good sensitivity (96% and 94%, respectively) and specificity (98 and 100%, respectively) have been observed (26, 41, 112). These tests, however, lack sensitivity in cases of cutaneous sporotrichosis (2, 196) and do not permit the determination of the immunoglobulin isotype involved in the response. Immunoenzymatic assays are currently being used more frequently for serodiagnosis purposes. The publication of an immunoblot assay for serodiagnosis of sporotrichosis dates back to 1989, when molecules of 40 and 70 kDa from exoantigen preparations from the S. schenckii yeast form showed 100% sensitivity and 95% specificity (229). Our group, however, in an attempt to reproduce these data, found high cross-reactivity of this antigenic preparation with sera from patients with paracoccidioidomycosis (unpublished results), which is not an endemic disease in the United States, where the first study was conducted. Antibodies against a concanavalin A binding peptide-rhamnomannan from the S. schenckii yeast cell wall could be detected in an enzyme-linked immunosorbent assay (ELISA), showing 100% sensitivity when 35 serum samples from patients with culture-proven sporotrichosis were tested. However, sera from patients with cutaneous leishmaniasis showed cross-reactions in this assay format (140). This antigenic preparation was further evaluated with sera from 92 patients with sporotrichosis in Rio de Janeiro and 77 heterologous sera, with 90% sensitivity and 80% specificity (23). Other studies showed that the use of different strains in the preparation of the antigen may lead to different sensitivity and specificity results, despite the process of purification of the antigen involved in this methodology. This difference is due to O-glycan residues linked to the molecules. The strain that had better results was the 1099-18 strain obtained from the Mycology Section, Department of Dermatology, Columbia University, New York, NY (24). Efforts to contribute to this field culminated in the development of an enzyme immunoassay with exoantigens produced by a mycelial-phase S. schenckii strain isolated during the Rio de Janeiro epidemic of sporotrichosis (7). This antigen was described by Mendoza and collaborators (161) and had no cross-reaction with antigens and serum samples from patients with coccidioidomycosis, histoplasmosis, or paracoccidioidomycosis. The same antigen was previously used in immunodiffusion and immunoelectrophoresis techniques, without cross-reactions with sera from patients with leishmaniasis or chromoblastomycosis (2). The methodology for production of this antigen is simple and does not require chromatographic steps, making it easy for laboratories with limited resources (7), although more variations can occur with this kind of preparation than with those involving purification procedures. Detection of IgG antibodies against these exoantigens distinguished 90 sera from patients with different clinical forms of
VOL. 24, 2011
SPOROTHRIX SCHENCKII AND SPOROTRICHOSIS
sporotrichosis, 72 sera from patients with other infectious diseases, and 76 sera from healthy controls, yielding 97% sensitivity and 89% specificity (7). These values are slightly higher than those for the concanavalin A binding fraction of the S. schenckii yeast cell wall (23), and similar observations were made with this purified antigen and crude exoantigens in the serodiagnosis of feline sporotrichosis. Purified antigens exhibited 90% sensitivity and 96% specificity, whereas crude exoantigens showed 96% sensitivity and 98% specificity (65). It has also been demonstrated that in order to improve the overall efficiency of antibody detection for diagnosis and follow-up of human sporotrichosis with the mycelial exoantigen preparation, a search for IgG and IgA antibodies for diagnosis and a search for IgG and IgM antibodies for follow-up purposes must be undertaken (6). Importantly, the results from all antibody detection tests provide a presumptive diagnosis of sporotrichosis and require clinical and epidemiological correlation for an accurate evaluation and determination of the final diagnosis. EPIDEMIOLOGY The natural history of sporotrichosis has been changing gradually in frequency, mode of transmission, and demographic and geographic distributions. It is possible that environmental factors, increased urbanization, and improved diagnostics partly explain the alterations in the profile of the disease. Furthermore, since sporotrichosis is not a reportable disease in most countries, there is little information on the incidence, and the known data are those generated by case publications. Geographic Distribution At the beginning of the last century, sporotrichosis was a common disease in France; it declined after 2 decades and today sporadically appears in Europe. In 2009, an autochthonous case was reported in France (146), and in 2008, another one was reported in the southern region of Italy (49), but these reports are rare and isolated. Despite having been described on five continents, sporotrichosis has a higher prevalence in tropical and temperate zones. The main areas of endemicity are located in Japan (248), India (156), Mexico (144), Brazil (17, 218, 222), Uruguay (45, 47), and Peru (124). In the United States, especially in the Mississippi Valley, outbreaks related to pine seedlings and manipulation of moss have been cited (185). A bibliography search performed in PubMed with the term “Sporothrix schenckii” or “sporotrichosis” for the last 10 years (from January 2001 to November 2010) yielded 407 results. Of these, 83 were excluded (because they were book chapters, reports of other diseases, etc.). Of the remaining 324 references retrieved, 142 were case reports and case series for humans, 22 were case reports and case series for animals, 119 were laboratory studies (molecular studies, antifungal susceptibility tests, environmental studies, etc.), and 41 were various (reviews, letters, comments, or guidelines). These 324 publications were produced by authors from 27 countries. Obviously, these data reflect solely the scientific papers published by workers in these countries, and it is not possible to correlate with disease prevalence (Fig. 6). In the United States, where the incidence of cases is low and usually related to handling
643
sphagnum moss (92), the large number of publications reflects the development of research in the country. The lack of infrastructure for laboratory diagnosis and the lack of research in many countries do not allow for accurate knowledge of disease distribution and environmental sources of the fungus. Newton et al. (175), reporting a case of cutaneous-lymphatic sporotrichosis in a patient from Laos, highlighted the difficulties in laboratory diagnosis of fungal infections in Southeast Asian countries, resulting in a shortage of reports. These authors point out that in regions such as the highlands of China, Laos, Vietnam, and Burma, which have favorable conditions for Sporothrix growth, the prevalence of cases must be much higher than is estimated according to the literature. Distribution by Age and Gender Sporotrichosis affects both genders and all ages. In most regions, the difference in case distribution by age and sex is related to occupation and exposure to the fungus. Among the cases studied by Takenaka et al. (248), 70% were older than 50 years, with an equal division between sexes. In Japan, where that study was conducted, working in agricultural activities has been associated with a higher risk for acquiring sporotrichosis. In Colombia (205) and the southern region of Brazil (10), there was a higher prevalence in men over 40 who were involved in agricultural as well as other high-risk activities. Also in Brazil, in the state of Rio de Janeiro, there was a predominance in women over 40 who were involved in housework and the care of cats with sporotrichosis, the highest risk group for acquiring the disease (18, 218). In Abancay, a rural area of Peru, of the 238 cases studied from 1995 to 1997, 60% occurred in children younger than 15 years old. In that study, no association between age, sex, and exposure to the fungus could be found (184). Transmission and Sources of Infection Sporotrichosis has been traditionally known as “gardeners’ disease,” especially affecting those involved in the cultivation of roses (62). Although in most cases the infection results from inoculation of the fungus by thorn or other pricks, scratches, and other small injuries, a history of trauma can be absent (17, 184, 191). Certain occupational and leisure activities, such as floriculture, horticulture, gardening, fishing, hunting, farming, mining, and others that facilitate exposure to the fungus, have over the years been associated with the transmission of the disease (196). In Uruguay, and more recently in southern Brazil, the hunting of armadillos has been related to cases of sporotrichosis (10, 47). There have been reports of the mycosis following bites or scratches by animals such as cats and squirrels, insect bites, and other injuries. These conditions may either result in direct inoculation or facilitate the entry of the fungus (15, 166). In some situations, such as in an area of endemicity in Peru, the mode of transmission had not been made clear (115, 184) until another study in the same region identified the ownership of cats, outdoor activities, and low socioeconomic status as risk factors for acquiring sporotrichosis (142). Some cases have been reported in laboratory professionals who were infected by manipulating cultures of S. schenckii (48). Interhuman transmission is rare (215). Sporo-
644
BARROS ET AL.
CLIN. MICROBIOL. REV.
FIG. 6. Geographic distribution, by country, of scientific production on sporotrichosis in the 21st century according to the type of publication.
trichosis usually occurs in isolated cases or small outbreaks in families and professionals engaged in high-risk activities. Epidemics are rare and, when they occur, are commonly related to a single source of infection (30). The largest outbreak occurred in Witwatersrand, South Africa, and its description contributed significantly to the current knowledge of sporotrichosis, representing so far the most complete epidemiological investigation of the disease. Between 1941 and 1944, more than 3,000 gold miners were infected by the fungus, which was present in the timber of these mines (96). In the United States, the largest epidemic took place in 1988 and involved a total of 84 cases in 15 states, affecting workers who participated in reforestation programs. The cases were associated with exposure to sphag-
num moss used for the packing of seedlings from a nursery in Pennsylvania (42). Zoonotic Transmission Sporotrichosis has been sporadically associated with scratches or bites from animals such as mice, armadillos, squirrels, dogs, and cats (114). The role of felines in the transmission of the mycosis has gained attention since the 1980s, when Read and Sperling (191) reported an outbreak involving five people exposed to a cat with sporotrichosis. Since then, successive reports from different geographical regions have characterized a new risk group for acquisition of sporotrichosis, composed of
VOL. 24, 2011
SPOROTHRIX SCHENCKII AND SPOROTRICHOSIS
cat owners and veterinarians (98, 269). The first epidemic of zoonotic sporotrichosis was detected in Rio de Janeiro (17, 222). From 1998 to December 2009, more than 2,000 cases in humans and over 3,000 cases in cats were diagnosed at Instituto de Pesquisa Clínica Evandro Chagas (IPEC)/Fiocruz, representing the largest epidemic of zoonotic transmission of this mycosis ever recorded (19). A study of 178 human cases assessed from 1998 to 2001 showed that of 156 patients who reported professional or household contact with cats with sporotrichosis, 97 had been scratched or bitten by these animals (17). Some authors believe that cats are the only animals with zoonotic transmission potential because of the large amount of yeast cells in the lesions (225, 245). Although dogs have also been affected, they do not seem to have significant zoonotic potential (223). Several studies have been conducted in an attempt to understand why sporotrichosis has reached epidemic proportions in Rio de Janeiro as well as the reason for the high susceptibility of cats to infection by Sporothrix (192, 224–226). However, the lack of studies on environmental, molecular, and feline immune responses against the fungus leave many questions unanswered. Gutierrez-Galhardo et al. (90) investigated the phenotypes and genotypes of Sporothrix schenckii isolates recovered from different clinical forms of the disease. A total of 88 isolates recovered from 59 human cases associated with the epidemic and 29 controls (cases from other Brazilian regions and Spain) were studied. Fingerprinting analysis showed that the Rio de Janeiro epidemic strains were genetically related. Although nine subtypes were found, they were not associated with specific clinical forms. Similar results were obtained by ribosomal DNA sequencing of the internal transcribed spacer sequence. These data suggest that the strains isolated from the cases of sporotrichosis in Rio de Janeiro all originated from a common source. PATHOGENESIS AND CLINICAL FORMS Human Disease Clinical presentations of sporotrichosis may vary according to the immunological status of the host, the load and depth of the inoculum, and the pathogenicity and thermal tolerance of the strain, among other factors (14). Lavalle and Mariat (132) considered that the localized cutaneous form occurs by reinfection of patients who had previously developed immunity to S. schenckii, while the lymphocutaneous form manifests in patients without prior contact with the fungus. According to Rippon (196), continuous exposure to small amounts of conidia in an area of endemicity could gradually confer immunity. An experimental murine model adopted to study the genotypes, virulence, and clinical forms of S. schenckii showed a close relationship between genotype and clinical form. Mice inoculated with isolates from disseminated sporotrichosis presented a shorter time to the onset of the disease and more severe lesions than those inoculated with isolates from lymphocutaneous sporotrichosis. Those inoculated with isolates from the fixed form showed less severe lesions (123). Other studies have reported similar results. Brito et al. (29) studied the virulence of two strains of Sporothrix schenckii, isolated from patients with lymphocutaneous (group 1) or disseminated (group 2) sporotrichosis, by inoculating BALB/c mice. Com-
645
parison of the two groups revealed more severe disease in group 2 mice. The histopathology and large number of viable microorganisms isolated from the spleen confirmed the higher invasive ability of this strain. Furthermore, a decrease of an in vitro specific lymphoproliferative response and IFN-␥ production was observed over time in group 2. These results reinforce the existence of different virulence profiles in S. schenckii strains. According to the location of the lesions, sporotrichosis can be classified into cutaneous, mucosal, and extracutaneous forms. Cutaneous forms. In cutaneous forms, the infection usually appears after minor trauma with disruption of epidermis integrity. After penetrating through the skin, the fungus converts into the yeast form and may remain localized in the subcutaneous tissue or extend along the adjacent lymphatic vessels, constituting the fixed or the lymphocutaneous form, respectively. More rarely it may spread by the hematogenous route, characterizing the disseminated cutaneous form (239). In cases of cat-transmitted sporotrichosis, infection by the yeast form can also occur. This hypothesis is based on the large amount of this form in the lesions from cats associated with transmission without a history of scratches or bites (18). Moreover, the isolation of yeast forms in cats’ claws also favors this idea (226). A molecular study revealed that DNA fingerprints of S. schenckii isolated from the nails and the oral cavities of cats were identical to those of related human samples, suggesting that there is a common infection source for animals and humans in the current epidemic in Rio de Janeiro (192). It is clear that cats act as a vehicle for S. schenckii dissemination. However, the lack of environmental studies on this epidemic and the deficit of information on natural sources that can serve as a reservoir of the fungus do not allow a conclusion to be drawn. The fixed form is represented by a single lesion or a few lesions at the inoculation site, which is often ulcerated with erythematous edges. The morphology can also be vegetative, verrucous, plaque infiltrated, or tuberous, without lymphatic involvement. Some cases may spontaneously regress (4). Most authors report the fixed cutaneous form as the main clinical presentation in children (252). However, the lymphocutaneous form is the most frequent overall, being present in more than 75% of cases (28, 190). The primary lesion is usually located on the extremities, especially hands and forearms, corresponding to the sites most exposed to trauma. Initially, a papule or pustule is followed by formation of a subcutaneous nodule. This lesion, exerting pressure beneath the skin, causes ischemia under the epidermis, evolves into gum, ulcerates, and oozes a purulent secretion. With the progression, secondary lesions arise along the path of regional lymphatics, featuring “sporotrichoid aspect” of the infection. Lymph node involvement or the presence of systemic symptoms is unusual. A disseminated cutaneous form is characterized by multiple skin lesions at noncontiguous sites without extracutaneous involvement. Lesions of the fixed and lymphocutaneous forms may coexist in the same patient. Until the emergence of zoonotic transmission, this form was rare and was caused by hematogenous spread of the fungus, usually associated with immunosuppression (39, 239). In transmission by cats, several inoculations in different locations may occur, during either treatment or play with animals (20). Although there is a dis-
646
BARROS ET AL.
tinct pathogenesis for each situation, it is difficult to identify whether the clinical presentation is due to dissemination from a single lesion or to multiple inoculations. Mucosal form. Some authors consider the mucosal form to be a variant of the cutaneous form. In the nasal mucosa, the lesions often involve the septum, with drainage of bloody secretions and detachment of crusts. In the conjunctiva, the granulomatous lesion is accompanied by a serous-purulent discharge, redness, and presence or not of lid edema (219). Mucosal forms are frequently accompanied by preauricular and submandibular lymph node enlargement (93, 219). These signs can be a consequence of self-inoculation through hands contaminated with the fungus, hematogenous dissemination, and inhalation of conidia (18, 20, 93). Although rare, conjunctival and nasal mucosal involvement has been diagnosed even in pediatric patients (16, 218). In cats with sporotrichosis, the nose is the most affected region and respiratory signs are common (83, 222). As the owners play with their animals in close contact, transmission is made easier. Extracutaneous form. The extracutaneous forms are rare and difficult to diagnose, although they are more frequent after the onset of AIDS (31, 94, 234, 263). After the skin, bone tissue is the most affected. The osteoarticular form may occur by contiguity or hematogenous spread (120, 170). The lesions may vary from small granulomas to large lytic lesions identical to osteomyelitis (125). One or several joints and bones can be involved, as well as tenosynovitis or bursitis (115, 227). In immunocompetent patients, monoarthritis is more frequent than multiple articular involvement. The rarity of musculoskeletal disease in addition to the scarcity of fungal elements in synovial fluid culture and synovial histopathology often delays the diagnosis (11). According to Howell and Toohey, there were only 51 cases of sporothrical arthritis reported in the English literature up to 1998 (102). Primary pulmonary sporotrichosis, resulting from inhalation of the fungus, is usually associated with chronic obstructive pulmonary disease, alcoholism, chronic use of corticosteroids and, immunosuppressive diseases (189). The clinical presentation is similar to that of tuberculosis, and the diagnosis is often delayed due to the rarity of pulmonary involvement. Radiological patterns include cavitary disease, tracheobronchial lymph nodes enlargement, and nodular lesions (183). Systemic sporotrichosis is extremely rare and always associated with immune system deficiency. De Beurmann and Gougerot (51) had suggested that sporotrichosis could be considered an opportunistic disease. Most of their patients had some comorbidity, and all cases with the extracutaneous form presented impaired health or malnutrition. Reports on meningitis associated with Sporothrix infection are not frequent, and these cases are often associated with immunological impairment, mainly after onset of HIV infection. Diagnosis of this form of chronic meningitis is challenging because of the rarity of demonstration of Sporothrix schenckii in smears of cerebrospinal fluid and the difficulty in isolating the yeast on culture. Thus, any other method that provides early and specific diagnosis, such as antibody detection in cerebrospinal fluid, may be helpful in the diagnosis (23, 228). According to Salaki et al. (209), there has been a marked increase in the number of reported cases of meningitis and brain abscess due to fungi and yeasts. This increase is due in part to better diagnostic techniques and greater awareness of the possibility
CLIN. MICROBIOL. REV.
of fungal invasion of the nervous system, but the increase can also be attributed to a growing pool of severely compromised hosts. Besides AIDS, other conditions such as diabetes, alcoholism, granulomatous diseases, cirrhosis, renal transplantation, malignancies, corticosteroids, and use of immunosuppressive agents are commonly reported in patients with extracutaneous sporotrichosis (72, 82, 85). HIV-infected patients with preserved immunity seem to respond to infection by Sporothrix schenckii in the same way as individuals without coinfection (220). In patients with AIDS, sporotrichosis assumes the role of an opportunistic disease, with severe cases, systemic involvement, and often spread to the meninges (263). Skin lesions may be atypical, with a minimal inflammatory response (114). There are cases of disseminated sporotrichosis described in the literature as the first manifestation of AIDS (8) and associated with immune reconstitution inflammatory syndrome (76, 87). Associated signs and symptoms. Erythema nodosum and erythema multiforme have been reported in cases of sporotrichosis by zoonotic transmission. These conditions appear to be associated with a hypersensitivity reaction, resulting from continuous exposure to large amounts of fungus and subclinical reinfections (86, 89). Differential diagnosis. The differential diagnoses should be considered in accordance with the diversity of clinical forms and the morphology of the lesions. In the fixed form, the main differential diagnosis is cutaneous leishmaniasis. A study with application of the Montenegro skin test in 107 cases of sporotrichosis in Rio de Janeiro from 1998 to 2001 produced 48.6% positivity (21). In such cases, only mycological and parasitological examinations can establish a definitive diagnosis. Apart from cutaneous leishmaniasis, other causes, including noninfectious skin ulcers, should be considered. In the lymphocutaneous form, other disorders that present nodular lymphangitis should be investigated (58, 253), particularly mycobacteriosis. Among the mycobacteria, Mycobacterium marinum infection often accompanies lymphocutaneous lesions. There has been a report of sporotrichoid infection caused by Mycobacterium fortuitum in a pregnant woman (208). Nocardiosis (caused mainly by Nocardia brasiliensis), chromoblastomycosis, cryptococcosis, blastomycosis, and cat scratch disease also can be differential diagnoses. Sporotrichosis can also mimic cutaneous bacterial infections, sarcoidosis, lupus vulgaris, tuberculosis, and scrofuloderma, among others (11, 188, 268). These conditions should be differentiated by history, areas of endemicity, and lab tests. Feline Disease De Beurmann et al. (52) experimentally demonstrated the susceptibility of cats to S. schenckii in 1909. However, naturally acquired feline sporotrichosis was reported only in 1952 by Singer and Muncie (236). Sporotrichosis in cats has been considered to be sporadic and transmission to humans to be accidental (61). In 1998 the first epizootic of cat sporotrichosis was detected. By December 2010, over 3,000 cases in cats were diagnosed at Fiocruz/Rio de Janeiro (19). A study by Schubach et al. evaluated 337 cats with sporotrichosis diagnosed by isolation of S. schenckii in culture, 10 asymptomatic cat carriers, and 91 asymptomatic apparently healthy cats in the period
VOL. 24, 2011
SPOROTHRIX SCHENCKII AND SPOROTRICHOSIS
from 1998 to 2001 (221, 222). In those 4 years of monitoring the epidemic, there was a broad spectrum in clinical presentation, ranging from subclinical infection to single lesions with spontaneous regression to fatal systemic forms. The lymphocutaneous form was determined in only 19.3% of the cases, the involvement of the mucous membranes of the respiratory tract and upper digestive tract in 34.9%, and multiple cutaneous lesions in 39.5% (222). Systemic disease was demonstrated by in vivo detection of S. schenckii in the skin and various internal organs in 10 cats necropsied (225). In cats, unlike in humans, the low frequency of granuloma (12%) and the richness of fungal elements found in the histopathology of the skin demonstrate the increased susceptibility of animals to S. schenckii (222). An evaluation of 142 cats with sporotrichosis regarding feline immunodeficiency virus (FIV) and/or feline leukemia virus (FeLV) infection revealed 21.8% positivity (222). There were no significant differences in clinical and laboratory profiles between animals coinfected and not coinfected with FIV and/or FeLV. Unlike in humans, in whom disseminated sporotrichosis typically affects immunocompromised individuals, systemic disease in cats was frequent and was not associated with immunodeficiency caused by FIV and/or FeLV. TREATMENT Potassium iodide has been traditionally used in the treatment of sporotrichosis since the early 20th century, with satisfactory results (51). Some suggest that this salt acts on the resolution of granulomas through increased proteolysis (196), while others claim that it promotes an increase of phagocytosis. However, the exact mechanism of action remains unknown. Due to adverse effects related to this medication, in the 1990s the azole compounds were introduced, and itraconazole is currently the first-choice treatment (115). Itraconazole has been used effectively and safely in most cases of sporotrichosis, with low toxicity and good tolerance, even in long-term treatments. The dose varies from 100 to 200 mg/day orally for cutaneous and lymphocutaneous forms. A dose of 400 mg/day orally should be administered for cutaneous forms with a poor initial response to a lower dosage, for osteoarticular forms, for pulmonary forms, and as suppressive therapy in immunocompromised patients after induction with amphotericin B. For children weighing up to 20 kg, 5 to 10 mg/kg/day is recommended. Itraconazole is metabolized by the cytochrome P450 3A4 and has numerous drug interactions associated with the inhibition or induction of this system. The drug is contraindicated in pregnancy, and women of childbearing age should be counseled in favor of effective contraceptive methods. The safety and efficacy of itraconazole were evaluated in 645 patients with culture-proven sporotrichosis from Rio de Janeiro, Brazil. Six hundred ten (94.6%) of the patients were cured with itraconazole (50 to 400 mg/day), 547 with 100 mg/day, 59 with 200 to 400 mg/day, and 4 children with 50 mg/day. Four hundred sixty-two (71.6%) completed clinical follow-up for 3 to 6 months, and all remained cured. This study highlighted the good response to a minimal dose of itraconazole (55). Several reports have demonstrated the excellent efficacy and tolerability of the drug, even for the disseminated cutaneous and extracutaneous forms (119, 149, 165, 239, 268). The intermittent
647
administration of itraconazole in pulses of 400 mg/day orally for 1 week has also been studied (27). A randomized controlled study comparing the safety and efficacy of an itraconazole pulse regimen to a continuous regimen for cutaneous sporotrichosis found similar results for both groups (238). Potassium iodide and itraconazole are contraindicated in pregnant women. These patients can use thermotherapy with daily application of local heat (42 to 43°C) through a hot water bag, a source of infrared, or a similar method until healing of the lesions (115). The mechanism of action of local heat has been demonstrated in the laboratory. When cells of S. schenckii in serum are incubated with neutrophils at 40°C and 37°C, there is no difference related to phagocytosis in the two groups. However, once the cells are phagocytosed, the death rate of the fungus is higher at 40°C than at 37°C (99). Amphotericin B has been given for initial treatment of disseminated forms, particularly in immunocompromised subjects (115). Patients coinfected with HIV should subsequently receive suppressive therapy with itraconazole until immune system restoration. In pregnant women, amphotericin B may be used after 12 weeks of pregnancy, but this medication is to be reserved for pulmonary and disseminated forms for which treatment cannot be delayed. Fluconazole is less effective than itraconazole and is given to patients who do not tolerate or have drug interactions with itraconazole. Ketoconazole, in addition to having greater toxicity, has not demonstrated a good response (115). Susceptibility studies concerning good in vitro activity of terbinafine and posaconazole against Sporothrix schenckii have been encouraging (157, 235). The three studies using terbinafine in human patients demonstrated a good efficacy for doses ranging from 250 to 1,000 mg/day (43, 73, 74). A study comparing 250 mg/day of terbinafine to 100 mg/day of itraconazole resulted in healing in 92.7% and 92% of patients, respectively, indicating terbinafine to be an effective and well-tolerated option for the treatment of cutaneous sporotrichosis (73). However, the cost, which is even higher than that of itraconazole, is a barrier for developing countries. Posaconazole is a broadspectrum triazole, but its use in clinical sporotrichosis is yet to be evaluated (214, 235). Susceptibility testing with voriconazole, ravuconazole, micafungin, and other new antifungal agents is still incipient, and so far there is no indication for use of these drugs for the treatment of sporotrichosis (9, 169, 178, 233). There are studies showing different results for the same antifungal agent according to geographic area, the species of Sporothrix, and the method used (9, 88, 169). Antifungal Susceptibility Tests Nowadays, there is an ever-increasing interest in testing the susceptibilities of filamentous and yeast fungal pathogens to the available antifungal drugs (80). Of the available methods, two are standardized for S. schenckii testing. The Clinical and Laboratory Standards Institute (CLSI) proposes a microdilution test with a test inoculum of 0.4 ⫻ 104 to 5 ⫻ 104 CFU/ml, rendered from a 7-day-old S. schenckii filamentous colony, used to inoculate RPMI 1640 medium, where antifungal drugs are serially diluted and, after 46 to 50 h of incubation at 35°C without agitation, MICs determined (46). Another protocol for S. schenckii antifungal susceptibility testing was elaborated by the European Committee for Antimicrobial Susceptibility
648
BARROS ET AL.
CLIN. MICROBIOL. REV.
TABLE 1. MIC ranges for 13 antifungal drugs against S. schenckii described in various publicationsa Reference
64 106 155 172 121 179 169 81 258 122 10 157 91 152 208 235
Location
USA UK Not reported Japan Brazil USA Peru Mexico Brazil Brazil Peru Brazil Brazil/Spain Several Not reported Several
MIC (g/ml)b
No. of strains analyzed
AMB
FLC
ITR
KET
VOR
5 10 100 7 30 3 22 15 34 43 19 12 88 92 10 62
0.5–16 0.5–4 0.25–2 1–2 NT 1–4 NT NT 1–4 0.5–8 0.06–⬎16 NT 0.12–4 0.5–32 NT 0.03–16
64 NT NT ⬎64 NT NT NT ⬎64 ⬎64 NT ⬎64 NT 64 128 NT NT
0.03–16 0.06–⬎16 0.03–8 0.5–1 0.06–4 NT 0.06–1 0.25–2 0.25–⬎16 0.25–4 0.25–1 0.2–1.75 0.12–⬎8 0.5–32 0.5–2 0.03–2
0.25–4 NT NT NT NT NT NT NT 0.03–16 NT 0.06–0.5c NT NT 0.06–8 NT NT
NT 0.12–⬎16 0.5–8 NT NT ⬎16 2–16 1–4 0.5–⬎16 NT 4–16 NT 1–⬎8 0.5–32 NT NT
a
Results were obtained by microdilution reference methods unless otherwise specified. AMB, amphotericin B; FLC, fluconazole; ITR, itraconazole; KET, ketoconazole; VOR, voriconazole; MFG, micafungin; ADF, anidulafungin; TRB, terbinafine; 5FC, 5-fluorocytosine; RVC, ravuconazole; POS, posaconazole; ABC, albaconazole; EBC, eberconazole; NT, not tested. c The MIC was determined by the Etest method. b
Testing (EUCAST), which uses final test inoculums of 1 ⫻ 105 to 2.5 ⫻ 105 CFU/ml obtained from 2- to 5-day-old cultures to inoculate microplates with RPMI 1640 supplemented with 2% glucose. The endpoint is read visually after a 48 h of incubation at 35 ⫾ 2°C (201). Commercial methods for S. schenckii susceptibility testing, however, have been adopted by some investigators. The Etest technique shows average agreement rates of 77.5% and 87.8% for amphotericin B and fluconazole, respectively, but for itraconazole and voriconazole agreement is lower, with values of 56.4% and 54.5%, respectively. MIC values for itraconazole and voriconazole determined by Etest were significantly lower than those obtained by microdilution (87). The Sensititre YeastOne and ATB Fungus 2 methods compared with CLSI M38-A2 show high agreement with microdilution for fluconazole, itraconazole, and 5-fluorocytosine, but for amphotericin B and voriconazole, agreement is lower (9). Up to now, breakpoints have not been established for molds, including the dimorphic fungus S. schenckii. However, studies showed that MICs of below 1 g/ml are usually found for Scedosporium apiospermum and Paecilomyces lilacinus with posaconazole and voriconazole, for Alternaria spp. and Bipolaris spicifera with posaconazole, voriconazole, and itraconazole, for zygomycetes with amphotericin B and posaconazole, and for Aspergillus spp. with posaconazole, voriconazole, itraconazole, amphotericin, and caspofungin. Based on this, isolates can be grouped as susceptible (MIC ⱕ 1 g/ml), intermediate (MIC ⫽ 2 g/ml), or resistant (MIC ⱖ 4 g/ml) only for analytical purposes. Breakpoints with proven relevance have yet to be identified by the regulatory agencies (46). Despite the use of the nonparasitic S. schenckii mycelial phase in standardized methods, some studies have compared susceptibilities for the mycelial and yeast fungal morphological phases. Agreements of above 80% were found for amphotericin B, fluconazole, itraconazole, ravuconazole, and terbinafine. For posaconazole, an agreement of 76.5% was found for mycelial and yeast forms, and only 47.6% was verified for
voriconazole (87) in a study with Brazilian and Spanish S. schenckii strains. Another study found similar MICs for itraconazole and terbinafine, although the MIC of amphotericin B was slightly higher for mycelia (122). It has been also demonstrated that micafungin is more active against the mycelial than the yeast S. schenckii form (172). Table 1 displays the MIC range for several drugs tested in 16 different studies concerning S. schenckii susceptibility profiles. Since the methodologies used in these studies may have slight differences, comparison of results is difficult. However, some conclusions can be reached. MICs for S. schenckii show high variability (63), as we can see in studies on itraconazole susceptibility. S. schenckii susceptibility to this triazole drug ranges from 0.03 to more than 16 g/ml. Although some strains can show resistance to this drug, geometric means commonly are low, ranging from 0.4 g/ml (9) to 4.08 g/ml (257). In general, despite the use of fluconazole as a therapeutic agent in some human and veterinary sporotrichosis cases (31, 50), this antifungal does not inhibit S. schenckii growth in vitro (9, 63, 90, 152, 172, 257). Some S. schenckii strains are susceptible to voriconazole in vitro, since MIC values of as low as 0.12 g/ml have been found (107); however, the high geometric mean MIC values, ranging from 6.50 g/ml (155) to 13.2 g/ml (152), suggest that most isolates are resistant in vitro to this drug. High micafungin MIC values have been reported by all but one study (152, 172, 207, 257). However, the interaction of micafungin and itraconazole shows a synergy against S. schenckii (207). The geographic distribution of S. schenckii strains also appears to play an important role in antifungal susceptibility. Strains from the sporotrichosis area of endemicity in Rio de Janeiro are more susceptible to itraconazole and terbinafine than strains from Spain or Sa˜o Paulo, a neighbor state Rio de Janeiro in Brazil (90). Low terbinafine MIC values were described for strains from Venezuela, and high minimal fungicidal concentration values for posaconazole were found in Peruvian strains (235). This behavior must be related to differences in susceptibility of the newly characterized species
VOL. 24, 2011
SPOROTHRIX SCHENCKII AND SPOROTRICHOSIS
649
TABLE 1—Continued MIC (g/ml)b MFG
ADF
TRB
5FC
RVC
POS
ABC
EBC
NT NT NT 0.5–1 NT NT NT NT ⬎128 NT NT NT NT 256 2–64 NT
NT NT NT NT NT 2–4 NT NT NT NT NT NT NT NT NT NT
NT NT NT NT 0.007–0.5 NT NT NT 0.12–4 0.015–1 NT 0.05–0.875 0.02–⬎16 0.06–4 NT 0.03–1
NT NT NT NT NT NT NT NT 16–⬎64 NT 4–⬎64 NT 4–⬎64 1–128 NT NT
NT NT NT NT NT NT NT 0.5–4 1–16 NT NT NT 0.12–⬎8 0.06–32 NT NT
NT NT NT NT NT NT NT 1–4 NT NT NT NT 0.06–⬎8 0.25–16 NT 0.03–2
NT NT NT NT NT NT NT NT 0.12–16 NT NT NT NT 0.25–32 NT NT
NT NT NT NT NT NT NT NT 0.06–4 NT NT NT NT 0.06–32 NT NT
from the Sporothrix complex. In fact, S. mexicana shows high MIC values of amphotericin B and several azoles, being susceptible to terbinafine only. S. brasiliensis also is more susceptible to azole drugs than the other species (152). PREVENTION Most cases of sporotrichosis occur when the fungus is introduced through a cut or puncture in the skin while handling vegetation or organic matter containing the fungal spores. Control measures include wearing gloves and long sleeves during high-risk activities such as handling sphagnum moss, wires, rose bushes, hay bales, conifer (pine) seedlings, or other materials that may facilitate the exposure to the fungus. A study by Hajjeh et al. (92) showed that the risk of sporotrichosis increased significantly with the duration of working with sphagnum moss, in particular with filling topiaries, and with having less gardening experience. Wearing gloves was protective. It is also advisable to wear heavy boots to prevent puncture wounds. Sporotrichosis in cats requires preventive measures to avoid transmission within the species and from animals to humans. Due to the itinerant nature of cats, where males frequently engage in disputes over females, infection is quite common. Cats with sporotrichosis should be correctly treated and kept isolated in a proper place. Any physical contact with the animal should be avoided until complete healing of the lesions. When handling the sick cat, during either injury treatment or medication administration, protocols must be adopted to reduce exposure to the fungus, such as using latex gloves. Another important measure is not to abandon the animal, as this facilitates the dissemination of the disease. In the case of cats with extensive lesions and no possibility of treatment, euthanasia and cremation of the body should be standard procedures in a veterinary health centers. Castration encumbers the instinct for hunting, mating, and roaming the neighborhood, therefore reducing the chance of transmission of the mycosis. Some intervention in the environment may be necessary, such as cleaning yards and removing remnants of construction materials and decaying organic matter debris. Only the treatment of
sick cats and measures regarding feline sporotrichosis will afford zoonotic transmission control (19). ACKNOWLEDGMENTS We thank Rosani Santos Reis, who kindly provided Fig. 5. This study was partially supported by the Conselho Nacional de Desenvolvimento Cientı´fico e Technolo ´gico (CNPq), Brazil, by the programa de Apoio a Pesquisa Estrate´gica em Sau ´de (PAPES)— Fundac¸˜ao Oswaldo Cruz (Fiocruz)/CNPq, and by the Fundac¸˜ao de Apoia a Pesquisa do Estado do Rio de Janeiro (FAPERJ), Brazil. REFERENCES 1. Ahearn, D. G., and W. Kaplan. 1969. Occurrence of Sporotrichum schenckii on a cold-stored meat product. Am. J. Epidemiol. 89:116–124. 2. Albornoz, M. B., E. Villanueva, and E. D. Torres. 1984. Application of immunoprecipitation techniques to the diagnosis of cutaneous and extracutaneous forms of sporotrichosis. Mycopathologia 85:177–183. 3. Albuquerque, P. C., et al. 2008. Vesicular transport in Histoplasma capsulatum: an effective mechanism for trans-cell wall transfer of proteins and lipids in ascomycetes. Cell. Microbiol. 10:1695–1710. 4. Almeida, H. L., Jr, C. B. Lettnin, J. L. Barbosa, and M. C. Dias. 2009. Spontaneous resolution of zoonotic sporotrichosis during pregnancy. Rev. Inst. Med. Trop. Sao Paulo 51:237–238. 5. Almeida-Paes, R., et al. 2009. Growth conditions influence melanization of Brazilian clinical Sporothrix schenckii isolates. Microbes Infect. 11:554–562. 6. Almeida-Paes, R., M. A. Pimenta, P. C. Monteiro, J. D. Nosanchuk, and R. M. Zancope-Oliveira. 2007. Immunoglobulins G, M, and A against Sporothrix schenckii exoantigens in patients with sporotrichosis before and during treatment with itraconazole. Clin. Vaccine Immunol. 14:1149–1157. 7. Almeida-Paes, R., et al. 2007. Use of mycelial-phase Sporothrix schenckii exoantigens in an enzyme-linked immunosorbent assay for diagnosis of sporotrichosis by antibody detection. Clin. Vaccine Immunol. 14:244–249. 8. Al-Tawfiq, J. A., and K. K. Wools. 1998. Disseminated sporotrichosis and Sporothrix schenckii fungemia as the initial presentation of human immunodeficiency virus infection. Clin. Infect. Dis. 26:1403–1406. 9. Alvarado-Ramirez, E., and J. M. Torres-Rodriguez. 2007. In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods. Antimicrob. Agents Chemother. 51:2420–2423. 10. Alves, S. H., et al. 2010. Sporothrix schenckii associated with armadillo hunting in Southern Brazil: epidemiological and antifungal susceptibility profiles. Rev. Soc. Bras. Med. Trop. 43:523–525. 11. Appenzeller, S., et al. 2006. Sporothrix schenckii infection presented as monoarthritis: report of two cases and review of the literature. Clin. Rheumatol. 25:926–928. 12. Area-Lea ˜o, A. E., and M. Goto. 1946. Esporotricose. Observac¸˜ao e estudo de um novo caso. Hospital 30:409–417. 13. Arenas, R., D. Miller, and P. Campos-Macias. 2007. Epidemiological data and molecular characterization (mtDNA) of Sporothrix schenckii in 13 cases from Mexico. Int. J. Dermatol. 46:177–179. 14. Arrillaga-Moncrieff, I., et al. 2009. Different virulence levels of the species of Sporothrix in a murine model. Clin. Microbiol. Infect. 15:651–655.
650
BARROS ET AL.
15. Barba Borrego, J. A., J. Mayorga, and V. M. Tarango-Martinez. 2009. Esporotricosis linfangitica bilateral y simultanea. Rev. Iberoam. Micol. 26:247–249. 16. Barros, M. B., et al. 2008. Endemic of zoonotic sporotrichosis: profile of cases in children. Pediatr. Infect. Dis. J. 27:246–250. 17. Barros, M. B. L., A. O. Schubach, A. C. do Valle, et al. 2004. Cat-transmitted sporotrichosis epidemic in Rio de Janeiro, Brazil: description of a series of cases. Clin. Infect. Dis. 38:529–535. 18. Barros, M. B. L., A. O. Schubach, T. M. Schubach, B. Wanke, and S. R. Lambert-Passos. 2008. An epidemic of sporotrichosis in Rio de Janeiro, Brazil: epidemiological aspects of a series of cases. Epidemiol. Infect. 136: 1192–1196. 19. Barros, M. B. L., et al. 2010. Esporotricose: a evoluc¸˜ao e os desafios de uma epidemia. Rev. Panam. Salud Publ. 27:455–460. 20. Barros, M. B. L., et al. 2003. Sporotrichosis with widespread cutaneous lesions: report of 24 cases related to transmission by domestic cats in Rio de Janeiro, Brazil. Int. J. Dermatol. 42:677–681. 21. Barros, M. B. L., A. Schubach, A. C. Francesconi-do-Valle, et al. 2005. Positive Montenegro skin test among patients with sporotrichosis in Rio De Janeiro. Acta Trop. 93:41–47. 22. Berbee, M. L., and J. W. Taylor. 1992. Convergence in ascospore discharge mechanism among pyrenomycete fungi based on 18S ribosomal RNA gene sequence. Mol. Phylogenet. Evol. 1:59–71. 23. Bernardes-Engemann, A. R., et al. 2005. Development of an enzyme-linked immunosorbent assay for the serodiagnosis of several clinical forms of sporotrichosis. Med. Mycol. 43:487–493. 24. Bernardes-Engemann, A. R., et al. 2009. A comparative serological study of the SsCBF antigenic fraction isolated from three Sporothrix schenckii strains. Med. Mycol. 47:874–878. 25. Betancourt, S., L. J. Torres-Bauza, and N. Rodriguez-Del Valle. 1985. Molecular and cellular events during the yeast to mycelium transition in Sporothrix schenckii. Sabouraudia 23:207–218. 26. Blumer, S. O., L. Kaufman, W. Kaplan, D. W. McLaughlin, and D. E. Kraft. 1973. Comparative evaluation of five serological methods for the diagnosis of sporotrichosis. Appl. Microbiol. 26:4–8. 27. Bonifaz, A., L. Fierro, A. Saul, and R. M. Ponce. 2008. Cutaneous sporotrichosis. Intermittent treatment (pulses) with itraconazole. Eur. J. Dermatol. 18:61–64. 28. Bonifaz, A., et al. 2007. Sporotrichosis in childhood: clinical and therapeutic experience in 25 patients. Pediatr. Dermatol. 24:369–372. 29. Brito, M. M., et al. 2007. Comparison of virulence of different Sporothrix schenckii clinical isolates using experimental murine model. Med. Mycol. 45:721–729. 30. Bustamante, B., and P. E. Campos. 2001. Endemic sporotrichosis. Curr. Opin. Infect. Dis. 14:145–149. 31. Callens, S. F., et al. 2006. Pulmonary Sporothrix schenckii infection in a HIV positive child. J. Trop. Pediatr. 52:144–146. 32. Carlos, I. Z., M. F. Sassa, D. B. da Graca Sgarbi, M. C. Placeres, and D. C. Maia. 2009. Current research on the immune response to experimental sporotrichosis. Mycopathologia 168:1–10. 33. Carlos, I. Z., D. B. Sgarbi, J. Angluster, C. S. Alviano, and C. L. Silva. 1992. Detection of cellular immunity with the soluble antigen of the fungus Sporothrix schenckii in the systemic form of the disease. Mycopathologia 117:139–144. 34. Carlos, I. Z., D. B. Sgarbi, and M. C. Placeres. 1998. Host organism defense by a peptide-polysaccharide extracted from the fungus Sporothrix schenckii. Mycopathologia 144:9–14. 35. Carlos, I. Z., D. B. Sgarbi, G. C. Santos, and M. C. Placeres. 2003. Sporothrix schenckii lipid inhibits macrophage phagocytosis: involvement of nitric oxide and tumour necrosis factor-alpha. Scand. J. Immunol. 57:214–220. 36. Carlos, I. Z., et al. 1994. Disturbances in the production of interleukin-1 and tumor necrosis factor in disseminated murine sporotrichosis. Mycopathologia 127:189–194. 37. Carmichael, J. W. 1962. Chrysosporium and some other aleuriosporic Hyphomycetes. Can. J. Bot. 40:1137–1173. 38. Carvalho, L. P., et al. 2007. Differential immune regulation of activated T cells between cutaneous and mucosal leishmaniasis as a model for pathogenesis. Parasite Immunol. 29:251–258. 39. Carvalho, M. T., et al. 2002. Disseminated cutaneous sporotrichosis in a patient with AIDS: report of a case. Rev. Soc. Bras. Med. Trop. 35:655–659. 40. Casadevall, A. 2006. Cards of virulence and the global virulome for humans. Microbe 1:359–364. 41. Casserone, S., I. A. Conti-Diaz, E. Zanetta, and M. E. P. Pereira. 1983. Serologia de la esporotricosis cutaˆnea. Sabouraudia 21:317–321. 42. Centers for Disease Control and Prevention. 1988. Multistate outbreak of sporotrichosis in seedling handlers. Morb. Mortal. Wkly. Rep. 37:652–653. 43. Chapman, S. W., et al. 2004. Comparative evaluation of the efficacy and safety of two doses of terbinafine (500 and 1000 mg day(⫺1)) in the treatment of cutaneous or lymphocutaneous sporotrichosis. Mycoses 47: 62–68. 44. Chua, S. S., M. Momany, L. Mendoza, and P. J. Szaniszlo. 1994. Identifi-
CLIN. MICROBIOL. REV.
45.
46.
47. 48. 49.
50.
51. 52. 53. 54.
55. 56.
57.
58. 59.
60.
61.
62. 63.
64.
65.
66.
67.
68. 69.
70.
71. 72. 73.
cation of three chitin synthase genes in the dimorphic fungal pathogen Sporothrix schenckii. Curr. Microbiol. 29:151–156. Civila, E. S., J. Bonasse, I. A. Conti-Diaz, and R. A. Vignale. 2004. Importance of the direct fresh examination in the diagnosis of cutaneous sporotrichosis. Int. J. Dermatol. 43:808–810. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dillution antifungal susceptibility testing of filamentous fungi; approved standard, 2nd ed. Clinical and Laboratory Standards Institute, Wayne, PA. Conti Diaz, I. A. 1989. Epidemiology of sporotrichosis in Latin America. Mycopathologia 108:113–116. Cooper, C. R., D. M. Dixon, and I. F. Salkin. 1992. Laboratory-acquired sporotrichosis. J. Med. Vet. Mycol. 30:169–171. Criseo, G., G. Malara, O. Romeo, and A. Puglisi Guerra. 2008. Lymphocutaneous sporotrichosis in an immunocompetent patient: a case report from extreme southern Italy. Mycopathologia 166:159–162. Crothers, S. L., S. D. White, P. J. Ihrke, and V. K. Affolter. 2009. Sporotrichosis: a retrospective evaluation of 23 cases seen in northern California (1987–2007). Vet. Dermatol. 20:249–259. De Beurmann, L., and H. Gougerot. 1912. Les sporotrichoses. Librarie Fe´lix Alcan, Paris, France. De Beurmann, L., H. Gougerot, and A. B. Vaucher. 1909. Sporotichoses cutane´es du chat. C. R. Soc. Biol. 66:370–372. de Hoog, G. S., and J. Guarro. 1995. Atlas of clinical fungi. Centraalbureau voor Shimmelcultures, Baarn and Delft, The Netherlands. de Hoog, G. S., and R. G. Vitale. 2007. Bipolaris, Exophiala, Scedosporium, Sporothrix and other dematiaceous fungi, p. 1898–1917. In P. R. Murray, E. J. Baron, J. H. Jorgensen, M. L. Landry, and M. A. Pfaller (ed.), Manual of clinical microbiology, 9th ed., vol. 2. ASM Press, Washington, DC. de Lima Barros, M. B., et al. 2011. Treatment of cutaneous sporotrichosis with itraconazole—study of 645 patients. Clin. Infect. Dis. 52:e200–e206. de Meyer, E. M., et al. 2008. Taxonomy and phylogeny of new wood- and soil-inhabiting Sporothrix species in the Ophiostoma stenoceras-Sporothrix schenckii complex. Mycologia 100:647–661. de Miranda, L. H., L. P. Quintella, I. B. dos Santos, et al. 2009. Histopathology of canine sporotrichosis: a morphological study of 86 cases from Rio de Janeiro (2001-2007). Mycopathologia 168:79–87. DiNubile, M. J. 2008. Nodular lymphangitis: a distinctive clinical entity with finite etiologies. Curr. Infect. Dis. Rep. 10:404–410. Dixon, D. M., R. A. Duncan, and N. J. Hurd. 1992. Use of a mouse model to evaluate clinical and environmental isolates of Sporothrix spp. from the largest U.S. epidemic of sporotrichosis. J. Clin. Microbiol. 30:951–954. Dixon, D. M., et al. 1991. Isolation and characterization of Sporothrix schenckii from clinical and environmental sources associated with the largest U.S. epidemic of sporotrichosis. J. Clin. Microbiol. 29:1106–1113. Dunstan, R. W., R. F. Langham, K. A. Reimann, and P. S. Wakenell. 1986. Feline sporotrichosis: a report of five cases with transmission to humans. J. Am. Acad. Dermatol. 15:37–45. Engle, J., J. Desir, and J. M. Bernstein. 2007. A rose by any other name. Skinmed 6:139–141. Espinel-Ingroff, A., et al. 1995. Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi. Antimicrob. Agents Chemother. 39:314–319. Feeney, K. T., I. H. Arthur, A. J. Whittle, S. A. Altman, and D. J. Speers. 2007. Outbreak of sporotrichosis, Western Australia. Emerg. Infect. Dis. 13:1228–1231. Fernandes, G. F., et al. 2011. Serodiagnosis of sporotrichosis infection in cats by enzyme-linked immunosorbent assay using a specific antigen, SsCBF, and crude exoantigens. Vet. Microbiol. 147:445–449. Fernandes, K. S., A. L. Coelho, L. M. Lopes Bezerra, and C. Barja-Fidalgo. 2000. Virulence of Sporothrix schenckii conidia and yeast cells, and their susceptibility to nitric oxide. Immunology 101:563–569. Fernandes, K. S., H. L. Mathews, and L. M. Lopes Bezerra. 1999. Differences in virulence of Sporothrix schenckii conidia related to culture conditions and cell-wall components. J. Med. Microbiol. 48:195–203. Fernandes, K. S., et al. 2008. Detrimental role of endogenous nitric oxide in host defence against Sporothrix schenckii. Immunology 123:469–479. Figueiredo, C. C., O. C. De Lima, L. De Carvalho, L. M. Lopes-Bezerra, and V. Morandi. 2004. The in vitro interaction of Sporothrix schenckii with human endothelial cells is modulated by cytokines and involves endothelial surface molecules. Microb. Pathog. 36:177–188. Figueiredo, C. C., P. M. Deccache, L. M. Lopes-Bezerra, and V. Morandi. 2007. TGF-beta1 induces transendothelial migration of the pathogenic fungus Sporothrix schenckii by a paracellular route involving extracellular matrix proteins. Microbiology 153:2910–2921. Flournoy, D. J., J. B. Mullins, and R. J. McNeal. 2000. Isolation of fungi from rose bush thorns. J. Okla. State Med. Assoc. 93:271–274. Fonseca-Reyes, S., et al. 2007. Extracutaneous sporotrichosis in a patient with liver cirrhosis. Rev. Iberoam. Micol. 24:41–43. Francesconi, G., A. C. Francesconi do Valle, et al. 2011. Comparative study of 250 mg/day terbinafine and 100 mg/day itraconazole for the treatment of cutaneous sporotrichosis. Mycopathologia 171:349–354.
VOL. 24, 2011 74. Francesconi, G., A. C. Valle, S. Passos, R. Reis, and M. C. Galhardo. 2009. Terbinafine (250 mg/day): an effective and safe treatment of cutaneous sporotrichosis. J. Eur. Acad. Dermatol. Venereol. 23:1273–1276. 75. Fujii, H., et al. 2008. A case of atypical sporotrichosis with multifocal cutaneous ulcers. Clin. Exp. Dermatol. 33:135–138. 76. Galhardo, M. C., et al. 2010. Sporothrix schenckii meningitis in AIDS during immune reconstitution syndrome. J. Neurol. Neurosurg Psych. 81:696–699. 77. Garrison, R. G., K. S. Boyd, and F. Mariat. 1975. Ultrastructural studies of the mycelium-to yeast transformation of Sporothrix schenckii. J. Bacteriol. 124:959–968. 78. Gezuele, E., and D. Da Rosa. 2005. Relevancia del cuerpo asteroide esporotricosico en el diagnostico rapido de la esporotricosis. Rev. Iberoam. Micol. 22:147–150. 79. Ghosh, A., P. K. Maity, B. M. Hemashettar, V. K. Sharma, and A. Chakrabarti. 2002. Physiological characters of Sporothrix schenckii isolates. Mycoses 45:449–454. 80. Gonzalez, G. M., A. W. Fothergill, D. A. Sutton, M. G. Rinaldi, and D. Loebenberg. 2005. In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi. Med. Mycol. 43:281–284. 81. Gordon, M. A., E. W. Lapa, M. S. Fitter, and M. Lindsay. 1980. Susceptibility of zoopathogenic fungi to phytoalexins. Antimicrob. Agents Chemother. 17:120–123. 82. Gottlieb, G. S., C. F. Lesser, K. K. Holmes, and A. Wald. 2003. Disseminated sporotrichosis associated with treatment with immunosuppressants and tumor necrosis factor-alpha antagonists. Clin. Infect. Dis. 37:838–840. 83. Gremiao, I. D., et al. 2009. Intralesional amphotericin B in a cat with refractory localised sporotrichosis. J. Feline Med. Surg. 11:720–723. 84. Guarro, J., J. Gene, and A. M. Stchigel. 1999. Developments in fungal taxonomy. Clin. Microbiol. Rev. 12:454–500. 85. Gullberg, R. M., A. Quintanilla, M. L. Levin, J. Williams, and J. P. Phair. 1987. Sporotrichosis: recurrent cutaneous, articular, and central nervous system infection in a renal transplant recipient. Rev. Infect. Dis. 9:369–375. 86. Gutierrez-Galhardo, M. C., et al. 2005. Erythema multiforme associated with sporotrichosis. J. Eur. Acad. Dermatol. Venereol. 19:507–509. 87. Gutierrez-Galhardo, M. C., A. C. do Valle, et al. 2010. Disseminated sporotrichosis as a manifestation of immune reconstitution inflammatory syndrome. Mycoses 53:78–80. 88. Gutierrez-Galhardo, M. C., R. M. Zancope-Oliveira, A. Monzon, J. L. Rodriguez-Tudela, and M. Cuenca-Estrella. 2010. Antifungal susceptibility profile in vitro of Sporothrix schenckii in two growth phases and by two methods: microdilution and E-test. Mycoses 53:227–231. 89. Gutierrez Galhardo, M. C., et al. 2002. Erythema nodosum associated with sporotrichosis. Int. J. Dermatol. 41:114–116. 90. Gutierrez Galhardo, M. C., et al. 2008. Molecular epidemiology and antifungal susceptibility patterns of Sporothrix schenckii isolates from a cattransmitted epidemic of sporotrichosis in Rio de Janeiro, Brazil. Med. Mycol. 46:141–151. 91. Haddad, V. J., H. A. Miot, L. D. Bartoli, C. Cardoso Ade, and R. M. de Camargo. 2002. Localized lymphatic sporotrichosis after fish-induced injury (Tilapia sp.). Med. Mycol. 40:425–427. 92. Hajjeh, R., et al. 1997. Outbreak of sporotrichosis among tree nursery workers. J. Infect. Dis. 176:499–504. 93. Hampton, D. E., A. Adesina, and J. Chodosh. 2002. Conjunctival sporotrichosis in the absence of antecedent trauma. Cornea 21:831–833. 94. Hardman, S., I. Stephenson, D. R. Jenkins, M. J. Wiselka, and E. M. Johnson. 2005. Disseminated Sporothix schenckii in a patient with AIDS. J. Infect. 51:e73–77. 95. Hektoen, L., and C. F. Perkins. 1900. Refractory subcutaneous abscess caused by Sporothrix schenckii: a new pathogenic fungus. J. Exp. Med. 5:77–91. 96. Helm, M., and C. Berman. 1947. The clinical, therapeutic and epidemiological features of the sporotrichosis infection on the mines, p. 59–67. In Sporotrichosis infection on mines of the Witwatersrand. Proceedings of the Transvaal Mine Medical Officers’ Association, December 1944, Johannesburg, South Africa. The Transvaal Chamber of Mines, Johannesburg, South Africa. 97. Hintz, W. E. 1999. Sequence analysis of the chitin synthase A gene of the Dutch elm pathogen Ophiostoma novo-ulmi indicates a close association with the human pathogen Sporothrix schenckii. Gene 237:215–221. 98. Hirano, M., et al. 2006. A case of feline sporotrichosis. J. Vet. Med. Sci. 68:283–284. 99. Hiruma, M., T. Katoh, I. Yamamoto, and S. Kagawa. 1987. Local hyperthermia in the treatment of sporotrichosis. Mykosen 30:315–321. 100. Hogan, L. H., B. S. Klein, and S. M. Levitz. 1996. Virulence factors of medically important fungi. Clin. Microbiol. Rev. 9:469–488. 101. Howard, D. H., and G. F. Orr. 1963. Comparison of strains of Sporotrichum schenckii isolated from nature. J. Bacteriol. 85:816–821. 102. Howell, S. J., and J. S. Toohey. 1998. Sporotrichal arthritis in south central Kansas. Clin. Orthop. Relat. Res. 1998:207–214. 103. Ishizaki, H., et al. 2009. Mitochondrial DNA analysis of Sporothrix schenckii in India, Thailand, Brazil, Colombia, Guatemala and Mexico. Nippon Ishinkin Gakkai Zasshi 50:19–26.
SPOROTHRIX SCHENCKII AND SPOROTRICHOSIS
651
104. Ishizaki, H., et al. 2004. Mitochondrial DNA analysis of Sporothrix schenckii from China, Korea and Spain. Nippon Ishinkin Gakkai Zasshi 45:23–25. 105. Itoh, M., S. Okamoto, and H. Kariya. 1986. Survey of 200 cases of sporotrichosis. Dermatologica 172:209–213. 106. Jacobson, E. S. 2000. Pathogenic roles for fungal melanins. Clin. Microbiol. Rev. 13:708–717. 107. Johnson, E. M., A. Szekely, and D. W. Warnock. 1998. In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. J. Antimicrob. Chemother. 42:741–745. 108. Kajiwara, H., M. Saito, S. Ohga, T. Uenotsuchi, and S. Yoshida. 2004. Impaired host defense against Sporothrix schenckii in mice with chronic granulomatous disease. Infect. Immun. 72:5073–5079. 109. Kanbe, T., et al. 2005. Rapid and specific identification of Sporothrix schenckii by PCR targeting the DNA topoisomerase II gene. J. Dermatol. Sci. 38:99–106. 110. Kano, R., Y. Nakamura, S. Watanabe, H. Tsujimoto, and A. Hasegawa. 2001. Identification of Sporothrix schenckii based on sequences of the chitin synthase 1 gene. Mycoses 44:261–265. 111. Kaplan, W., J. R. Broderson, and J. N. Pacific. 1982. Spontaneous systemic sporotrichosis in nine-banded armadillos (Dasypus novemcinctus). Sabouraudia 20:289–294. 112. Karlin, J. V., and H. S. Nielsen, Jr. 1970. Serologic aspects of sporotrichosis. J. Infect. Dis. 121:316–327. 113. Kashima, T., R. Honma, S. Kishi, and J. Hirato. 2010. Bulbar conjunctival sporotrichosis presenting as a salmon-pink tumor. Cornea 29:573–576. 114. Kauffman, C. A. 1999. Sporotrichosis. Clin. Infect. Dis. 29:231–237. 115. Kauffman, C. A., B. Bustamante, S. W. Chapman, and P. G. Pappas. 2007. Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 45:1255–1265. 116. Kazanas, N. 1986. Foodborne Sporothrix schenckii: infectivity for mice by intraperitoneal and intragastric inoculation with conidia. Mycopathologia 95:3–16. 117. Kazanas, N., and G. J. Jackson. 1983. Sporothrix schenckii isolated from edible black fungus mushrooms. J. Food Prot. 46:714–716. 118. Kenyon, E. M., L. H. Russell, and D. N. McMurray. 1984. Isolation of Sporothrix schenckii from potting soil. Mycopathologia 87:128. 119. Kikuchi, I., K. Morimoto, S. Kawana, and H. Tanuma. 2006. Usefulness of itraconazole for sporotrichosis in Japan: study of three cases and literature comparison of therapeutic effects before and after release on the market. Eur. J. Dermatol. 16:42–47. 120. Kohler, L. M., J. S. Hamdan, and T. C. Ferrari. 2007. Successful treatment of a disseminated Sporothrix schenckii infection and in vitro analysis for antifungal susceptibility testing. Diagn. Microbiol. Infect. Dis. 58:117–120. 121. Kohler, L. M., P. C. Monteiro, R. C. Hahn, and J. S. Hamdan. 2004. In vitro susceptibilities of isolates of Sporothrix schenckii to itraconazole and terbinafine. J. Clin. Microbiol. 42:4319–4320. 122. Kohler, L. M., B. M. Soares, D. de Assis Santos, M. E. Da Silva Barros, and J. S. Hamdan. 2006. In vitro susceptibility of isolates of Sporothrix schenckii to amphotericin B, itraconazole, and terbinafine: comparison of yeast and mycelial forms. Can. J. Microbiol. 52:843–847. 123. Kong, X., T. Xiao, J. Lin, Y. Wang, and H. D. Chen. 2006. Relationships among genotypes, virulence and clinical forms of Sporothrix schenckii infection. Clin. Microbiol. Infect. 12:1077–1081. 124. Kovarik, C. L., E. Neyra, and B. Bustamante. 2008. Evaluation of cats as the source of endemic sporotrichosis in Peru. Med. Mycol. 46:53–56. 125. Kumar, R., E. van der Smissen, and J. Jorizzo. 1984. Systemic sporotrichosis with osteomyelitis. J. Can. Assoc. Radiol. 35:83–84. 126. Kwon-Chung, K. J., and J. E. Bennet. 1992. Medical mycology. Lea & Febiger, Philadelphia, PA. 127. Kwon-Chung, K. J., W. B. Hill, and J. E. Bennett. 1981. New, special stain for histopathological diagnosis of cryptococcosis. J. Clin. Microbiol. 13:383– 387. 128. Lacaz, C. S., E. Porto, E. M. Heins-Vaccari, and N. T. Melo. 1998. Guia para identificac¸˜ao: fungos, actinomicetos e algas de interesse me´dico. Sarvier, Sa˜o Paulo, Brazil. 129. Lacaz, C. S., E. Porto, J. E. C. Martins, E. M. Heins-Vaccari, and N. T. Melo. 2002. Tratado de micologia me´dica. Sarvier, Sa˜o Paulo, Brazil. 130. Larone, D. H. 2002. Medically important fungi: a guide to identification, 4th ed. ASM Press, Washington, DC. 131. Latge, J. P. 1999. Aspergillus fumigatus and aspergillosis. Clin. Microbiol. Rev. 12:310–350. 132. Lavalle, P., and F. Mariat. 1983. Sporotrichosis. Bull. Inst. Pasteur 81:295– 322. 133. Lima, O. C., et al. 2004. Immunofluorescence and flow cytometry analysis of fibronectin and laminin binding to Sporothrix schenckii yeast cells and conidia. Microb. Pathog. 37:131–140. 134. Lima, O. C., et al. 1999. Adhesion of the human pathogen Sporothrix schenckii to several extracellular matrix proteins. Braz. J. Med. Biol. Res. 32:651–657. 135. Lima, O. C., et al. 2001. Involvement of fungal cell wall components in
652
136. 137.
138.
139. 140.
141. 142.
143.
144.
145. 146.
147.
148.
149. 150.
151. 152.
153.
154.
155.
156.
157.
158. 159.
160.
161. 162.
163.
164.
BARROS ET AL. adhesion of Sporothrix schenckii to human fibronectin. Infect. Immun. 69: 6874–6880. Lin, J., et al. 1999. Mitochondrial DNA analysis of Sporothrix schenckii clinical isolates from China. Mycopathologia 148:69–72. Lindsley, M. D., S. F. Hurst, N. J. Iqbal, and C. J. Morrison. 2001. Rapid identification of dimorphic and yeast-like fungal pathogens using specific DNA probes. J. Clin. Microbiol. 39:3505–3511. Lloyd, K. O., and M. A. Bitoon. 1971. Isolation and purification of a peptido-rhamnomannan from the yeast form of Sporothrix schenckii. Structural and immunochemical studies. J. Immunol. 107:663–671. Reference deleted. Loureiro y Penha, C. V., and L. M. Lopes Bezerra. 2000. Concanavalin A-binding cell wall antigens of Sporothrix schenckii: a serological study. Med. Mycol. 38:1–7. Lutz, A., and A. Splendore. 1907. Sobre uma mycose observada em homens e ratos. Rev. Med. Sa˜o Paulo 21:433–450. Lyon, G. M., et al. 2003. Population-based surveillance and a case-control study of risk factors for endemic lymphocutaneous sporotrichosis in Peru. Clin. Infect. Dis. 36:34–39. Mackinnon, J. E., I. A. Conti-Diaz, E. Gezuele, E. Civila, and S. da Luz. 1969. Isolation of Sporothrix schenckii from nature and considerations on its pathogenicity and ecology. Sabouraudia 7:38–45. Macotela-Ruiz, E., and E. Nochebuena-Ramos. 2006. Esporotricosis en algunas comunidades rurales de la sierra norte de Puebla: informe de 55 casos (Septiembre 1995-Diciembre 2005). Gac. Med. Mex. 142:377–380. Madrid, H., et al. 2009. Sporothrix globosa, a pathogenic fungus with widespread geographical distribution. Rev. Iberoam. Micol. 26:218–222. Magand, F., J. L. Perrot, F. Cambazard, M. H. Raberin, and B. Labeille. 2009. Sporotrichose cutane´e autochtone franc¸aise. Ann. Dermatol. Venereol. 136:273–275. Maia, D. C., M. F. Sassa, M. C. Placeres, and I. Z. Carlos. 2006. Influence of Th1/Th2 cytokines and nitric oxide in murine systemic infection induced by Sporothrix schenckii. Mycopathologia 161:11–19. Malliaris, S. D., J. N. Steenbergen, and A. Casadevall. 2004. Cryptococcus neoformans var. gattii can exploit Acanthamoeba castellanii for growth. Med. Mycol. 42:149–158. Manohar, A., and M. N. Nizlan. 2008. Chronic nonhealing ulcer of the right thumb with multiple subcutaneous nodules. Orthopedics 31:710. Marimon, R., et al. 2007. Sporothrix brasiliensis, S. globosa, and S. mexicana, three new Sporothrix species of clinical interest. J. Clin. Microbiol. 45:3198– 3206. Marimon, R., J. Gene, J. Cano, and J. Guarro. 2008. Sporothrix luriei: a rare fungus from clinical origin. Med. Mycol. 46:621–625. Marimon, R., C. Serena, J. Gene, J. Cano, and J. Guarro. 2008. In vitro antifungal susceptibilities of five species of Sporothrix. Antimicrob. Agents Chemother. 52:732–734. Masoko, P., L. K. Mdee, L. J. Mampuru, and J. N. Eloff. 2008. Biological activity of two related triterpenes isolated from Combretum nelsonii (Combretaceae) leaves. Nat. Prod. Res. 22:1074–1084. Masoko, P., J. Picard, R. L. Howard, L. J. Mampuru, and J. N. Eloff. 2010. In vivo antifungal effect of Combretum and Terminalia species extracts on cutaneous wound healing in immunosuppressed rats. Pharm. Biol. 48:621– 632. McGinnis, M. R., N. Nordoff, R. K. Li, L. Pasarell, and D. W. Warnock. 2001. Sporothrix schenckii sensitivity to voriconazole, itraconazole and amphotericin B. Med. Mycol. 39:369–371. Mehta, K. I., N. L. Sharma, A. K. Kanga, V. K. Mahajan, and N. Ranjan. 2007. Isolation of Sporothrix schenckii from the environmental sources of cutaneous sporotrichosis patients in Himachal Pradesh, India: results of a pilot study. Mycoses 50:496–501. Meinerz, A. R., et al. 2007. Suscetibilidade in vitro de isolados de Sporothrix schenckii frente `a terbinafina e itraconazol. Rev. Soc. Bras. Med. Trop. 40:60–62. Mendes-Giannini, M. J., et al. 2006. Binding of extracellular matrix proteins to Paracoccidioides brasiliensis. Microbes Infect. 8:1550–1559. Mendonca-Hagler, L. C., L. R. Travassos, K. O. Lloyd, and H. J. Phaff. 1974. Deoxyribonucleic acid base composition and hybridization studies on the human pathogen Sporothrix schenckii and Ceratocystis species. Infect. Immun. 9:934–938. Mendoza, M., P. Alvarado, E. Diaz de Torres, L. Lucena, and M. C. de Albornoz. 2005. Comportamiento fisiologico y de sensibilidad in vitro de aislamientos de Sporothrix schenckii mantenidos 18 an ˜os por do ´s metodos de preservacio ´n. Rev. Iberoam. Micol. 22:151–156. Mendoza, M., et al. 2002. Production of culture filtrates of Sporothrix schenckii in diverse culture media. Med. Mycol. 40:447–454. Mendoza, M., E. Diaz, P. Alvarado, E. Romero, and M. C. Bastardo de Albornoz. 2007. Aislamiento de Sporothrix schenckii del medio ambiente en Venezuela. Rev. Iberoam. Micol. 24:317–319. Mesa-Arango, A. C., et al. 2002. Phenotyping and genotyping of Sporothrix schenckii isolates according to geographic origin and clinical form of sporotrichosis. J. Clin. Microbiol. 40:3004–3011. Migaki, G., R. L. Font, W. Kaplan, and E. D. Asper. 1978. Sporotrichosis in
CLIN. MICROBIOL. REV.
165. 166. 167.
168.
169.
170. 171.
172.
173.
174.
175.
176. 177.
178.
179. 180. 181.
182.
183.
184. 185. 186. 187.
188. 189.
190. 191. 192.
193. 194.
195. 196.
a Pacific white-sided dolphin (Lagenorhynchus obliquidens). Am. J. Vet. Res. 39:1916–1919. Milby, A. H., N. D. Pappas, J. O’Donnell, and D. J. Bozentka. 2010. Sporotrichosis of the upper extremity. Orthopedics 16:273–275. Miller, S. D., and J. H. Keeling. 2002. Ant sting sporotrichosis. Cutis 69:439–442. Miranda, L. H., et al. 2010. Comparative histopathological study of sporotrichosis and American tegumentary leishmaniasis in dogs from Rio de Janeiro. J. Comp. Pathol. 143:1–7. Mora-Cabrera, M., R. A. Alonso, R. Ulloa-Arvizu, and H. Torres-Guerrero. 2001. Analysis of restriction profiles of mitochondrial DNA from Sporothrix schenckii. Med. Mycol. 39:439–444. Morera-Lopez, Y., J. M. Torres-Rodriguez, and T. Jimenez-Cabello. 2005. Estudio de la sensibilidad in vitro de aislamientos clínicos de mohos y levaduras a itraconazol y voriconazol. Rev. Iberoam. Micol. 22:105–109. Morris-Jones, R. 2002. Sporotrichosis. Clin. Exp. Dermatol. 27:427–431. Morris-Jones, R., et al. 2003. Synthesis of melanin-like pigments by Sporothrix schenckii in vitro and during mammalian infection. Infect. Immun. 71:4026–4033. Nakai, T., et al. 2003. In vitro antifungal activity of Micafungin (FK463) against dimorphic fungi: comparison of yeast-like and mycelial forms. Antimicrob. Agents Chemother. 47:1376–1381. Nascimento, R. C., and S. R. Almeida. 2005. Humoral immune response against soluble and fractionate antigens in experimental sporotrichosis. FEMS Immunol. Med. Microbiol. 43:241–247. Nascimento, R. C., et al. 2008. Passive immunization with monoclonal antibody against a 70-kDa putative adhesin of Sporothrix schenckii induces protection in murine sporotrichosis. Eur. J. Immunol. 38:3080–3089. Newton, P. N., W. H. Chung, R. Phetsouvanh, and N. J. White. 2005. Sporotrichosis, Plain of Jars, Lao People’s Democratic Republic. Emerg. Infect. Dis. 11:1496–1497. Nobre, M. O., et al. 2005. Differences in virulence between isolates of feline sporotrichosis. Mycopathologia 160:43–49. Noriega, C. T., R. R. Garay, G. Sabanero, R. T. Basurto, and M. SabaneroLopez. 1993. Sporothrix schenckii: culturas en diferentes suelos. Rev. Latinoam. Micol. 35:191–194. Odabasi, Z., V. L. Paetznick, J. R. Rodriguez, E. Chen, and L. OstroskyZeichner. 2004. In vitro activity of anidulafungin against selected clinically important mold isolates. Antimicrob. Agents Chemother. 48:1912–1915. Oliveira, M. M. E. 2009. M.Sc. thesis. Fundac¸˜ao Oswaldo Cruz, Rio de Janeiro, Brazil. Oliveira, M. M. E., et al. 2010. Sporotrichosis caused by Sporothrix globosa in Rio de Janeiro, Brazil: case report. Mycopathologia 169:359–363. O’Reilly, L. C., and S. A. Altman. 2006. Macrorestriction analysis of clinical and environmental isolates of Sporothrix schenckii. J. Clin. Microbiol. 44: 2547–2552. Orellana, A., G. Moreno-Coutino, E. Poletti, M. E. Vega, and R. Arenas. 2009. Esporotricosis fija con cuerpo asteroide junto al fragmento vegetal. Rev. Iberoam. Micol. 26:250–251. Palomino, J., O. Saeed, P. Daroca, and J. Lasky. 2009. A 47-year-old man with cough, dyspnea, and an abnormal chest radiograph. Chest 135:872– 875. Pappas, P. G., et al. 2000. Sporotrichosis in Peru: description of an area of hyperendemicity. Clin. Infect. Dis. 30:65–70. Powell, K. E., et al. 1978. Cutaneous sporotrichosis in forestry workers. Epidemic due to contaminated Sphagnum moss. JAMA 240:232–235. Pupo, J. A. 1917. Frequencia da sporotrichose em Sa˜o Paulo. Ann. Paulistas Med. Cirurgia 8:53–68. Quintella, L. P., S. R. Lambert Passos, A. C. Francesconi do Vale, et al. 2011. Histopathology of cutaneous sporotrichosis in Rio de Janeiro: a series of 119 consecutive cases. J. Cutan. Pathol. 38:25–32. Ramesh, V. 2007. Sporotrichoid cutaneous tuberculosis. Clin. Exp. Dermatol. 32:680–682. Ramirez, J., R. P. Byrd, Jr., and T. M. Roy. 1998. Chronic cavitary pulmonary sporotrichosis: efficacy of oral itraconazole. J. Ky. Med. Assoc. 96:103– 105. Ramos-e-Silva, M., C. Vasconcelos, S. Carneiro, and T. Cestari. 2007. Sporotrichosis. Clin. Dermatol. 25:181–187. Read, S. I., and L. C. Sperling. 1982. Feline sporotrichosis. Transmission to man. Arch. Dermatol. 118:429–431. Reis, R. S., et al. 2009. Molecular characterisation of Sporothrix schenckii isolates from humans and cats involved in the sporotrichosis epidemic in Rio de Janeiro, Brazil. Mem. Inst. Oswaldo Cruz 104:769–774. Reiss, E. 1986. Molecular immunology of mycotic and actinomycotic infections. Elsevier, Amsterdam, The Netherlands. Reiss, E., T. Obayashi, K. Orle, M. Yoshida, and R. M. Zancope-Oliveira. 2000. Non-culture based diagnostic tests for mycotic infections. Med. Mycol. 38(Suppl. 1):147–159. Resto, S., and N. Rodriguez-del Valle. 1988. Yeast cell cycle of Sporothrix schenckii. J. Med. Vet. Mycol. 26:13–24. Rippon, J. 1988. Sporotrichosis, p. 325–352. In J. Rippon (ed.), Medical
VOL. 24, 2011
197.
198.
199.
200.
201.
202.
203.
204.
205.
206.
207.
208.
209. 210.
211.
212.
213.
214. 215.
216.
217. 218. 219.
220. 221.
222. 223.
mycology—the pathogenic fungi and the pathogenic actinomycetes, 3rd ed. W. B. Saunders Company, Philadelphia, PA. Rodrigues, M. L., L. Nimrichter, D. L. Oliveira, J. D. Nosanchuk, and A. Casadevall. 2008. Vesicular trans-cell wall transport in fungi: a mechanism for the delivery of virulence-associated macromolecules? Lipid Insights 2:27–40. Rodrigues, M. T., and M. A. Resende. 1996. Epidemiologic skin test survey of sensitivity to paracoccidioidin, histoplasmin and sporotrichin among gold mine workers of Morro Velho Mining, Brazil. Mycopathologia 135:89–98. Rodriguez-del Valle, N., and J. R. Rodriguez-Medina. 1993. Calcium stimulates molecular and cellular events during the yeast-to-mycelium transition in Sporothrix schenckii. J. Med. Vet. Mycol. 31:43–53. Rodriguez-Del Valle, N., M. Rosario, and G. Torres-Blasini. 1983. Effects of pH, temperature, aeration and carbon source on the development of the mycelial or yeast forms of Sporothrix schenckii from conidia. Mycopathologia 82:83–88. Rodriguez-Tudela, J. L., et al. 2008. Method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia forming moulds. EUCAST E.DEF. 9.1. Romero-Martinez, R., M. Wheeler, A. Guerrero-Plata, G. Rico, and H. Torres-Guerrero. 2000. Biosynthesis and functions of melanin in Sporothrix schenckii. Infect. Immun. 68:3696–3703. Rosa, W. D., E. Gezuele, L. Calegari, and F. Goni. 2008. Asteroid body in sporotrichosis. Yeast viability and biological significance within the host immune response. Med. Mycol. 46:443–448. Rosa, W. D., E. Gezuele, L. Calegari, and F. Gon ˜ i. 2009. Excretion-secretion products and proteases from live Sporothrix schenckii yeast phase: immunological detection and cleavage of human IgG. Rev. Inst. Med. Trop. Sa˜o Paulo 51:1–7. Rubio, G., G. Sanchez, L. Porras, and Z. Alvarado. 2010. Esporotricosis: prevalencia, perfil clinico y epidemiologico en un centro de referencia en Colombia. Rev. Iberoam. Micol. 27:75–79. Ruiz-Baca, E., et al. 2009. Isolation and some properties of a glycoprotein of 70 kDa (Gp70) from the cell wall of Sporothrix schenckii involved in fungal adherence to dermal extracellular matrix. Med. Mycol. 47:185–196. Ruiz-Cendoya, M., M. M. Rodriguez, M. Marine, F. J. Pastor, and J. Guarro. 2008. In vitro interactions of itraconazole and micafungin against clinically important filamentous fungi. Int. J. Antimicrob. Agents 32:418– 420. Safdar, A. 2003. Clinical microbiological case: infection imitating lymphocutaneous sporotrichosis during pregnancy in a healthy woman from the south-eastern USA. Clin. Microbiol. Infect. 9:221, 224–226. Salaki, J. S., D. B. Louria, and H. Chmel. 1984. Fungal and yeast infections of the central nervous system. A clinical review. Medicine 63:108–132. Sanchez-Aleman, M. A., J. Araiza, and A. Bonifaz. 2004. Aislamiento y caracterizacion de cepas silvestres de Sporothrix schenckii e investigacion de reactores a la esporotricina. Gac. Med. Mex. 140:507–512. Sandhu, G. S., B. C. Kline, L. Stockman, and G. D. Roberts. 1995. Molecular probes for diagnosis of fungal infections. J. Clin. Microbiol. 33:2913– 2919. Saravanakumar, P. S., P. Eslami, and F. A. Zar. 1996. Lymphocutaneous sporotrichosis associated with a squirrel bite: case report and review. Clin. Infect. Dis. 23:647–648. Sashidhara, K. V., S. P. Singh, and P. K. Shukla. 2009. Antimicrobial evaluation of clerodane diterpenes from Polyalthia longifolia var. pendula. Nat. Prod. Commun. 4:327–330. Scheinfeld, N. 2007. A review of the new antifungals: posaconazole, micafungin, and anidulafungin. J. Drugs Dermatol. 6:1249–1251. Schell, W. 1998. Agents of chromoblastomycosis and sporotrichosis, p. 315–336. In L. Ajello and R. J. Hay (ed.), Topley & Wilson’s microbiology and microbial infections, 9th ed., vol. 4. Arnold, London, United Kingdom. Schell, W. A., I. F. Salkin, L. Pasarell, and M. R. McGinnis. 1999. Bipolaris, Exophiala, Scedosporium, Sporothrix and other dematiaceous fungi, p. 1295– 1317. In P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.), Manual of clinical microbiology, 7th ed. ASM Press, Washington, DC. Schenck, B. R. 1898. On refractory subcutaneous abscess caused by a fungus possibly related to the Sporotricha. Bull. Johns Hopkins Hosp. 9:286–290. Schubach, A., M. B. Barros, and B. Wanke. 2008. Epidemic sporotrichosis. Curr. Opin. Infect. Dis. 21:129–133. Schubach, A., M. B. de Lima Barros, T. M. Schubach, A. C. Francesconido-Valle, et al. 2005. Primary conjunctival sporotrichosis: two cases from a zoonotic epidemic in Rio de Janeiro, Brazil. Cornea 24:491–493. Schubach, A. O., T. M. Schubach, and M. B. Barros. 2005. Epidemic cat-transmitted sporotrichosis. N. Engl. J. Med. 353:1185–1186. Schubach, T. M., A. de Oliveira Schubach, R. S. dos Reis, et al. 2002. Sporothrix schenckii isolated from domestic cats with and without sporotrichosis in Rio de Janeiro, Brazil. Mycopathologia 153:83–86. Schubach, T. M., et al. 2004. Evaluation of an epidemic of sporotrichosis in cats: 347 cases (1998-2001). J. Am. Vet. Med. Assoc. 224:1623–1629. Schubach, T. M., et al. 2006. Canine sporotrichosis in Rio de Janeiro,
SPOROTHRIX SCHENCKII AND SPOROTRICHOSIS
224.
225. 226. 227.
228.
229. 230.
231.
232.
233.
234. 235.
236.
237.
238.
239. 240.
241. 242. 243.
244. 245.
246.
247.
248.
249.
250.
251.
252.
653
Brazil: clinical presentation, laboratory diagnosis and therapeutic response in 44 cases (1998-2003). Med. Mycol. 44:87–92. Schubach, T. M., et al. 2003. Haematogenous spread of Sporothrix schenckii in cats with naturally acquired sporotrichosis. J. Small Anim. Pract. 44:395– 398. Schubach, T. M., et al. 2003. Pathology of sporotrichosis in 10 cats in Rio de Janeiro. Vet. Rec. 152:172–175. Schubach, T. M., et al. 2001. Isolation of Sporothrix schenckii from the nails of domestic cats (Felis catus). Med. Mycol. 39:147–149. Schwartz, D. A. 1989. Sporothrix tenosynovitis—differential diagnosis of granulomatous inflammatory disease of the joints. J. Rheumatol. 16:550– 553. Scott, E. N., L. Kaufman, A. C. Brown, and H. G. Muchmore. 1987. Serologic studies in the diagnosis and management of meningitis due to Sporothrix schenckii. N. Engl. J. Med. 317:935–940. Scott, E. N., and H. G. Muchmore. 1989. Immunoblot analysis of antibody responses to Sporothrix schenckii. J. Clin. Microbiol. 27:300–304. Scott, E. N., H. G. Muchmore, and D. P. Fine. 1986. Activation of the alternative complement pathway by Sporothrix schenckii. Infect. Immun. 51:6–9. Sgarbi, D. B., et al. 1997. Isolation of ergosterol peroxide and its reversion to ergosterol in the pathogenic fungus Sporothrix schenckii. Mycopathologia 139:9–14. Sia, R. A., K. B. Lengeler, and J. Heitman. 2000. Diploid strains of the pathogenic basidiomycete Cryptococcus neoformans are thermally dimorphic. Fungal Genet. Biol. 29:153–163. Sigler, L., et al. 1990. Microbiology and potential virulence of Sporothrix cyanescens, a fungus rarely isolated from blood and skin. J. Clin. Microbiol. 28:1009–1015. Silva-Vergara, M. L., et al. 2005. Multifocal sporotrichosis with meningeal involvement in a patient with AIDS. Med. Mycol. 43:187–190. Silveira, C. P., et al. 2009. MICs and minimum fungicidal concentrations of amphotericin B, itraconazole, posaconazole and terbinafine in Sporothrix schenckii. J. Med. Microbiol. 58:1607–1610. Singer, J. I., and J. E. Muncie. 1952. Sporotrichosis. Etiologic considerations and report of additional cases from New York. N. Y. State J. Med. 52:2147–2153. Smith, M. T., and W. H. Batenburg-Van der Vegte. 1985. Ultrastructure in septa in Blastobotrys and Sporothrix. Antonie Van Leeuwenhoek 51:121– 128. Song, Y., et al. 2011. Efficacy and safety of itraconazole pulses vs. continuous regimen in cutaneous sporotrichosis. J. Eur. Acad. Dermatol. Venereol. 25:302–305. Stalkup, J. R., K. Bell, and T. Rosen. 2002. Disseminated cutaneous sporotrichosis treated with itraconazole. Cutis 69:371–374. Steenbergen, J. N., J. D. Nosanchuk, S. D. Malliaris, and A. Casadevall. 2004. Interaction of Blastomyces dermatitidis, Sporothrix schenckii, and Histoplasma capsulatum with Acanthamoeba castellanii. Infect. Immun. 72: 3478–3488. Stevens, D. A. 2002. Diagnosis of fungal infections: current status. J. Antimicrob. Chemother. 49(Suppl. 1):11–19. St-Germain, G., and R. C. Summerbell. 1996. Identifying filamentous fungi. A clinical laboratory handbook. Star Publishing Company, Belmont, CA. Suzuki, K., M. Kawasaki, and H. Ishizaki. 1988. Analysis of restriction profiles of mitochondrial DNA from Sporothrix schenckii and related fungi. Mycopathologia 103:147–151. Svoboda, A., and A. Trujillo-Gonzalez. 1990. Sporothrix schenckii—a freezefracture study. J. Basic Microbiol. 30:371–378. Taboada, J. 2000. Systemic mycoses, p. 453–476. In S. Ettinger and E. Feldman (ed.), Textbook of veterinary internal medicine—diseases of the dog and cat, 5th ed., vol. 1. W. B. Saunders Company, Philadelphia, PA. Tachibana, T., T. Matsuyama, and M. Mitsuyama. 1998. Characteristic infectivity of Sporothrix schenckii to mice depending on routes of infection and inherent fungal pathogenicity. Med. Mycol. 36:21–27. Tachibana, T., T. Matsuyama, and M. Mitsuyama. 1999. Involvement of CD4⫹ T cells and macrophages in acquired protection against infection with Sporothrix schenckii in mice. Med. Mycol. 37:397–404. Takenaka, M., S. Sato, and K. Nishimoto. 2009. Survey of 155 sporotrichosis cases examined in Nagasaki Prefecture from 1951 to 2007. Nippon Ishinkin Gakkai Zasshi 50:101–108. Tateishi, T., S. Y. Murayama, F. Otsuka, and H. Yamaguchi. 1996. Karyotyping by PFGE of clinical isolates of Sporothrix schenckii. FEMS Immunol. Med. Microbiol. 13:147–154. Teixeira, P. A., et al. 2010. L-DOPA accessibility in culture medium increases melanin expression and virulence of Sporothrix schenckii yeast cells. Med. Mycol. 48:687–695. Teixeira, P. A., et al. 2009. Cell surface expression of adhesins for fibronectin correlates with virulence in Sporothrix schenckii. Microbiology 155:3730– 3738. Tlougan, B. E., J. O. Podjasek, S. P. Patel, X. H. Nguyen, and R. C. Hansen. 2009. Neonatal sporotrichosis. Pediatr. Dermatol. 26:563–565.
654
BARROS ET AL.
CLIN. MICROBIOL. REV.
253. Tobin, E. H., and W. W. Jih. 2001. Sporotrichoid lymphocutaneous infections: etiology, diagnosis and therapy. Am. Fam. Physician 63:326–332. 254. Toledo, M. S., et al. 2010. Effect of anti-glycosphingolipid monoclonal antibodies in pathogenic fungal growth and differentiation. Characterization of monoclonal antibody MEST-3 directed to Manpa133Manpa32IPC. BMC Microbiol. 10:47. 255. Torinuki, W., and H. Tagami. 1985. Complement activation by Sporothrix schenckii. Arch. Dermatol. Res. 277:332–333. 256. Torres-Guerrero, H. 1999. Ploidy studies in Sporothrix schenckii. Fungal Genet. Biol. 27:49–54. 257. Trilles, L., et al. 2005. In vitro antifungal susceptibilities of Sporothrix schenckii in two growth phases. Antimicrob. Agents Chemother. 49:3952– 3954. 258. Uenotsuchi, T., et al. 2006. Differential induction of Th1-prone immunity by human dendritic cells activated with Sporothrix schenckii of cutaneous and visceral origins to determine their different virulence. Int. Immunol. 18: 1637–1646. 259. Valentin-Berrios, S., W. Gonzalez-Velazquez, L. Perez-Sanchez, R. Gonzalez-Mendez, and N. Rodriguez-Del Valle. 2009. Cytosolic phospholipase A2: a member of the signalling pathway of a new G protein alpha subunit in Sporothrix schenckii. BMC Microbiol. 9:100. 260. Valle-Aviles, L., S. Valentin-Berrios, R. R. Gonzalez-Mendez, and N. Rodriguez-Del Valle. 2007. Functional, genetic and bioinformatic characterization of a calcium/calmodulin kinase gene in Sporothrix schenckii. BMC Microbiol. 7:107. 261. van Duin, D., A. Casadevall, and J. D. Nosanchuk. 2002. Melanization of Cryptococcus neoformans and Histoplasma capsulatum reduces their susceptibilities to amphotericin B and caspofungin. Antimicrob. Agents Chemother. 46:3394–3400.
262. Vicentini, A. P., et al. 1994. Binding of Paracoccidioides brasiliensis to laminin through surface glycoprotein gp43 leads to enhancement of fungal pathogenesis. Infect. Immun. 62:1465–1469. 263. Vilela, R., G. F. Souza, G. Fernandes Cota, and L. Mendoza. 2007. Cutaneous and meningeal sporotrichosis in a HIV patient. Rev. Iberoam. Micol. 24:161–163. 264. Wenker, C. J., L. Kaufman, L. N. Bacciarini, and N. Robert. 1998. Sporotrichosis in a nine-banded armadillo (Dasypus novemcinctus). J. Zoo Wildl. Med. 29:474–478. 265. Woods, J. P. 2003. Knocking on the right door and making a comfortable home: Histoplasma capsulatum intracellular pathogenesis. Curr. Opin. Microbiol. 6:327–331. 266. Xu, T. H., et al. 2010. Identification of Sporothrix schenckii of various mtDNA types by nested PCR assay. Med. Mycol. 48:161–165. 267. Xue, S. L., and L. Li. 2009. Oral potassium iodide for the treatment of sporotrichosis. Mycopathologia 167:355–356. 268. Yang, D. J., et al. 2006. Disseminated sporotrichosis mimicking sarcoidosis. Int. J. Dermatol. 45:450–453. 269. Yegneswaran, P. P., et al. 2009. Zoonotic sporotrichosis of lymphocutaneous type in a man acquired from a domesticated feline source: report of a first case in southern Karnataka, India. Int. J. Dermatol. 48:1198–1200. 270. Zarnowski, R., and J. P. Woods. 2005. Glutathione-dependent extracellular ferric reductase activities in dimorphic zoopathogenic fungi. Microbiology 151:2233–2240. 271. Zhang, X., and J. H. Andrews. 1993. Evidence for growth of Sporothrix schenckii on dead but not on living sphagnum moss. Mycopathologia 123: 87–94.
Mo ˆnica Bastos de Lima Barros obtained her medical degree from the Federal University of the State of Rio de Janeiro, Brazil, in 1984. She completed her residency in public health at Oswaldo Cruz Foundation and subsequently her M.Sc. and Ph.D. degrees in infectious diseases from the Federal University of Rio de Janeiro. Her thesis was on sporotrichosis and the first description of an epidemic due to zoonotic transmission. During the past 10 years she has gained broad experience in the clinical aspects, epidemiology, treatment, and prevention of sporotrichosis. She works as a researcher and professor at the Oswaldo Cruz Foundation, affiliated with the Ministry of Health, developing studies in infectious diseases.
Armando de Oliveira Schubach obtained his medical degree from the University of the State of Rio de Janeiro, Brazil, in 1980, a specialization in dermatology from the Federal University of the State of Rio de Janeiro in 1990, an M.Sc. degree in tropical medicine from the Oswaldo Cruz Foundation (Fiocruz) in 1990, and a Ph.D. degree in parasite biology from Fiocruz in 1997. He is currently a senior researcher at the Evandro Chagas Clinical Research Institute (IPEC/Fiocruz), coordinator of the Laboratory of Leishmaniasis Surveillance at IPEC/Fiocruz, coordinator of the Postgraduation Program in Clinical Research in Infectious Diseases of IPEC/Fiocruz, Level 2 researcher of the National Council of Scientific and Technological Development (CNPq), leader of the Parasitic Diseases (CNPq) research group, and a “Scientist of Our State” from the Foundation for Research of Rio de Janeiro (FAPERJ). He has experience in the study of infectious and parasitic diseases, mainly the clinical, diagnostic, treatment, and epidemiological aspects of sporotrichosis and leishmaniasis.
Rodrigo Almeida Paes obtained his undergraduate degree from the Federal University of the State of Rio de Janeiro, Brazil, in 2004. Since 2002 he has worked at the Oswaldo Cruz Foundation, where he completed his M.Sc. degree in cellular and molecular biology in 2007. He is now a Ph.D. student, working on several aspects of S. schenckii virulence. He is also the supervisor of the Mycological Diagnosis section of the Mycology Laboratory of the Oswaldo Cruz Foundation and teaches medical mycology to technicians and undergraduate students.
CLINICAL MICROBIOLOGY REVIEWS, Oct. 2011, p. 655–681 0893-8512/11/$12.00 doi:10.1128/CMR.00005-11 Copyright © 2011, American Society for Microbiology. All Rights Reserved.
Vol. 24, No. 4
Trypanosoma cruzi and Chagas’ Disease in the United States Caryn Bern,1* Sonia Kjos,2 Michael J. Yabsley,3 and Susan P. Montgomery1 Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia1; Marshfield Clinic Research Foundation, Marshfield, Wisconsin2; and Department of Population Health, College of Veterinary Medicine, University of Georgia, Athens, Georgia3 INTRODUCTION .......................................................................................................................................................656 TRYPANOSOMA CRUZI LIFE CYCLE AND TRANSMISSION ..........................................................................656 Life Cycle .................................................................................................................................................................656 Transmission Routes ..............................................................................................................................................657 Vector-borne transmission.................................................................................................................................657 Congenital transmission ....................................................................................................................................657 Blood-borne transmission..................................................................................................................................657 Organ-derived transmission ..............................................................................................................................657 Oral transmission ...............................................................................................................................................657 TRIATOMINE VECTOR BIOLOGY AND ECOLOGY ........................................................................................657 Background ..............................................................................................................................................................657 Triatomine Distribution in the United States ....................................................................................................658 Description of U.S. Triatomine Species...............................................................................................................659 Triatoma gerstaeckeri (Stål) ................................................................................................................................659 Triatoma incrassata Usinger...............................................................................................................................660 Triatoma indictiva Neiva .....................................................................................................................................660 Triatoma lecticularia (Stål) .................................................................................................................................660 Triatoma neotomae Neiva....................................................................................................................................661 Triatoma protracta (Uhler) .................................................................................................................................661 Triatoma recurva (Stål).......................................................................................................................................661 Triatoma rubida (Uhler) .....................................................................................................................................661 Triatoma rubrofasciata (DeGeer) .......................................................................................................................661 Triatoma sanguisuga (Leconte) ..........................................................................................................................662 Paratriatoma hirsuta Barber...............................................................................................................................662 Human-Vector Interactions and T. cruzi Transmission Potential in the United States...............................662 ANIMAL RESERVOIRS OF TRYPANOSOMA CRUZI..........................................................................................663 Background ..............................................................................................................................................................663 Wildlife Reservoirs of T. cruzi in the United States ..........................................................................................663 Domestic and Exotic Animal Infections in the United States..........................................................................665 Canine Chagas’ disease......................................................................................................................................665 Primates and other exotic animals...................................................................................................................666 MOLECULAR EPIDEMIOLOGY OF T. CRUZI ...................................................................................................666 General Molecular Epidemiology .........................................................................................................................666 T. cruzi Genotypes in the United States ..............................................................................................................667 CLINICAL ASPECTS OF CHAGAS’ DISEASE.....................................................................................................668 Acute T. cruzi Infection ..........................................................................................................................................668 Congenital T. cruzi Infection .................................................................................................................................668 Chronic T. cruzi Infection ......................................................................................................................................668 Indeterminate form of chronic T. cruzi infection ...........................................................................................668 Cardiac Chagas’ disease ....................................................................................................................................668 Digestive Chagas’ disease ..................................................................................................................................668 T. cruzi Infection in the Immunocompromised Host .........................................................................................669 Acute T. cruzi infection in organ transplantation recipients........................................................................669 Reactivation of chronic T. cruzi infection in organ recipients......................................................................669 Reactivation Chagas’ disease in HIV/AIDS patients .....................................................................................669 DIAGNOSIS ................................................................................................................................................................669 Diagnosis of Acute T. cruzi Infection ...................................................................................................................669 Diagnosis of Congenital T. cruzi Infection ..........................................................................................................669 Diagnosis of Chronic T. cruzi infection ...............................................................................................................670
* Corresponding author. Mailing address: Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, 1600 Clifton Rd. N.E., Atlanta, GA 30333. Phone: (404) 718-4726. Fax: (404) 718-4816. E-mail:
[email protected]. 655
656
BERN ET AL.
CLIN. MICROBIOL. REV.
Utility of PCR for Diagnosis or Monitoring .......................................................................................................670 TREATMENT..............................................................................................................................................................670 Antitrypanosomal Drugs ........................................................................................................................................670 Treatment of Acute and Congenital T. cruzi infection.......................................................................................670 Treatment of Chronic T. cruzi Infection ..............................................................................................................670 Management of the Immunocompromised Host ................................................................................................671 EPIDEMIOLOGY OF CHAGAS’ DISEASE ...........................................................................................................671 HUMAN CHAGAS’ DISEASE IN THE UNITED STATES..................................................................................671 Autochthonous Transmission to Humans ...........................................................................................................671 Chagas’ Disease Burden among Latin American Immigrants .........................................................................672 Blood-Borne Transmission and Blood Donor Screening ..................................................................................672 Organ Donor-Derived Transmission and Organ Donor Screening.................................................................673 Unanswered Questions and Priorities for Research and Programs................................................................673 REFERENCES ............................................................................................................................................................674 TRYPANOSOMA CRUZI LIFE CYCLE AND TRANSMISSION
INTRODUCTION Chagas’ disease is caused by the protozoan parasite Trypanosoma cruzi (234). World Health Organization disease burden estimates place Chagas’ disease first among parasitic diseases in the Americas, accounting for nearly 5 times as many disability-adjusted life years lost as malaria (343). An estimated 8 million people are currently infected, and 20 to 30% of these will develop symptomatic, potentially life-threatening Chagas’ disease (Table 1) (214). T. cruzi is carried in the guts of hematophagous triatomine bugs; transmission occurs when infected bug feces contaminate the bite site or intact mucous membranes. T. cruzi can also be transmitted through transfusion, through transplant, and congenitally (177, 234). Historically, transmission and morbidity were concentrated in rural areas of Latin America where poor housing conditions favor vector infestation. However, in the last several decades, successful vector control programs have substantially decreased transmission in rural areas, and migration has brought infected individuals to cities both within and outside Latin America (87, 111, 196). Since 1991, several subregional initiatives have made major advances in decreasing vector infestation in human dwellings and extending screening of the blood supply for T. cruzi (87, 269). In 2007, control efforts in Latin America were formally joined by an initiative to address the “globalization” of Chagas’ disease, recognizing the increasing presence of imported cases in Europe, North America, and Japan and the potential for local transmission through nonvectorial routes (344). The United States occupies an ambiguous position in this new initiative. While the United States has never participated in Latin American Chagas’ disease control programs, it cannot be classified as an area where the disease is “not endemic” in the same sense as Europe or Japan. The southern tier of states from Georgia to California contains established enzootic cycles of T. cruzi, involving several triatomine vector species and mammalian hosts such as raccoons, opossums, and domestic dogs (26, 151, 345). Nevertheless, most T. cruzi-infected individuals in the United States are immigrants from areas of endemicity in Latin America (29). This article will present an overview of clinical and epidemiological aspects of Chagas’ disease, with a focus on data and issues specific to T. cruzi and Chagas’ disease in the United States. Topics to be covered include vector biology and ecology, animal reservoirs, T. cruzi strain typing, human Chagas’ disease, and future research needed for control of Chagas’ disease in the United States.
Life Cycle Nearly all the salient features of the T. cruzi life cycle were described by Carlos Chagas, the scientist who discovered the organism, in 1909 (62). T. cruzi is a kinetoplastid protozoan which infects vertebrate and invertebrate hosts during defined stages in its life cycle (234, 292). The triatomine vector ingests circulating trypomastigotes when it takes a blood meal from an infected mammalian host. In the midgut of the vector, trypomastigotes transform through an intermediate form sometimes
TABLE 1. Countries where Chagas’ disease is endemic and estimates of the seroprevalence and number of infected inhabitants Region
Country where Chagas’ disease is endemica
Estimated seroprevalence (%)b
Estimated no. of infected individualsb
North America
United States Mexico
NDA 1.03
300,167c 1,100,000
Central America
Belize Costa Rica El Salvador Honduras Guatemala Nicaragua Panama
0.74 0.53 3.37 3.05 1.98 1.14 0.01
2,000 23,000 232,000 220,000 250,000 58,600 21,000
South America
Argentina Bolivia Brazil Chile Colombia Ecuador Guyana Suriname French Guiana Paraguay Peru Uruguay Venezuela
4.13 6.75 1.02 0.99 0.96 1.74 1.29 NDA NDA 2.54 0.69 0.66 1.16
1,600,000 620,000 1,900,000 160,200 436,000 230,000 18,000 NDA NDA 150,000 192,000 21,700 310,000
a Vector-borne T. cruzi transmission occurs, or occurred until recently, in parts of these countries. b Disease burden estimates are for the year 2005, based on references 29 and 214. NDA, No data available. c The number for the United States reflects the estimated number of infected immigrants from countries in Latin America where the disease is endemic. No estimate of the number of locally acquired infections is currently available.
VOL. 24, 2011
T. CRUZI AND CHAGAS’ DISEASE IN THE UNITED STATES
657
called a spheromastigote to epimastigotes, the main replicating stage in the invertebrate host. Epimastigotes migrate to the hindgut and differentiate into infective metacyclic trypomastigotes, which are excreted with the feces of the vector. Metacyclic trypomastigotes enter through the bite wound or intact mucous membrane of the mammalian host and invade many types of nucleated cells through a lysosome-mediated mechanism (50). In the cytoplasm, trypomastigotes differentiate into the intracellular amastigote form, which replicates with a doubling time of about 12 h over a period of 4 to 5 days. At the end of this period, the amastigotes transform into trypomastigotes, the host cell ruptures, and the trypomastigotes are released into the circulation. The circulating parasites can then invade new cells and initiate new replicative cycles, and they are available to infect vectors that feed on the host. In the absence of successful antitrypanosomal treatment, the infection lasts for the lifetime of the mammalian host.
been documented in the literature (13 kidney, 1 kidney and pancreas, 3 liver, and 2 heart transplants) (16, 61, 66, 79, 99, 101, 157, 238, 279). The risk from heart transplantation is thought to be higher than that from kidney or liver transplantation (65). One case of transmission through unrelated cord blood transplantation has been reported (104). Oral transmission. Recently, increasing attention has focused on the oral route of T. cruzi transmission; several outbreaks attributed to contaminated fruit or sugar cane juice have been reported from Brazil and Venezuela (28, 82, 208). Most outbreaks are small, often affecting family groups in the Amazon region, where the palm fruit ac¸aí is a dietary staple that appears to be particularly vulnerable to contamination, perhaps from infected vectors living in the trees themselves (74, 208). The largest reported outbreak to date led to more than 100 infections among students and staff at a school in Caracas; locally prepared guava juice was implicated (82).
Transmission Routes
TRIATOMINE VECTOR BIOLOGY AND ECOLOGY
Vector-borne transmission. The vector-borne transmission route, occurring exclusively in the Americas, is still the predominant mechanism for new human infections. The feces of infected bugs contain metacyclic trypomastigotes that can enter the human body through the bite wound or through intact conjunctiva or other mucous membranes. Congenital transmission. Between 1 and 10% of infants of T. cruzi-infected mothers are born with congenital Chagas’ disease (14, 24, 289). Congenital transmission can occur from women themselves infected congenitally, perpetuating the disease in the absence of the vector (263). Factors reported to increase risk include higher maternal parasitemia level, less robust anti-T. cruzi immune responses, younger maternal age, HIV and, in an animal model, parasite strain (9, 32, 34, 107, 289). Blood-borne transmission. Transfusional T. cruzi transmission was postulated in 1936 and first documented in 1952 (109, 307). The risk of T. cruzi transmission per infected unit transfused is estimated to be 10 to 25%; platelet transfusions are thought to pose a higher risk than other components such as packed red cells (31, 308). In 1991, the prevalence of T. cruzi infection in donated blood units ranged from 1 to 60% in Latin American cities (268). Since then, blood donation screening has become accepted as an important pillar of the Chagas’ disease control initiatives (220, 269). Serological screening of blood components for T. cruzi is now compulsory in all but one of the countries in Latin America where the disease is endemic, and the prevalence of infection in screened donors has decreased substantially (196, 269). Nevertheless, Chagas’ disease screening coverage by country was estimated to vary from 25% to 100% in 2002, and the risk of transmission, though much decreased, has not been eliminated (269). The residual risk in Latin America where screening has been implemented is estimated to be 1:200,000 units (269, 308). Organ-derived transmission. Uninfected recipients who receive an organ from a T. cruzi-infected donor may develop acute T. cruzi infection. However, transmission is not universal; in a series of 16 uninfected recipients of kidneys from infected donors, only 3 (19%) acquired T. cruzi infection (238). Nineteen instances of transmission by organ transplantation have
Background The epidemiology of vector-borne T. cruzi is closely linked to the biological and ecological characteristics of local vectors and mammalian reservoir hosts. Triatomines of both sexes must take blood meals to develop through their nymphal stages to adults, and females require a blood meal to lay eggs. Thus, nymphs and adults of either sex may be infected with T. cruzi, but infection rates increase with increasing vector stage and age. Most domestic triatomine species feed nocturnally and are able to complete their blood meal without waking the host (169). The major Latin American vectors defecate during or immediately after taking a blood meal. T. cruzi infection is transmitted to wild mammals by sylvatic triatomine species; these bugs often colonize the nests of rodent or marsupial reservoir hosts (169, 311). Sylvatic triatomine adults may fly into human dwellings because of attraction by light and cause sporadic human infections (74). Domestic transmission cycles occur where vectors have become adapted to living in human dwellings and nearby animal enclosures; domestic mammals such as dogs, cats, and guinea pigs play important roles as triatomine blood meal sources and T. cruzi reservoir hosts (69, 124, 131). Some triatomine species can infest both domestic and sylvatic sites and may play a bridging role (192). There are more than 130 triatomine species in the Americas, many of which can be infected by and transmit T. cruzi (169, 311). However, a small number of highly domiciliated vectors are of disproportionate importance in the human epidemiology of disease (Table 2) (311). The domestic environment provides abundant blood meal sources, and poor quality housing with adobe or unfinished brick walls provides crevices and other diurnal hiding places for triatomines (170, 201). Thatch roofs provide an attractive habitat for some species (117). In communities where the disease is endemic, 25 to 100% of houses may be infested, and a house and its immediate surroundings may support large colonies of juvenile and adult bugs (170, 201, 230). In areas of the Amazon where deforestation and human immigration have occurred, tree-dwelling sylvatic triatomine
658
CLIN. MICROBIOL. REV.
BERN ET AL.
TABLE 2. The major triatomine species that colonize the domestic and peridomestic environment and play an important role in the epidemiology of Chagas’ disease in Latin Americaa Vector species
Locations b
c
c
b
Triatoma infestans ..................................................Argentina, Brazil, Chile, Paraguay, southern Peru, Uruguayc Rhodnius prolixus ...................................................Colombia, El Salvador, Guatemala,d Honduras, southern Mexico, Nicaragua, Venezuela Triatoma dimidiata ................................................Belize, Colombia, Costa Rica, Ecuador, El Salvador, Guatemala, Honduras, Mexico, Nicaragua, Panama, northern Peru, Venezuela Panstrongylus megistus ...........................................Argentina, Brazil, Paraguay, Uruguay Triatoma brasiliensis ..............................................Northeastern Brazil a
Data are from reference 311. T. cruzi transmission by T. infestans has been certified as interrupted in 6 provinces of Argentina and 1 department of Paraguay (220). T. cruzi transmission by T. infestans has been certified as interrupted throughout the country (220). d T. cruzi transmission by R. prolixus has been certified as interrupted throughout the country (220). b c
populations have survived and rebounded by adapting to new vertebrate host species (2). These opportunistic vertebrates (opossums and rodents) are competent Chagas’ disease reservoirs and are acclimated to living in close proximity to humans where remnant vegetation is located. The concentration of triatomines and vertebrate reservoirs in the peridomestic realm has lead to increased interactions between sylvatic triatomine species and humans in deforested areas of the Amazon and Panama and to an apparent increase in the incidence of Chagas’ disease in humans (4, 244). Triatomine Distribution in the United States Eleven species of triatomine bugs have been reported from the United States: Triatoma gerstaeckeri, T. incrassata, T. indictiva, T. lecticularia, T. neotomae, T. protracta, T. recurva, T. rubida, T. rubrofasciata, T. sanguisuga, and Paratriatoma hirsuta (Fig. 1 and Table 3). Triatomines are present across the southern half of the country, distributed from the Pacific to Atlantic coasts (Fig. 2). One species (T. rubrofasciata) is found in Hawaii. A high degree of polymorphism has been noted in several species across their geographic ranges, particularly T. protracta, T. rubida, and T. sanguisuga, resulting in proposed subspecies classifications (249, 251, 254, 296). However, due to the recognition of morphological intermediates across some subspecies groups and the absence of supporting data (e.g., paired molecular and morphological studies), these subspecies have not been universally accepted as valid taxonomic groups (110, 169). All U.S. species except T. rubrofasciata and T. sanguisuga
have been collected in Mexico; the distribution of T. sanguisuga likely extends into northeastern Mexico as well (255). A review of the published literature from 1939 to 2010 resulted in reports of wild-caught triatomine bugs from 262 counties in 28 states. The greatest species diversity occurs in the southwest, particularly Texas, Arizona, and New Mexico. More specifically, high species diversity is concentrated in south-central Arizona and southwestern Texas, where up to five species have been recorded in a single county (Fig. 2). T. cruzi-infected specimens have been reported from 10 states, predominantly from counties in the Southwest (Fig. 3A). All species except T. incrassata and P. hirsuta have been found naturally infected with T. cruzi (Fig. 3B to L). County-level maps (Fig. 2 and 3) reflect in part where collection efforts have been focused over the past 70 years. There is no evidence of a temporal or spatial trend in the published reports to suggest any recent migration of species into or within the United States. The county maps do not necessarily reflect triatomine population densities or provide a complete representation of their distributions. Rather, the maps more likely provide an indication of where the bugs have been considered a pest to humans or animals and where field efforts were concentrated as a consequence or where specimens were collected coincidentally by researchers studying other animal systems (i.e., reports based on museum specimens). Collection records are more comprehensive in the southwestern states and Florida, with sparse records in the southeastern states. Early discovery of the association of U.S. triatomine bugs with Neotoma species of woodrats may have aided field research in
FIG. 1. Photographs of U.S. triatomine species, Triatoma and Paratriatoma. The image size relative to the scale bar represents the average length of each species. Photographs for T. incrassata, T. recurva, and P. hirsuta were unavailable. All photographs are by S. Kjos.
VOL. 24, 2011
T. CRUZI AND CHAGAS’ DISEASE IN THE UNITED STATES
659
TABLE 3. Geographic location, Trypanosoma cruzi prevalence, human interaction, and sites of collection of Triatoma and Paratriatoma species in the United States Species
State(s)
Total no. tested
No. (%) positive
Human bites/allergic reactions
1,800
1,038 (58)
⫹/⫹
Not reported 4 (33) 144 (51)
⫺/⫺ ⫺/⫺ ⫹/⫺
40 (76) 723 (18)
⫺/⫺ ⫹/⫹
71 (13)
⫹/⫹
1,340
96 (7)
⫹/⫹
2 1031
2 (100) 151 (15)
⫹/⫹ ⫹/⫹
0 (0)
⫹/⫺
T. gerstaeckeri
NM, TX
T. incrassata T. indictiva T. lecticularia
AZ Not reported AZ, NM, TX 12 FL, GA, MO, NM, 282 OK, SC, TN, TX TX 53 AZ, CA, CO, NM, NV, 4,124 TX, UT
T. neotomae T. protracta
T. recurva
AZ
T. rubida
AZ, CA, NM, TX
T. rubrofasciata FL, HI T. sanguisuga AL, AR, FL, GA, IL, IN, KS, KY, LA, MD, MO, MS, NC, NJ, OH, OK, PA, SC, TN, TX, VA P. hirsuta AZ, CA, NV a
565
66
Collection site(s)a
References
B, C, D, H, L, LS, WR
26, 49, 94, 150, 160, 169, 195, 217, 228, 239, 259, 282, 296, 330–332, 341 L 169, 255 H, L, WR 150, 151, 229, 259, 296, 332, 341 D, H, L, T, WR 150, 169, 195, 218, 250, 256, 259, 282, 312, 332, 341 D, WR 49, 85, 94, 150, 282, 296 H, L, R, T, WR 95, 96, 135, 150, 152, 153, 159, 187, 203, 204, 217, 237, 243, 255, 256, 259, 273, 282, 285, 296, 304, 320–322, 326, 327, 329, 330, 332, 335, 336, 339–341 C, H, L, R, WR 95, 96, 152, 237, 255, 256, 296, 321, 325, 329, 330, 332, 335, 336, 339 H, L, WR 95, 96, 150, 152, 153, 156, 237, 256, 259, 273, 282, 296, 321, 324, 329, 330, 332, 335, 336, 341 H, LS, WP 12, 169, 255, 296, 337 D, H, L, LS, T, WP, 27, 41, 49, 54, 77, 90, 94, 116, WR 120, 128, 134, 147, 150, 152, 169, 195, 212, 218, 228, 231, 239, 254, 259, 282, 286, 296, 332, 345, 347 H, L, WR 169, 251, 252, 255, 256, 296, 324, 333, 335, 336
B, bird nest; C, cave; D, dog kennel; H, house; L, lights; LS, livestock pens; R, roadbed; RK, rocks; T, trees; WP, woodpile; WR, woodrat nest.
the southwestern states, because woodrat species in this region build easily identifiable, above-ground dens. The absence of records in some areas of the southeastern United States may reflect a paucity of field studies or published records in those
locations rather than being an indication of true absence of the bug. The detection of T. cruzi-infected wild mammals in many of these areas suggests the presence of the vectors. Additionally, recent efforts to model the geographic distribution of U.S. species based on the land cover, climate, and host composition of known collection sites indicate favorable habitat suitability in many of these unsurveyed or underreported regions (26, 137, 158, 259). Characteristics of each species are summarized in Table 3 and described in detail in the sections that follow.
Description of U.S. Triatomine Species
FIG. 2. Triatomine species diversity in the continental United States and Hawaii by county. States shaded gray have reported at least one species. The states of Kentucky, Maryland, Mississippi, New Jersey, and Pennsylvania have each reported one species but with no locality specified. References are provided in Table 3.
Triatoma gerstaeckeri (Stål). T. gerstaeckeri is one of the most frequently collected and tested species in the United States; 57.7% (1,038/1,800) of tested specimens were found to harbor T. cruzi. T. cruzi-infected specimens have been found in both Texas and New Mexico and in the majority of the counties where testing has been reported (Fig. 3B). Published reports from the 1930s to 1960s describe T. gerstaeckeri as a pest species of humans and livestock; the adult bugs were frequent invaders of rural houses in Texas, and reports of humans being bitten were common (217, 330, 332). Human encounters have been less frequently reported in recent decades (49, 151). Infected T. gerstaeckeri specimens were recently recovered from the residence of a child with acute Chagas’ disease in southern Texas (151). In northeastern Mexico, this species is considered an important Chagas’ disease vector due to its close association
660
BERN ET AL.
CLIN. MICROBIOL. REV.
FIG. 3. Triatomine species geographic distribution by state (gray areas) and county and Trypanosoma cruzi infection status by county in the continental United States and Hawaii. (A) All species; (B) Triatoma gerstaeckeri; (C) T. incrassata; (D) T. indictiva; (E) T. lecticularia; (F) T. neotomae; (G) T. protracta; (H) T. recurva; (I) T. rubida; (J) T. rubrofasciata; (K) T. sanguisuga; (L) Paratriatoma hirsuta. Red, T. cruzi-positive specimens; blue, negative specimens; yellow, no testing reported. References are provided in Table 3.
with human dwellings (184, 288). U.S. T. gerstaeckeri data derive predominantly from Texas, where the bug has been found in a wide variety of habitats. The species was collected from a rock squirrel burrow in a cave in the southeastern corner of New Mexico (341). Triatoma incrassata Usinger. T. incrassata is somewhat similar to T. protracta in size and general appearance of legs and head, but it has a distinctive abdominal margin which is largely yellow on the dorsal surface and entirely yellow on the ventral surface. It has been collected at lights in the two southern Arizona counties of Santa Cruz and Pima (Fig. 3C) (169, 255). The major mammalian hosts and T. cruzi infection prevalence for this species are unknown. Triatoma indictiva Neiva. T. indictiva was considered a subspecies of T. sanguisuga in the past but is currently accorded full species status (110, 169, 296). This species is very similar in appearance to T. sanguisuga, with the exception of the uniformly black pronotum and narrower horizontal markings on the abdominal edge. The distributions of the two species overlap in the central regions of Texas, with T. indictiva continuing
further west to Arizona and T. sanguisuga continuing east to the Atlantic coast (Fig. 3D and K). Reported collection of T. indictiva is much less frequent than that of T. sanguisuga. Additional collection sites for T. indictiva in New Mexico and Arizona were provided in a map by Lent and Wygodzinsky in 1979, but specific location designations were not given (169). Specimens were collected from woodrat nests in New Mexico and at lights in Texas (229, 332). T. indictiva has been found naturally infected with T. cruzi in specimens from Texas (151, 229). Triatoma lecticularia (Stål). T. lecticularia has a geographic distribution similar to that of T. sanguisuga, from the southcentral United States east to the Atlantic coast (Fig. 3E). Its range probably includes Oklahoma, Arkansas, Louisiana, Mississippi, and Alabama based on similarities in ecological characteristics between these states and adjacent areas where it has been reported. Specimens of T. lecticularia from New Mexico have been reported, but specific location information was not provided (254, 296). T. lecticularia had been variously classified as a subspecies of as well as synonymized with T. sanguisuga
VOL. 24, 2011
T. CRUZI AND CHAGAS’ DISEASE IN THE UNITED STATES
prior to Usinger’s 1944 reclassification (296). Therefore, early reports of T. lecticularia and T. sanguisuga may be difficult to confirm without reviewing the actual specimens. Ryckman in 1984 contended that reports of T. lecticularia from Arizona and California are erroneous, presumably based on earlier taxonomic confusion and contemporary knowledge of the species distribution (254). T. lecticularia can be distinguished from T. sanguisuga and T. indictiva based on its shorter, domed head and uniform covering of all body surfaces with dark hairs. T. lecticularia has been collected from houses, dog kennels, woodrat nests, and rock squirrel burrows in hollow logs in Texas, from houses in South Carolina, and at lights in Missouri (151, 195, 256, 312, 345). In early reports, this species was described as a nuisance species, commonly found in well-constructed homes of central Texas (218). In 1940, Packchanian conducted experimental inoculation of the gut contents of a T. cruziinfected T. lecticularia bug into the eye of a human subject in order to demonstrate the infectivity of a T. cruzi strain from Texas (216). Localized symptoms, fever, lymphadenopathy, and trypomastigotes visualized on blood films confirmed infection in this individual. The high T. cruzi infection prevalence (144/282; 51%) in T. lecticularia was derived primarily from specimens collected from woodrat nests in Texas (282, 332). Triatoma neotomae Neiva. In the United States, T. neotomae is known only from Texas, primarily the southern tip (Fig. 3F). The inclusion of other states in its range by some authors is most likely an error, as published records of T. neotomae outside Texas or northeastern Mexico could not be found. This species is similar in size to T. protracta but with distinctive yellow markings around the abdominal margin and basal half of wings, a glossy body surface, and a ventrally flattened abdomen. Also like T. protracta, this species is closely associated with Neotoma spp. of woodrats, for which it was named. It has been found almost exclusively in woodrat nests throughout its range, with a single report from a dog kennel in Cameron County, TX (151). The small sample size limits interpretation of this species’ high cumulative T. cruzi infection prevalence (40/53; 76%); however, this is likely related to the high infection levels reported among woodrats in this region (49, 93, 219). Triatoma protracta (Uhler). T. cruzi was first reported in the United States from a T. protracta specimen collected in 1916 in a woodrat nest in San Diego County, CA (155). T. cruzi testing data are most abundant for this species, with an overall prevalence of 17.5% (723/4,124). Infected specimens have been reported from four of seven states across its range: California, Arizona, New Mexico, and Texas (Fig. 3G). T. protracta is closely associated with western woodrat species and is commonly found in nests throughout the bug’s geographic distribution. Large aggregations of T. protracta were reported from roadbeds in southern California in an area where woodrat nests were removed as a consequence of highway construction (340). Attracted by lights, the displaced bugs frequently entered houses in the area and became a source of annoyance for residents. T. protracta has also been reported as frequently entering houses in other areas of California, New Mexico, and Arizona (187, 273, 304, 332, 336). First reported as a pest of humans in Yosemite Valley, CA, in the 1860s, T. protracta continues to be an important cause of severe allergic reactions in humans who are bitten (152, 198). This species was impli-
661
cated in a human case of Chagas’ disease in north-central California (203). Triatoma recurva (Stål). T. recurva naturally infected with T. cruzi has been found in the southern half of Arizona (Fig. 3H). A single report of T. recurva collected in western Texas has not been confirmed or replicated (138, 151). Early reports describe T. recurva as a pest of humans, primarily in the Alvardo Mine area of Yavapai County, AZ, where it was a common invader of houses and tents of mining employees (332, 336). Recent reports describe home invasions and hypersensitivity reactions due to bites that occurred in and around houses in Pima and Cochise Counties, AZ (152, 237). Although the species has been collected occasionally from woodrat nests, the woodrat is not considered the primary host of T. recurva (96, 255, 321). The preferred host for this species is unknown, but it has been observed in association with rodents, particularly rock squirrels, and feeds on reptiles and guinea pigs in laboratory settings (96, 255, 324, 334, 336). T. recurva is the largest of the U.S. species (average length, 29 mm) and has relatively hairless body surfaces, including the first two segments of the mouthparts. It is brown to black in appearance, with slender, long legs and head and an orange-yellow abdominal margin. Its body size, head and leg characteristics, and uniformly colored pronotum distinguish this species from others in its range. Triatoma rubida (Uhler). In the United States, T. rubida has been found from western Texas to southern California; T. cruzi-positive specimens have been reported from Arizona and Texas (Fig. 3I). The cumulative infection prevalence in the published literature is low (96/1,340; 7.2%). However, in a recent study, the gut contents of 65 (41%) of 158 T. rubida specimens collected in and around houses in Pima County, AZ, yielded positive results by T. cruzi PCR (237). Despite the presence of nymphal stages inside houses in this study, the authors remarked that the numbers were too low to conclude that colonization was established. In contrast, a study from Sonora, Mexico, reported that 68% of houses were colonized by T. rubida, suggesting that this species was domesticated in that region (221). Both the U.S. and Mexican study areas had experienced disruption of previously undisturbed environments considered suitable habitats for both triatomine and T. cruzi vertebrate hosts. Human bite encounters, including hypersensitivity reactions due to T. rubida, continue to be a public health issue in Arizona (152, 226, 237). This species has been frequently collected from woodrat nests throughout its range (96, 256, 321, 332, 336). It can be distinguished morphologically from other species in its range by the first antennal segment, which reaches or surpasses the tip of the head. Triatoma rubrofasciata (DeGeer). Described in 1733, T. rubrofasciata was the first species classified in the Triatominae subfamily and is the current type species for the Triatoma genus (270). It is the only triatomine species found in both the Eastern and Western Hemispheres and is frequently found in port cities in close association with the roof rat (Rattus rattus) (255). Molecular and morphometric data support the hypothesis that Old World triatomine species derive from T. rubrofasciata carried from North America with rats on sailing ships during the colonial period (136, 223, 270). In the United States, this species has been collected from houses in Florida and Hawaii and in chicken and pigeon coops and cat houses in
662
BERN ET AL.
Hawaii. Specimens have been reported from Jacksonville, FL, and Honolulu, HI (Fig. 3J) (296, 337). Wood (in 1946) reported 2 specimens collected from Honolulu to be infected with T. cruzi based on morphological and motility characteristics (337). Allergic reactions to T. rubrofasciata bites have been reported in humans from Hawaii (12). Triatoma sanguisuga (Leconte). T. sanguisuga is one of the most widely distributed species in the United States, with its range spanning from Texas and Oklahoma eastward to the Atlantic coast (Fig. 3K). This species has been reported in Pennsylvania, New Jersey, Maryland, and Kentucky, but without specific location data (169, 254, 296). Although published records are lacking, its range probably includes West Virginia. Reports of T. sanguisuga from states west of Texas were likely mistaken due to taxonomic reclassification (see “Triatoma indictiva Neiva” above). In every state where testing has been conducted, T. cruzi-infected T. sanguisuga has been found, including Texas, Oklahoma, Louisiana, Alabama, Tennessee, Georgia, and Florida. It has been collected from diverse natural settings across its range, in association with many different vertebrate hosts, including woodrats, cottonrats, armadillos, raccoons, opossums, frogs, dogs, chickens, horses, and humans (120, 150, 212, 215, 332, 348). Human annoyance and allergic reactions to T. sanguisuga bites were reported as early as the mid-1800s in Georgia, Kansas, Oklahoma, and Florida and recently in Louisiana (116, 147, 152, 161, 215). This species was found inside the residences of human Chagas’ disease patients in Tennessee and Louisiana and in the vicinity of the home of a T. cruzi-seropositive blood donor in Mississippi (54, 90, 134). Paratriatoma hirsuta Barber. P. hirsuta is known from the western United States, collected from arid regions of California, Nevada, and Arizona (Fig. 3L). Although it has been demonstrated to be a competent vector of T. cruzi in experimental settings, a naturally infected specimen has yet to be reported (321). It has been most frequently collected from woodrat nests in its range but has also been found in houses and other human dwellings in Yavapai County, AZ, and Riverside County, CA, and at lights in Palm Springs, CA (251, 296, 336). Ryckman (in 1981) described this species as having important public health significance due to allergic reactions caused by its bite (252). This is one of the smallest U.S. triatomine species (average length, 13 mm) and can be distinguished from T. protracta, which is similar in size and geographic distribution, by a pervasive covering of dark hairs on all body surfaces. Human-Vector Interactions and T. cruzi Transmission Potential in the United States Eight of the 11 species have been associated with human bites, and seven have been implicated in allergic reactions (Table 3). Allergic reactions occur in response to antigens delivered in the vector saliva during blood feeding and are unrelated to the T. cruzi infection status of the bug. Most allergic reactions are localized at the bite site, characterized by a large welt and intense itching (315). Severe reactions are generally systemic and may involve angiodema, urticaria, difficulty breathing, nausea, diarrhea, and/or anaphylaxis (152, 226). Although allergic reactions to triatomine bites have been
CLIN. MICROBIOL. REV.
reported from states throughout the southern United States, the incidence is highest in the southwestern states, with T. protracta and T. rubida most frequently implicated (106, 152, 204, 226, 237). The most common scenario involves invasion of an adult bug into a human dwelling, where it bites a sleeping individual. Contemporary encounters between humans and triatomine bugs in the United States are often associated with destruction or invasion of vertebrate host habitats, compromised housing structures, or both. Disruption of host burrows (as described above for T. protracta) provokes the bugs to seek new refuges, and their innate attraction to lights often leads them to nearby human dwellings. Most triatomine species show flexibility in host and habitat requirements, which allows them to adapt to changing environments. A host preference for some species has been difficult to establish due to association with multiple vertebrate habitats and the ability of the insects to mature and reproduce successfully on multiple host species in laboratory settings. Although mammals are the only vertebrate reservoirs for T. cruzi, many triatomine species utilize other animal groups as blood hosts, including reptiles and amphibians (T. gerstaeckeri, T. protracta, T. recurva, T. rubida, and T. sanguisuga) and birds (T. gerstaeckeri and T. sanguisuga) (169, 228, 253, 338). A recent blood meal analysis study of Texas field specimens provides evidence of a broad host range for T. gerstaeckeri and T. sanguisuga. The DNAs from nine vertebrate species (woodrat, dog, cat, cow, pig, raccoon, skunk, armadillo, and human) were detected in T. gerstaeckeri gut specimens, and DNAs from three species (dog, avian, and human) were detected in T. sanguisuga gut specimens (149). Because vector colonization of houses in the United States is rare, the risk of vector-borne transmission to humans is considered to be quite low. With the exception of the 2006 Louisiana case in which the residence was found to harbor triatomine colonies, vector-borne transmission to humans in the United States has been attributed to adult bugs invading houses (90, 134, 203). Expansion of human settlements into environments that support an active sylvatic disease cycle could result in an increase in adult invaders and, potentially, colonization events. Colonization of houses by triatomines is an important factor in vector-borne transmission because it increases the probability of encounters between humans and potentially infected vectors. In addition to adaptability to domestic structures, triatomine feeding and defecation behaviors are important risk factors for vector-borne transmission and vary across species. The timing and placement of defecation after feeding greatly influence the risk of transmission via fecal contamination of the host bite site or other exposed tissues. A small number of studies have reported on these characteristics in U.S. species. In 1951 Wood reported the following average postfeeding defecation times (minutes) for the adults of four U.S. species: T. protracta, 30.6 (n ⫽ 10); T. rubida, 1.6 (n ⫽ 5); T. recurva, 75.7 (n ⫽ 3); and P. hirusta, 35.0 (n ⫽ 2) (327). In a similar study in 2007 using both nymphs and adults of three Mexican species (also present in the United States), Martinez-Ibarra et al. reported the following results: T. protracta, 6.7 (n ⫽ 475); T. lecticularia, 8.3 (n ⫽ 368); and T. gerstaeckeri, 11.5 (n ⫽ 733) (183). Likewise, Zeledon et al. (1970) reported the following results for nymphs and adults of three Latin American species: R. prolixus, 3.2
VOL. 24, 2011
T. CRUZI AND CHAGAS’ DISEASE IN THE UNITED STATES
(n ⫽ 210); T. infestans, 3.5 (n ⫽ 210); and T. dimidiata, 11.3 (n ⫽ 210) (352). In 1970 Pippin reported the proportion of bugs defecating within 2 min postfeeding for adults of two U.S. and one Latin American species: R. prolixus, 74.6% (n ⫽ 169); T. gerstaeckeri 19.4% (n ⫽ 160); and T. sanguisuga 16.9% (n ⫽ 136) (228). Similarly, in 2009 Klotz et al. reported the proportion of bugs defecating before or directly after feeding for adults of two U.S. species: T. rubida, 45% (n ⫽ 40); and T. protracta, 19.4% (n ⫽ 31) (153). In that study, it was noted that none of the bugs of either species defecated on the host during the experiment. Although direct comparisons across studies is problematic due to variation in methods and conditions (e.g., temperature, blood host, and feeding apparatus), it appears that U.S. species in general exhibit greater postfeeding defecation delays than important Latin American vector species. Delayed defecation and a low frequency of domestic colonization contribute to a low probability of autochthonous U.S. human infection due to vector-borne transmission, which is the primary route of infection in areas of hyperendemicity in Latin America.
ANIMAL RESERVOIRS OF TRYPANOSOMA CRUZI Background Concurrent with the demonstration of T. cruzi in the first recognized human patient, Carlos Chagas observed the parasite in the blood of a domestic cat in the same household (62). Subsequently, Chagas went on to demonstrate T. cruzi in armadillos and primates, confirming the role of wildlife as reservoirs (63, 64). To date, over 100 mammalian species have been reported as natural hosts for T. cruzi, and all mammals are considered to be susceptible to infection. Birds are refractory to infection due to complement-mediated lysis and macrophage-induced killing of the parasites (146, 188). Although T. cruzi has a wide host range, the epidemiologically important reservoirs vary by geographic region due to the biology and ecology of the mammals and vectors and how these interactions translate to risk of human exposure. Opossums and armadillos are important reservoirs throughout the Americas, a finding consistent with genetic data suggesting that these two groups are the ancestral hosts for the two major ancestral lineages of T. cruzi (112, 349). Transmission routes for wildlife and domestic animal species are similar to those for humans. Sylvatic animals become infected during feeding activity of vectors present in their burrows, dens, or temporary shelters. As in humans, infection occurs when bug feces containing the parasites enters a wound or mucous membrane. In addition, the insectivorous behavior of many animals (e.g., woodrats) increases the likelihood of infection via the ingestion of infected bugs (78, 241, 250). Transplacental transmission has been documented in laboratory mice and rats (15, 81, 127). Although not proven to occur in wildlife, this route likely contributes to maintenance of the parasite in the sylvatic cycle as well. Ingestion of infected meat was once considered a possible route of transmission, but a recent study with raccoons suggests that this is probably uncommon (241).
663
Wildlife Reservoirs of T. cruzi in the United States In the United States, natural T. cruzi infection was first reported in the big-eared woodrat Neotoma macrotis (syn. N. fuscepes macrotis) in California (316). In the 1940s, natural infections were reported from house mice, southern plains woodrats (N. micropus), nine-banded armadillos (Dasypus novemcinctus), and Virginia opossums (Didelphis virginiana) in Texas and from brush mice (Peromyscus boylii rowleyi) and woodrats (N. albigula) in Arizona (219, 321). Early experimental infection trials with parasites from these hosts and Triatoma spp. indicated that laboratory rats, laboratory mice, guinea pigs, domestic dogs, rhesus macaques, opossums (D. virginiana), six species of Peromyscus, and four species of woodrats were susceptible (77, 154, 215, 217, 316, 321). In addition, an isolate from a naturally infected Triatoma species from Texas was shown to be infectious to a human (216). Subsequent surveys in the 1950s and 1960s documented infections in raccoons (Procyon lotor), Virginia opossums, striped skunks (Mephitis mephitis), and gray foxes (Urocyon cinereoargenteus) in the southeastern United States (185, 212, 305). Currently, at least 24 species are recognized as natural wildlife hosts for T. cruzi in the United States (Table 4). Reported T. cruzi infection rates vary widely by host species and geographic area. However, the observed variation may be due in part to the use of different diagnostic assays with very different sensitivities. As in humans, the majority of infected animals are in the chronic phase of the infection; therefore, serological testing is more sensitive than methods that rely on detection of parasites (346). However, unlike serological tests, visualization of the parasites allows the examiner to distinguish T. cruzi from other Trypanosoma species (e.g., T. neotomae, T. kansasensis, T. peromysci, and T. lewisi-like sp.) reported from rodents based on morphology (186, 207, 294, 317, 328; M. J. Yabsley, unpublished data). If serology is used for screening, infections should be confirmed with a T. cruzi-specific assay. Some PCR assays will amplify other Trypanosoma and/or Leishmania species, and more specific methods may be necessary to confirm the infection as T. cruzi. The primary reservoirs and transmission dynamics of T. cruzi differ between the eastern and western regions of the United States. The greatest vector diversity and density occur in the western United States (Fig. 2), where many triatomine species live in the nests of woodrats. In this region, woodrats are the most common reservoir; however, infection has also been demonstrated in other rodents, raccoons, skunks, and coyotes (Table 4; Fig. 4A and B). Rodents other than woodrats utilize habitats similar to those of woodrats (old woodrat nests, small caves, and holes in rock walls) where triatomines are found, while coyotes, raccoons, skunks, and opossums likely become infected when bugs feed on them in their dens or through ingestion of bugs. In the eastern United States, the prevalence of T. cruzi is highest in raccoons, opossums, armadillos, and skunks (Table 4; Fig. 4A and B). There are several woodrat species in the eastern United States, but densities are much lower than for woodrat species in the western United States, and nests are less evident because they utilize burrows instead of large above-ground constructed nests. Little is known about the prevalence of T. cruzi in eastern woodrat species. To date, only one survey for T. cruzi has been conducted, and none of 23
664
BERN ET AL.
CLIN. MICROBIOL. REV. TABLE 4. Hosts of Trypanosoma cruzi in the United Statesa
Species
Raccoon (Procyon lotor)
State(s)
Total no. tested
AL AZ FL FL FL FL, GA GA GA GA GA GA, SC KY
35 5 184 33 70 608 54 30 510 10 221 44
MD MD MO NC OK TN TN TX TX TX
No. (%) positive
Assay type (sample or specific assay)
Reference(s)
472 NKb 109 20 8 3 706 25 9 19
5 (14) 1 (20) 4 (2) 4 (12) 38 (54) 9 (1.5) 12 (22) 13 (43) 168 (33) 5 (50) 104 (47) 17 (39) 19 (43) 2 (0.4) 5 74 (68) 3 (15) 5 (63) 2 (66) 206 (29) 6 (24) 0 4 (21)
Culture (heart and blood) Serology (IFA) Blood smear Culture (blood) Serology (IFA) Culture (kidney) Culture (blood) Culture (blood) Serology (IFA) Culture (blood) Serology (IFA) Culture (blood) Serology (IFA) Culture (heart) Culture (blood) Serology (IFA) Culture (blood) Culture (blood) Culture (blood) Serology (IFA) Culture (blood) Serology (indirect hemagglutination) Culture (blood)
VA
464
153 (33)
Serology (IFA)
130 305 46 144 141 134 179 262 49 M. Yabsley et al., unpublished 129
Ringtail (Bassariscus astutus)
AZ
1
Serology (IFA)
46
Opossum (Didelphis virginiana)
AL FL GA GA GA GA, FL KY
126 27 39 421 29 552 48
212 46 231 46 222 185 118
MD NC OK LA TX TX VA
219 12 10 48 8 391 6
Culture (blood and heart) Serology (IFA) Culture (blood) Serology (IFA) PCR (liver) Culture (kidney) Culture (blood) Serology (IFA) Culture (heart) Culture (blood) Culture (blood) Culture (blood) Culture (blood) Blood smear Serology (IFA)
LA LA
98 80
19 348
TX
15
Culture (blood) Culture (blood) Serology (direct agglutination) Culture (blood)
Nine-banded armadillo (Dasypus novemcinctus)
1 (100) 17 (14) 14 (52) 6 (15) 118 (28) 3 (10) 88 (16) 0 (0) 6 (13) 0 (0) 1 (8) 0 16 (33) 5 (63) 63 (16) 1 (17) 1 (1) 23 (29) 30 (38) 1 (7)
212 46 262, 284 262 46 185 231 224 46 262 345 118
130 144 141 19 219 94 46
219
Striped skunk (Mephitis mephitis)
AZ CA GA, FL GA TX
34 1 306 1 3
3 (9) 1 (100) 3 (1) 1 (100) 2 (67)
Serology (IFA) Serology and histology Culture (kidney) Serology (IFA) Culture (blood)
46 248 185 46 Yabsley et al., unpublished
Gray fox (Urocyon cinereoargenteus)
GA, FL GA SC
118 21 26
2 (2) 0 2 (8)
Culture (kidney) Serology (IFA) Serology (IFA)
185 46 245
Bobcat (Felis rufus)
GA
62
2 (3)
Serology (IFA)
46
American badger (Taxidea taxus)
TX
8
2 (25)
Serology (indirect hemagglutination)
49
Coyote (Canis rufus)
GA TX
23 134
1 (4) 19 (14)
Serology (IFA) Serology (IFA)
46 119 Continued on following page
VOL. 24, 2011
T. CRUZI AND CHAGAS’ DISEASE IN THE UNITED STATES
665
TABLE 4—Continued Total no. tested
No. (%) positive
VA
26
1 (4)
Serology (IFA)
46
Feral swine (Sus scrofa)
GA
110
0
Serology (IFA)
46
Southern plains woodrat (Neotoma micropus)
TX TX TX NM
30 100 159 NK
Culture (blood) Culture (blood) PCR (liver) Xenodiagnosis
49 219 227 341
White-throated woodrat (Neotoma albigula)
AZ NM
NK NK
2 1
NK Xenodiagnosis
328 341
Big-eared woodrat (Neotoma macrotis ⫽ N. fuscipes subsp. macrotis) Brush mouse (Peromyscus boylii rowleyi) Gilbert white-footed mouse (Peromyscus truei gilberti) Pinon mouse (Peromyscus truei montipinoris) Western harvest mouse (Reithrodontomys megalotis) Hispid pocket mouse (Perognathus hispidus) House mouse (Mus musculus) Mexican spiny pocket mouse (Liomys irrorattus) Grasshopper mouse (Onychomys leucogaster) CA ground squirrel (Spermophilus beecheyi) Mexican ground squirrel (Spermophilus mexicanus) Whitetail antelope squirrel (Ammospermophilus leucurus) Hispid cotton rat (Sigmodon hispidus)
CA
99
9 (9)
Xenodiagnosis and blood smear
318, 319, 328, 339
AZ
NK
1
NK
328
CA
NK
2
NK
328
CA
NK
11
Xenodiagnosis
339
CA
NK
1
Xenodiagnosis
323
TX
25
4 (16)
Culture (blood)
49
TX TX
2 11
1 (5) 1 (9)
Culture (blood) Culture (blood)
219 49
TX
9
1 (11)
Culture (blood)
49
CA
19
2 (11)
Culture (blood)
203
TX
1
1 (100)
Culture (blood)
NM
NK
3
Xenodiagnosis
Yabsley et al., unpublished 339, 341
TX
1
1 (100)
Culture (blood)
Species
a b
State(s)
5 (17) 31 (31) 42 (26) 1
Assay type (sample or specific assay)
Reference(s)
Yabsley et al., unpublished
Only selected negative results are shown if large numbers of a particular species were examined. NK, not known.
Neotoma floridana animals in Kansas were positive (294). Reports of wildlife infections are shown at the county level (when possible) in Fig. 4A and B. Domestic and Exotic Animal Infections in the United States In addition to indigenous wildlife reservoirs, domestic and exotic animals can become infected if they are present in an enzootic area and come in contact with infected bugs. Transmission routes are similar to those for wildlife, with ingestion of bugs likely being an important route. Canine Chagas’ disease. In Central and South America, domestic dogs are important reservoirs in the domestic cycle and can be used as sentinels for local transmission (123). A similar cycle has been recognized in the United States, but the importance of domestic dogs as T. cruzi infection reservoirs is not as well understood (26). T. cruzi infection in domestic dogs has been reported widely throughout the southern United States since 1972 (Fig. 4C) (18, 20, 23, 41, 105, 134, 150, 189, 205, 206, 239, 274, 287, 298, 312). Infection has been documented in at least 48 different breeds in the United States, with
the sporting and working breeds accounting for the majority of cases, presumably due to greater exposure to infected vectors and mammalian tissues (150, 246). As in humans, transplacental transmission is also an important mode of transmission in dogs (23, 58). Domestic dogs can develop both acute and chronic disease similar to that in humans. Acute illness, particularly mortality, has been reported more frequently in very young dogs (⬍1 year old) and generally involves myocarditis and cardiac arrhythmias (150). Dogs that survive infection at a very young age or acquire infection as adults generally experience a chronic course of disease that may progress to significant cardiac dysfunction, typically involving cardiac dilatation, electrocardiogram (ECG) abnormalities, and clinical signs related to right-sided or bilateral cardiac failure (21, 22). In a recent seroprevalence study in Tennessee, older dogs (ages 6 to 10 years) were more likely to be infected (246), which is similar to results of studies in Latin America that reported increasing seropositivity with increasing age (97, 122). Dogs with clinically apparent infections are managed with appropriate supportive therapy. Chemotherapeutic agents developed for treatment of human Chagas’ disease (benznidazole and
666
BERN ET AL.
CLIN. MICROBIOL. REV.
inoculum from exposure to or ingestion of a large number of infected bugs but may also reflect variation in susceptibility of animal species to clinical Chagas’ disease. Mortality due to locally acquired T. cruzi infection has occurred in groups of captive animals in the United States, including baboons (Papio hamadryas), rhesus macaques, crab-eating macaques (M. fascicularis), Celebes black macaques (M. nigra), sugar gliders (Petaurus breviceps), and a hedgehog (Atelerix albiventris) (8, 115, 145, 213, 313). Asymptomatic T. cruzi infection has been reported in lion-tailed macaques (M. silenus), pigtailed macaques (M. nemestrina), rhesus macaques, baboons, ring-tailed lemurs (Lemur catta), and black and white ruffed lemurs (Varecia variegata) in the United States (11, 128, 145, 232, 264). MOLECULAR EPIDEMIOLOGY OF T. CRUZI General Molecular Epidemiology
FIG. 4. Reports of natural Trypanosoma cruzi infection in U.S. mammals. (A) Raccoons, Virginia opossums, and ringtails; infection of opossums has been reported in Virginia, but no locality was specified. (B) Rodents and mesomammals. An additional report of infected coyotes was published from Virginia, but no locality was specified. (C) Domestic canines. In some states (California, Georgia, Tennessee, and Virginia, shown in dark gray), additional canine clinical cases were reported, but no locality was specified. References are provided in Table 4 for panels A and B and in the text for panel C.
nifurtimox) have shown some efficacy in dogs (121, 125), but they are not currently approved for veterinary use in the United States. Primates and other exotic animals. Any mammals kept in areas where bugs may enter are at risk of acquiring T. cruzi infection. Because U.S. animal use guidelines require that nonhuman primates be housed in facilities with access to the outdoors, they may be at particular risk of acquiring T. cruzi infection. Exotic animals that acquire T. cruzi infection may be asymptomatic or may develop symptomatic, even lethal, clinical disease. Severe disease may be due to a large parasite
T. cruzi is a genetically heterogeneous species that also has wide variability in biological and biochemical characteristics (51, 174, 191, 192). The most common historical classification divided T. cruzi into two major groups, TcI and TcII; TcII was further divided into five subgroups (also called discrete typing units) designated TcIIa to TcIIe (51, 193, 309). Recently, a consensus was reached that the six major recognized lineages will be renamed TcI to TcVI; compared to the earlier system, TcI remained TcI, TcIIb became TcII, TcIIc became TcIII, TcIIa became TcIV, TcIId became TcV, and TcIIe became TcVI (353). For the purposes of this review, data from earlier studies that genotyped isolates as TcII (without a to d subtyping) will be referred to as “historic TcII” to differentiate these types from the current TcII, which is equivalent to the historic TcIIb lineage. The TcI and TcII lineages are considered ancestral, whereas the TcV and TcVI lineages are the products of at least two hybridization events (309, 353). The origins of TcIII and TcIV are as yet unresolved (353). Whereas some investigators consider TcIII to represent a third ancestral strain (80), others consider it to be the result of hybridization between TcI and TcII (309, 310). TcI and TcII to TcVI are estimated to have diverged between 88 and 37 million years ago (43, 175). Currently, T. cruzi genotypes are classified based on size polymorphism or sequence analysis of several gene loci, including the miniexon gene, the intergenic region of the miniexon gene, the 18S rRNA gene, the 24S␣ rRNA gene, internal transcribed spacer regions, and numerous housekeeping genes (171, 310). The TcI lineage is found throughout the Americas in both domestic and sylvatic cycles and is believed to have evolved with arboreal Didelphimorpha (opossums) and vectors in the triatomine tribe Rhodniini (112). In all parts of the Americas, Didelphis spp. are common reservoirs for this lineage, although natural infection with TcI has been reported in a wide range of mammals. TcI is the only lineage reported from humans in North and Central America and the predominant lineage reported in human Chagas’ disease in areas of South America north of the Amazon Basin (40, 139, 239, 258). Although TcI has long been recognized as genetically diverse, subtyping has not been widely conducted until very recently, and no generally accepted typing system or nomenclature currently exists. Additionally, many isolates have been
VOL. 24, 2011
T. CRUZI AND CHAGAS’ DISEASE IN THE UNITED STATES
667
TABLE 5. Genotypes of U.S. T. cruzi isolates Species
No.
State(s)
Genotype(s) (no.)
Reference(s)
Human Opossum Raccoon Ring-tailed lemur Rhesus macaque Nine-banded armadillo Striped skunk Domestic dog Triatoma spp.
5 15 79 3 2 3 1 7 8
CA, TX, LA GA, FL, LA, AL GA, FL, TN, MD, LA, KY GA GA LA, GA GA TN, OK, SC, CA, unknown GA, FL, TX
TcI (5) TcI (15) TcI (2), TcIV (74), mixed (2) TcIV (3) TcI (1), mixed (1) TcI (2), TcIV (1) TcIV (1) TcIV (6), mixed (1) TcI (6), TcIV (1) mixed (1)
239 68, 239 45, 68, 239 239 239 239 239 44, 45, 239 17, 68, 175, 239
examined only by sequencing of a single locus. Haplotypes were first recognized following sequence analysis of the intergenic regions of the miniexon genes of 12 isolates from Columbia (132). Based on single-nucleotide polymorphisms, insertions, and deletions, four haplotypes, TcIa to TcId, were proposed. Haplotypes TcIa and TcIc were associated with humans and domiciliated vectors. Haplotypes TcIb and TcId were found in specimens from one human, opossums, and sylvatic vectors; TcId was found exclusively in sylvatic samples (132). Interestingly, phylogenetic analysis of the same gene region of 20 TcI strains from the United States, Mexico, Bolivia, Brazil, Columbia, and Argentina showed that Didelphis sp. isolates grouped separately from other isolates (210). A fifth haplotype (TcIe) was recently detected in a human and a sylvatic vector (Mepraia spinolai) from Chile and in one domestic vector (T. infestans) from Argentina (76). Multilocus microsatellite profiling of 135 TcI isolates provided better discrimination and increased levels of variability among TcI sylvatic strains (173). However, in contrast to previous studies in which opossums were found to be infected with a particular haplotype (210), no host association was noted. The authors suggest that the ecological niche might be more important for parasite evolution and diversification than reservoir host species (173). Wider use of multilocus typing methods may provide further insight into TcI genetic diversity in the future. Lineage TcIII (historical TcIIc) is believed to have evolved with terrestrial burrowing edentates, specifically armadillos, and bugs in the triatomine tribe Triatomini (112, 349). Edentates and marsupials were the first mammal inhabitants of South America (⬃65 million years ago), whereas rodents, primates, and bats arrived in South America ⬃25 million years ago (112). Upon arrival, these mammals became hosts to the various lineages of T. cruzi. TcIII is found throughout South America and is rare in domestic cycles but common in sylvatic cycles (172, 349). The primary hosts for TcIII are several different species of armadillos, primarily D. novemcinctus. Additionally, TcIII has been reported from limited numbers of a terrestrial marsupial (Monodelphis domestica), rodents, and skunks (349). TcII, TcV, and TcVI (historic IIb, IId, and IIe, respectively) are the lineages most commonly reported in human Chagas’ disease in southern South America (193). All three lineages are closely associated with the domestic transmission cycle and the domestic vector Triatoma infestans. TcV and TcVI have been reported in cardiomyopathy and intestinal megasyndromes in the Southern Cone (Argentina, Chile, Bolivia, and Brazil) (57, 193). In contrast, intestinal Chagas’ disease is rare
in northern South America, Central America, and Mexico, where TcI is the predominant lineage (191). TcV is the lineage reported most frequently in infants with congenital infection, although this may simply reflect its predominance in Bolivia and Argentina, where these studies have been conducted (72, 303). The two hybrid lineages, TcV and TcVI, are hypothesized to have evolved in armadillos (181, 349). A single isolation of TcII (historic TcIIb) was reported from Euphractus sexcinctus (six-banded armadillo) in Paraguay, but its original mammalian host has not been established (193, 349). Currently, the TcIV (historic IIa) lineage is poorly understood. Studies of several gene targets indicate that TcIV strains from North and South America are genetically distinct and group separately in phylogenetic analyses (181; D. M. Roellig and M. J. Yabsley, unpublished data). In South America, TcIV is found in a wide range of mammals, including primates, rodents, armadillos, and terrestrial marsupials (349). In North America, the raccoon is the principal host for TcIV; infections have been reported in domestic dogs, striped skunks, armadillos, and primates (239). Interestingly, two terrestrial marsupial genera (Philander and Monodelphis) can harbor both TcI and several other genotypes, whereas only TcI has been reported from the arboreal genus Didelphis (163, 225, 240). The genus Philander also displays a more severe inflammatory response to T. cruzi (162, 163). Experimental inoculation of Monodelphis domestica with TcI, TcII, and TcVI strains resulted in infections, but a North American TcIV isolate failed to establish an infection (242). Collectively, these data suggest that the marsupial genera diverged before the establishment of host relationships with T. cruzi and that utilization of different ecological niches resulted in distinct T. cruzi lineage transmission patterns (163). T. cruzi Genotypes in the United States In the United States, only two genotypes (TcI and TcIV) have been reported from mammals and vectors (Table 5). Consistent with the findings in South American studies of Didelphis, TcI is the only genotype reported from D. virginiana, the Virginia opossum (17, 68, 239). In raccoons, TcIV predominates, but TcI has been detected in a small number of specimens. Both TcI and TcIV have been reported from ninebanded armadillos, domestic dogs, and rhesus macaques (68, 239). Lineage TcIV has been reported from a limited number of ring-tailed lemurs and a striped skunk (239). Although the majority of isolates from placental mammals in the United States have been TcIV, all five typed isolates from human
668
BERN ET AL.
autochthonous infection were TcI (239). Both TcI and TcIV have been reported from Triatoma spp. from Georgia, Florida, and Texas. CLINICAL ASPECTS OF CHAGAS’ DISEASE Acute T. cruzi Infection The incubation period following vector-borne T. cruzi exposure is 1 to 2 weeks, after which the acute phase begins (234). The acute phase lasts 8 to 12 weeks and is characterized by circulating trypomastigotes detectable by microscopy of fresh blood or buffy coat smears. Most patients are asymptomatic or have mild, nonspecific symptoms such as fever and therefore do not come to clinical attention during the acute phase. In some patients, acute infection is associated with inflammation and swelling at the site of inoculation, known as a chagoma. Chagomas typically occur on the face or extremities; parasites may be demonstrated in the lesion. Inoculation via the conjunctiva leads to the characteristic unilateral swelling of the upper and lower eyelids known as the Roman ˜a sign (234). Severe acute disease occurs in fewer than 1% of patients; manifestations include acute myocarditis, pericardial effusion, and/or meningoencephalitis (3, 177). Children younger than 2 years appear to be at higher risk of severe manifestations than older individuals. Severe acute Chagas’ disease carries a substantial risk of mortality. Orally transmitted T. cruzi infection appears to be associated with more severe acute morbidity and higher mortality than vector-borne infection (28, 271). For example, 75% of 103 infected individuals in the Caracas outbreak were symptomatic, 59% had ECG abnormalities, 20% were hospitalized, and there was one death from acute myocarditis (82). Recent laboratory data suggest that parasite contact with host gastric acid may render trypomastigotes more invasive through changes in parasite surface glycoproteins and that this interaction may underlie the increased clinical severity seen in orally acquired Chagas’ disease (75, 350). Congenital T. cruzi Infection Most infected newborns are asymptomatic or have subtle findings, but a minority present with severe life-threatening disease (32, 289). The manifestations of symptomatic congenital Chagas’ disease can include low birth weight, prematurity, low Apgar scores, hepatosplenomegaly, anemia, and thrombocytopenia (35, 36, 177, 289). Severely affected neonates may have meningoencephalitis, gastrointestinal megasyndromes, anasarca, pneumonitis, and/or respiratory distress (35–37, 289). Mortality among infected infants is significantly higher than in uninfected infants, ranging from ⬍5% to 20% in published studies (34, 289). However, even severe congenital Chagas’ disease may not be recognized because signs are often nonspecific or because the diagnosis is not considered (289). Chronic T. cruzi Infection Eight to 12 weeks after infection, parasitemia levels become undetectable by microscopy, and in the absence of effective etiological treatment, the individual passes into the chronic
CLIN. MICROBIOL. REV.
phase of T. cruzi infection. Despite the absence of microscopically detectable parasites in the peripheral blood, persons with chronic T. cruzi infection maintain the potential to transmit the parasite to the vector and directly to other humans through blood components, through organ donation, and congenitally (177, 311). Indeterminate form of chronic T. cruzi infection. Persons with chronic T. cruzi infection but without signs or symptoms of Chagas’ disease are considered to have the indeterminate form. The strict definition of the indeterminate form requires positive anti-T. cruzi serology, with no symptoms or physical examination abnormalities, normal 12-lead ECG, and normal radiological examination of the chest, esophagus, and colon (194). Current baseline evaluation guidelines in the United States recommend only a history, physical examination, and ECG (30). Further cardiac evaluation is recommended only if cardiac signs or symptoms are present, and barium studies are recommended only in patients with gastrointestinal symptoms (30). An estimated 20 to 30% of people who initially have the indeterminate form of Chagas’ disease progress over a period of years to decades to clinically evident cardiac and/or gastrointestinal disease (234). Cardiac Chagas’ disease. Chagas’ cardiomyopathy is characterized by a chronic inflammatory process that involves all chambers, damage to the conduction system, and often an apical aneurysm. The pathogenesis is hypothesized to involve parasite persistence in cardiac tissue and immune-mediated myocardial injury (182). The earliest manifestations are usually conduction system abnormalities, most frequently right-bundle branch block or left anterior fascicular block, and segmental left ventricular wall motion abnormalities (178). Later manifestations include complex ventricular extrasystoles and nonsustained and sustained ventricular tachycardia, sinus node dysfunction that may lead to severe bradycardia, high-degree heart block, apical aneurysm usually in the left ventricle, thromboembolic phenomena due to thrombus formation in the dilated left ventricle or aneurysm, and progressive dilated cardiomyopathy with congestive heart failure (233). These abnormalities lead to palpitations, presyncope, syncope, and a high risk of sudden death (235, 236). Digestive Chagas’ disease. Gastrointestinal involvement is less common than Chagas’ heart disease. This form is seen predominantly in patients infected in the countries of the Southern Cone (Argentina, Bolivia, Chile, Paraguay, Southern Peru, Uruguay, and parts of Brazil) and is rare in northern South America, Central America, and Mexico. This geographical pattern is thought to be linked to differences in the predominant T. cruzi genotypes (51, 192). Gastrointestinal Chagas’ disease usually affects the esophagus and/or colon, resulting from damage to intramural neurons (83, 84, 199). The effects on the esophagus span a spectrum from asymptomatic motility disorders through mild achalasia to severe megaesophagus (83). Symptoms include dysphagia, odynophagia, esophageal reflux, weight loss, aspiration, cough, and regurgitation. As in idiopathic achalasia, the risk of esophageal carcinoma is elevated (13, 47). Megacolon is characterized by prolonged constipation and may give rise to fecaloma, volvulus, and bowel ischemia.
VOL. 24, 2011
T. CRUZI AND CHAGAS’ DISEASE IN THE UNITED STATES
669
T. cruzi Infection in the Immunocompromised Host
DIAGNOSIS
Acute T. cruzi infection in organ transplantation recipients. Acute T. cruzi infection in organ recipients has several features that differ from those of acute T. cruzi infection in immunocompetent hosts. The incubation period can be prolonged: among the 15 patients for whom data were available in published reports, the mean time from transplantation to onset of symptoms of acute T. cruzi infection was 112 days (range, 23 to 420 days) (61, 66, 79, 99, 101, 157, 238, 279). A relatively severe clinical spectrum has been reported, with manifestations that included fever, malaise, anorexia, hepatosplenomegaly, acute myocarditis, and decreased cardiac function; two of the 18 reported patients presented with fulminant myocarditis and congestive heart failure (61, 279). Reactivation of chronic T. cruzi infection in organ recipients. Patients with chronic T. cruzi infection can be candidates for organ transplants. In a large cohort of heart transplant patients, survival of those who received the transplant because of chronic Chagas’ cardiomyopathy was longer than survival among those with idiopathic or ischemic cardiomyopathy, and T. cruzi reactivation was a rare cause of death (33, 38, 39). Reactivation should be considered in the differential diagnosis of febrile episodes and apparent rejection crises. In addition to fever and acute Chagas’ myocarditis in the transplanted heart, common manifestations of reactivation disease include inflammatory panniculitis and skin nodules (52, 102, 238). Central nervous system (CNS) involvement has been reported but is a much less frequent manifestation of reactivation among transplant recipients than in AIDS patients (5, 102, 180). Reactivation Chagas’ disease in HIV/AIDS patients. Reactivation of T. cruzi infection in HIV/AIDS patients can cause severe clinical disease with a high risk of mortality. However, as in organ transplant recipients, reactivation is not universal, even in those with low CD4⫹ lymphocyte counts. The only published prospective cohort study followed 53 HIV-T. cruzicoinfected patients in Brazil for 1 to 190 months; 11 (21%) had T. cruzi reactivation diagnosed based on symptoms and/or microscopically detectable parasitemia (260). Even among patients without clinical reactivation, the level of parasitemia is higher among HIV-coinfected than among HIV-negative patients (261). Symptomatic T. cruzi reactivation in AIDS patients is most commonly reported to cause meningoencephalitis and/or T. cruzi brain abscesses; the presentation may be confused with CNS toxoplasmosis and should be considered in the differential diagnosis of mass lesions on imaging or CNS syndromes in AIDS patients (70, 71, 88, 260). The second most commonly reported sign of reactivation is acute myocarditis, sometimes superimposed on preexisting chronic Chagas’ cardiomyopathy (260, 297). Patients may present with new arrhythmias, pericardial effusions, acute cardiac decompensation, or accelerated progression of existing chronic heart disease (100, 260). Acute meningoencephalitis and myocarditis can occur simultaneously. In the Brazilian cohort, cardiac reactivation was as frequent as CNS disease; cardiac manifestations of reactivated Chagas’ disease may pass undetected or mimic progression of chronic Chagas’ cardiomyopathy (260). Less common manifestations of reactivation in HIV/AIDS patients include skin lesions, erythema nodosum, and parasitic invasion of the peritoneum, stomach, or intestine (100, 261).
Appropriate diagnostic testing for T. cruzi infection varies depending on the phase of the disease and the status of the patient. In the United States, CDC provides consultation to health care providers concerning Chagas’ disease diagnostic testing (contact information is listed in “Antitrypanosomal Drugs” below).
Diagnosis of Acute T. cruzi Infection In the acute phase, motile trypomastigotes can be detected by microscopy of fresh preparations of anticoagulated blood or buffy coat (311). Parasites may also be visualized by microscopy of blood smears stained with Giemsa stain or other stains. Hemoculture in one of several types of standard parasitic medium (e.g., Novy-MacNeal-Nicolle) is relatively sensitive during the acute phase but requires 2 to 4 weeks to show replication. The level of parasitemia decreases within 90 days of infection, even without treatment, and becomes undetectable by microscopy in the chronic phase (306, 311). PCR is a sensitive diagnostic tool in the acute phase of Chagas’ disease and may also be used to monitor for acute T. cruzi infection in the recipient of an infected organ or after accidental exposure (133, 134, 157).
Diagnosis of Congenital T. cruzi Infection Early in life, congenital Chagas’ disease is an acute T. cruzi infection and similar diagnostic methods are employed. Concentration methods yield better sensitivity than direct examination of fresh blood. The microhematocrit method is the most widely used technique in Latin American health facilities. Fresh cord or neonatal blood is collected, sealed in four to six heparinized microhematocrit tubes, and centrifuged, and the buffy coat layer is examined by light microscopy (108). Parasitemia levels rise after birth and peak at or after 30 days of life (32). Repeated sampling on several occasions during the first months of life increases the sensitivity but may not be acceptable to parents (14, 32, 197). Hemoculture can increase sensitivity, but the technique is not widely available, and results are not available for 2 to 4 weeks. Molecular techniques have higher sensitivity and detect congenital infections earlier in life than the microhematocrit method (32, 92, 247). Transient detection of parasite DNA has occasionally been reported in specimens from infants who subsequently are found to be uninfected (32, 211). For this reason, a positive PCR on samples collected on two separate occasions may be used as a criterion for confirmation of congenital infection (32). PCR is increasingly used for the early diagnosis of congenital Chagas’ disease in Latin America and is the method of choice in industrialized countries (55, 140, 202, 247, 266). For infants not diagnosed at birth, conventional IgG serology (as outlined below for chronic T. cruzi infection) is recommended after 9 months of age, when transferred maternal antibody has disappeared and the congenital infection has passed into the chronic phase (32, 55, 56).
670
BERN ET AL.
CLIN. MICROBIOL. REV.
Diagnosis of Chronic T. cruzi infection
TREATMENT
Diagnosis of chronic infection relies on serological methods to detect IgG antibodies to T. cruzi, most commonly the enzyme-linked immunosorbent assay (ELISA) and immunofluorescent-antibody assay (IFA). No single assay has sufficient sensitivity and specificity to be relied on alone; two serological tests based on different antigens (e.g., whole parasite lysate and recombinant antigens) and/or techniques (e.g., ELISA, IFA, and immunoblotting) are used in parallel to increase the accuracy of the diagnosis (311). Inevitably, a proportion of individuals tested by two assays will have discordant serological results and need further testing to resolve their infection status. Specimens with positive results but low antibody titers are more likely to show discordance because results obtained by less sensitive tests may be negative. Published data suggest that the sensitivity of serological assays varies by geographical location, possibly due to T. cruzi strain differences and the resulting antibody responses (275, 293, 299). The status of some individuals remains difficult to resolve even after a third test, because there is no true gold standard assay for chronic T. cruzi infection (283). Assays such as the radioimmunoprecipitation assay (RIPA) and trypomastigote excreted-secreted antigen immunoblot (TESA-blot) are promoted as reference tests, but even these do not have perfect sensitivity and specificity and may not be capable of resolving the diagnosis (168, 272). Options for diagnostic T. cruzi serological testing are relatively limited in the United States. Several ELISA kits based on parasite lysate or recombinant antigens are Food and Drug Administration (FDA) cleared for diagnostic application. Use of an assay with validation data (e.g., a commercial kit shown to have acceptable sensitivity and specificity in a thorough study) is preferable to reliance on in-house tests for which no performance data are available (31).
Antitrypanosomal Drugs
Utility of PCR for Diagnosis or Monitoring PCR techniques provide the most sensitive tool to diagnose acute-phase and early congenital Chagas’ disease and to monitor for acute T. cruzi infection in the recipient of an infected organ or after accidental exposure (32, 65, 133). PCR assays usually show positive results days to weeks before circulating trypomastigotes are detectable on peripheral blood smears (267). Quantitative PCR assays (e.g., real-time PCR) are useful to monitor for reactivation in the immunosuppressed T. cruzi-infected host. In these patients, a positive result on conventional PCR does not prove reactivation, but quantitative PCR assays that indicate rising parasite numbers over time provide the earliest and most sensitive indicator of reactivation (89, 92). In chronic T. cruzi infection, PCR is used as a research tool but is not generally a useful diagnostic test. Although PCR results will be positive for a proportion of patients, the sensitivity is highly variable depending on the characteristics of the population tested, as well as the PCR primers and methods (25, 142, 314). For these reasons, negative results by PCR do not constitute evidence for lack of infection.
Nifurtimox and benznidazole are the only drugs with proven efficacy against Chagas’ disease (73, 177). Neither drug is approved by the U.S. FDA, but both can be obtained from the CDC and used under investigational protocols. Consultations and drug requests should be addressed to the Parasitic Diseases Public Inquiries line [(404) 718-4745; e-mail,
[email protected]], the CDC Drug Service [(404) 639-3670], and, for emergencies after business hours and on weekends and federal holidays, the CDC Emergency Operations Center [(770) 488-7100]. Nifurtimox (Lampit, Bayer 2502), a nitrofuran, interferes with T. cruzi carbohydrate metabolism by inhibiting pyruvic acid synthesis. Gastrointestinal side effects are common, occurring in 30 to 70% of patients. These include anorexia leading to weight loss, nausea, vomiting, and abdominal discomfort. Neurological toxicity is also fairly common, including irritability, insomnia, disorientation, and, less often, tremors. Rare but more serious side effects include paresthesias, polyneuropathy, and peripheral neuritis. The peripheral neuropathy is dose dependent, appears late in the course of therapy, and should prompt interruption of treatment. Higher doses are often used in infants than in older children, and tolerance is better in children than in adults. Benznidazole (Rochagon, Roche 7-1051) is a nitroimidazole derivative, considered more trypanocidal than nifurtimox. Dermatological side effects are frequent, and consist of rashes due to photosensitization, rarely progressing to exfoliative dermatitis. Severe or exfoliative dermatitis or dermatitis associated with fever and lymphadenopathy should prompt immediate cessation of the drug. The peripheral neuropathy is dose dependent, usually occurs late in the course of therapy, and is an indication for immediate cessation of treatment; it is nearly always reversible but may take months to resolve. Bone marrow suppression is rare and should prompt immediate interruption of drug treatment. Patients should be monitored for dermatological side effects beginning 9 to 10 days after initiation of treatment. Benznidazole was well tolerated in two placebo-controlled trials with children (12% had a rash and ⬍5% had gastrointestinal symptoms in one study; ⬍10% had moderate reversible side effects in the other study) (7, 277). Side effects are more common in adults than in children. Treatment of Acute and Congenital T. cruzi infection In acute and early congenital Chagas’ disease, both drugs reduce the severity of symptoms, shorten the clinical course, and reduce the duration of detectable parasitemia (53, 306). The earliest trials of antitrypanosomal drugs were conducted with patients with acute Chagas’ disease in the 1960s and 1970s using nifurtimox (53, 306). Serological cure was documented at the 12-month follow-up in 81% of those treated in the acute phase (306). Treatment of Chronic T. cruzi Infection Until recently, only the acute phase, including early congenital infection, was thought to be responsive to antiparasitic
VOL. 24, 2011
T. CRUZI AND CHAGAS’ DISEASE IN THE UNITED STATES
671
TABLE 6. Autochthonous human cases of Chagas’ disease in the United States Yr
State
Patient characteristics
1955
TX
1955 1982
TX CA
1983
TX
1998
TN
2006
LA
2006
TX
10-mo-old girl, acute Chagas’ disease, trypomastigotes on blood smear 2- to 3-wk-old boy, no details provided 56-yr-old woman with acute Chagas’ disease, trypomastigotes on blood smear 7-mo-old boy, fatal acute Chagas’ disease with myocarditis and pericardial effusion, postmortem diagnosis based on nests of T. cruzi in cardiac tissue 18-mo-old boy, febrile illness several wk after bug was found, positive T. cruzi PCR in multiple blood specimens 74-yr-old woman with history of triatomine bites but no symptoms of Chagas’ disease; positive IgG serology and T. cruzi hemoculture 12-mo-old boy with fever, large pericardial effusion and respiratory distress; trypomastigotes by microscopy in pericardial fluid
therapy. However, in the 1990s, 2 placebo-controlled trials of benznidazole treatment in children with chronic T. cruzi infection demonstrated approximately 60% cure as measured by conversion to negative serology 3 to 4 years after the end of treatment (7, 278). Several follow-up studies suggest that the earlier in life that children are treated, the higher the rate of reversion to negative serology (6, 281). Together with growing clinical experience across Latin America, these studies revolutionized management of children with Chagas’ disease, making early diagnosis and antitrypanosomal drug therapy the standard of care throughout the region (177, 311). There is currently a growing movement to offer treatment to older patients and those with early cardiomyopathy (30, 302, 311). In Latin America, most Chagas’ disease experts now believe that the majority of patients with chronic T. cruzi infection should be offered treatment, employing individual exclusion criteria such as an upper age limit of 50 or 55 years and the presence of advanced irreversible cardiomyopathy (276). This change in standards of practice is based in part on nonrandomized, nonblinded longitudinal studies that demonstrate decreased progression of Chagas’ cardiomyopathy and decreased mortality in adult patients treated with benznidazole (301, 302). A multicenter, randomized, placebo-controlled, double-blinded trial of benznidazole for patients with mild to moderate Chagas’ cardiomyopathy is under way and will help to clarify treatment efficacy for this group (http://clinicaltrials .gov/show/NCT00123916).
Evidence of autochthonous transmission
Reference(s)
Peridomestic infestation
342
No details provided Adult uninfected T. protracta found in house No vectors found, but household search was made in winter; house said to be in poor condition T. cruzi-infected T sanguisuga found in child’s crib
10 203, 265
Peridomestic and house T. sanguisuga infestation; 10/18 positive by T. cruzi PCR Mother uninfected; T. cruzi-infected T. gerstaeckeri collected near house
209 134 90 151; CDC, unpublished data
with standard courses of antitrypanosomal treatment; antiretroviral therapy should be optimized (143). EPIDEMIOLOGY OF CHAGAS’ DISEASE Since 1991, the estimated global prevalence of T. cruzi infection has fallen from 18 million to 8 million, due to intensive vector control and blood bank screening (87, 214). The Pan American Health Organization estimates that approximately 60,000 new T. cruzi infections occur each year (214). As other transmission routes have diminished, the proportion attributable to congenital infection has grown: an estimated 26% of incident infections now occur through mother-to-child transmission (214). In settings with endemic vector-borne transmission, T. cruzi infection is usually acquired in childhood. Because the infection is lifelong, the seroprevalence in an area with sustained vector-borne transmission rises with age, reflecting the cumulative incidence (98). Before widespread vector control was instituted in the early 1990s, it was common to find that ⬎60% of adults in an community where the disease was endemic were infected with T. cruzi (200, 230). In cross-sectional community surveys, most infected individuals are asymptomatic; an estimated 70 to 80% will remain asymptomatic throughout their lives (176, 234). Because cardiac and gastrointestinal manifestations usually begin in early adulthood and progress over a period of years to decades, the prevalence of clinical disease increases with increasing age (178).
Management of the Immunocompromised Host Antitrypanosomal treatment for reactivation in organ transplant recipients follows standard dosage regimens and promotes resolution of clinical symptoms and parasitemia. There are no data to indicate that prior treatment or posttransplant prophylaxis decreases the risk of reactivation; posttransplant prophylaxis is not routinely administered in heart transplant centers in Latin America (52). Antitrypanosomal therapy is thought to achieve a sterile cure in few, if any, adults with longstanding chronic infection, and treated patients should be considered to be at risk for reactivation. Reactivation in an HIV-coinfected patient should be treated
HUMAN CHAGAS’ DISEASE IN THE UNITED STATES Autochthonous Transmission to Humans Seven autochthonous vector-borne infections (four in Texas and one each in California, Tennessee, and Louisiana) have been reported since 1955 (Table 6) (10, 90, 134, 151, 209, 265, 342). Most reported cases have been in infants or small children; six of the seven infections were in the acute phase at the time of identification, and the diagnosis was sought because of symptoms and/or the presence of triatomine vectors. A survey conducted in the community of residence of the 1982 Califor-
672
BERN ET AL.
CLIN. MICROBIOL. REV. TABLE 7. Transfusion-related cases of Chagas’ disease in the United States Implicated blood component and donor origin
Yr
State
Recipient characteristics
1988
NY
1988
CA
1989
TX
1997
FL
2002
RI
11-yr-old girl with Hodgkin’s lymphoma, developed fever and pericarditis, trypomastigotes seen on blood smear; treated with nifurtimox and recovered 17-yr-old male post-bone marrow transplant with fulminant acute Chagas’ disease 59-yr-old female with metastatic colon cancer on chemotherapy, granulocytopenic, disseminated intravascular coagulation; developed fever, pulmonary infiltrates, bradycardia and atrioventricular block; parasites seen on bone marrow aspirate; died within 36 h of diagnosis 60-yr-old female with multiple myeloma; T. cruzi-infected donor unit detected during research study; recipient asymptomatic, treated with nifurtimox; died of underlying disease several yr later. 3-yr-old female with stage 4 neuroblastoma on chemotherapy, neutropenic, fever, trypomastigotes seen on blood smear; treated with nifurtimox but died of her underlying disease
nia case demonstrated positive complement fixation results in 6/241 (2.5%) residents tested (203). The rarity of autochthonous vector-borne transmission in the United States is assumed to result from better housing conditions that minimize vector-human contact. In addition, North American vectors may have lower transmission efficiency, due at least in part to delayed defecation (153, 203, 228). However, given that the vast majority of acute T. cruzi infections in immunocompetent individuals pass undiagnosed in Latin America, where the index of suspicion is much higher, undetected cases of autochthonous vector-borne transmission are presumed to occur.
Chagas’ Disease Burden among Latin American Immigrants The only direct assessments in Latin American populations living in the United States come from very limited local surveys and blood bank screening (see below) (42, 59, 148, 165, 167). No large representative surveys have ever been conducted, and blood bank data cannot be extrapolated with validity because donors are not representative of the larger population. The only recent data come from a survey of Latin American immigrants attending churches in Los Angeles County; a total of 10 (1%) of 985 adults tested had positive results by serological testing (290). Based on the reported number of immigrants from countries in Latin America where Chagas’ disease is endemic and the estimated national T. cruzi seroprevalences in their countries of origin, there are an estimated 300,000 persons with T. cruzi infection currently living in the United States (29). Patients with clinical manifestations of Chagas’ disease, especially cardiomyopathy, are assumed to be present but largely unrecognized in hospitals and health care facilities in the United States, but systematic data are sparse (126). Recent targeted studies in a Los Angeles hospital demonstrated positive results by T. cruzi serological tests among 15 (16%) of 93 Latin American patients with a diagnosis of idiopathic cardiomyopathy and 11 (4.6%) of 239 patients with conduction system abnormalities on ECG and at least 1 year of residence in Latin America (190, 291).
Reference
Platelets, Bolivia
114
Not specified, Mexico
113
Unknown; had received ⬎500 units, including red blood cells and platelets
67
Platelets, Bolivia
166
Platelets, Bolivia
351
Blood-Borne Transmission and Blood Donor Screening A total of 5 transfusion-associated T. cruzi infections have been documented in the United States since the late 1980s (Table 7) (59, 67, 114, 166, 351). All infected recipients had underlying malignancies and were immunosuppressed. Platelet units from Bolivian donors were implicated in 3 of 5 cases. Several patients had severe manifestations of Chagas’ disease, including acute myocarditis, acute atrioventricular block, severe congestive heart failure, pericarditis with T. cruzi in the pericardial fluid, and possible meningoencephalitis (67, 114, 351). The recipient of a platelet unit detected as infected during a research study had T. cruzi infection detected by PCR and serology during prospective monitoring but never developed symptoms (166). In December 2006, the FDA approved an ELISA to screen for antibodies to T. cruzi in donated blood (59). The radioimmunoprecipitation assay (RIPA) has been used as the confirmatory test (1, 31, 257). The American Red Cross and Blood Systems Inc. voluntarily began screening all blood donations in January 2007, and in subsequent months, many other blood centers starting screening as well. As of 2 September 2011, 1,459 confirmed seropositive donations have been detected in 43 states, with the largest numbers found in California, Florida, and Texas (1). A second T. cruzi antibody screening test was approved in April 2010. In December 2010, FDA issued specific guidance for appropriate use of the screening tests (103). Current FDA recommendations are to screen all blood donors initially, and if a donor’s sample tests negative using one of the two FDA-approved screening tests, no testing of future donations by that donor is necessary. No supplemental test has been approved, and donors are deferred indefinitely on the basis of positive screening test results alone. This strategy will be reviewed by FDA at upcoming meetings of the Blood Products Advisory Committee; the risk of newly acquired blood donor infections, including results from longitudinal studies of repeat blood donors, will be considered. Screening of blood donations remains voluntary, although most blood centers are currently following FDA recommendations. In data from the first 16 months of screening, comprising
VOL. 24, 2011
T. CRUZI AND CHAGAS’ DISEASE IN THE UNITED STATES
673
TABLE 8. Published reports of organ transplant-derived cases of Chagas’ disease in the United Statesa Yr
State of organ harvest
2001
GA
2001
Implicated organ
Recipient characteristics and outcome
Reference
El Salvador
Kidney-pancreas
61
GA
El Salvador
Kidney
2001
GA
El Salvador
Liver
2005
CA
US-born (mother from Mexico)
Heart
2006
CA
El Salvador
Heart
37-yr-old female with fever 6 wk posttransplant and T. cruzi on blood smear, died of Chagas’ myocarditis 7 mo posttransplant despite prolonged course of nifurtimox 69-yr-old female, asymptomatic, T. cruzi hemoculture positive; diagnosis sought because of recipient 1 above; treated with nifurtimox, survived 32-yr-old female, asymptomatic, T. cruzi hemoculture positive; diagnosis sought because of recipient 1 above; treated with nifurtimox but died of unrelated causes 64-yr-old male with anorexia, fever, diarrhea; diagnosed with organ rejection, treated with steroids; 8 wk posttransplant T. cruzi found on blood smear; PCRs became negative on nifurtimox; died of rejection 20 wk posttransplant 73-yr-old male with fever, fatigue, rash, T. cruzi on blood smear 7 wk posttransplant; parasitemia cleared with nifurtimox; switched to benznidazole because of tremors; died of heart failure 25 wk posttransplant
a
Donor origin
61 61 157
157
Three additional unpublished cases are known to have occurred (2 heart transplants and 1 liver transplant).
⬎14 million blood donations, the overall seroprevalence was 1:27,500 based on donations screened, with the highest rates in Florida (1:3,800), followed by California (1:8,300) (31). Because large blood donor studies prior to FDA approval of the screening ELISA were conducted in southern California with permanent deferral of all repeatedly reactive donors, a substantial number of infected individuals were already removed from the local donor pool, and the reported prevalence in California is thought to represent an underestimate (42, 59, 165, 167). From preliminary data, 29 (28%) of 104 T. cruziinfected donors were born in Mexico, 27 (26%) in the United States, 17 (16%) in El Salvador, and 11 (11%) in Bolivia; the remaining 20 donors were born in 9 other countries of Central and South America (31). Among confirmed infected donors born in the United States, 10 individuals reported no specific risk factors for T. cruzi infection. All of these donors reported outdoor activities (e.g., hunting, camping, or extensive gardening) in the southern United States, which may indicate potential autochthonous exposure to the vector or animal reservoirs.
curred. All three of these recipients were treated and survived their T. cruzi infection (65; S. Huprikar and B. Kubak, unpublished data). When an infected organ donor is detected, recipient monitoring relies primarily on detection of the parasite by microscopy, culture, and/or PCR, because seroconversion may be delayed or never occur in immunocompromised individuals (65, 238). Molecular techniques usually show positive results days to weeks before circulating trypomastigotes are visible by microscopy of peripheral blood. Transplant-transmitted T. cruzi infection may have a longer incubation period than vector-borne infection; parasitemia is usually detected within 2 to 3 months, but the delay can be as long as 6 months. A frequently recommended monitoring schedule consists of weekly specimens for 2 months, specimens every 2 weeks up to 4 months, and then monthly specimens afterwards (65, 238). In the absence of other indications and assuming no evidence of infection has been detected, the monitoring interval can be lengthened after 6 months posttransplantation.
Organ Donor-Derived Transmission and Organ Donor Screening
Unanswered Questions and Priorities for Research and Programs
A total of five instances of organ-derived transmission from three donors are documented in the published literature in the United States (Table 8) (60, 61, 157). Four of the five recipients died. One patient died from acute Chagas’ myocarditis; T. cruzi infection was not the primary cause of but may have contributed to the other deaths (61, 157). In all of these instances of transmission, donor infections were not suspected until at least one recipient presented with symptomatic acute Chagas’ disease (60, 61, 157). More recently, some organ procurement organizations have begun selective or universal screening of donated organs (65). Three transmission events (in two heart recipients in 2006 and 2010 and one liver recipient in 2006) were detected through systematic laboratory monitoring when their respective donors were identified as infected shortly after the transplants oc-
The United States faces important public health challenges for the prevention, control, and management of T. cruzi infection and Chagas’ disease (86). Patients with undiagnosed Chagas’ cardiomyopathy go unrecognized, impeding their optimal management. The large number of undetected T. cruzi infections sustains the risk of transmission through blood and organ donation and from mother to child. Currently, obstetricians have limited knowledge of congenital T. cruzi transmission risk, and almost no screening of at-risk women is carried out (48). Many health care providers in all specialties fail to consider the diagnosis of Chagas’ disease in patients at risk and are unaware that antitrypanosomal treatment is available (280, 300); the possibility that treatment could decrease the risk of progression of disease in infected individuals is therefore not realized. Worldwide, programs to control Chagas’ disease are ham-
674
BERN ET AL.
CLIN. MICROBIOL. REV.
pered by the lack of adequate tools, and these challenges are equally salient in the United States (283). Point-of-care diagnostic tests would allow physicians to make a rapid diagnosis in patients in whom Chagas’ disease is suspected and provide a practical means to identify women at risk of transmitting the infection to their infants. However, the sensitivity of current T. cruzi rapid tests shows wide geographic variation (275, 299); there is a need for screening tests with high sensitivity, especially for T. cruzi infections originating in geographic areas such as Mexico and the United States, where current tests appear to have low sensitivity (275; CDC, unpublished data). Two other diagnostic needs are critical: a practical, timely test of cure and indicators to distinguish patients who are likely to develop clinical disease from those likely to remain asymptomatic. Unfortunately, neither of these tools is currently on the horizon. Pediatric formulations of existing drugs are of immediate concern and expected to be available soon (91). However, new treatment drugs with high efficacy and better safety profiles, especially in adults, are needed (295). To inform effective policy for Chagas’ disease control in the United States, significant gaps in our knowledge must also be addressed. Systematic, rigorous population-based data to determine infection prevalence and morbidity are needed to inform prevention strategies. Pilot studies in hospitals with a high proportion of women born in Latin America would help to define practical methods to target screening for congenital transmission. More thorough identification of the T. cruzi strains circulating in the United States will add to our assessment of transfusion risk and understanding of the molecular epidemiology of the disease (164). More comprehensive assessment of the magnitude of local transmission risk and the factors influencing vector and reservoir host distribution and human contact are important to inform control efforts. Improved knowledge of the local epidemiology and ecology will allow more efficient, effective targeting of limited resources and raise awareness of Chagas’ disease in the United States. As improved control of vector- and blood-borne T. cruzi transmission decreases the burden in countries where the disease is historically endemic and imported Chagas’ disease is increasingly recognized outside Latin America, the United States— which confronts the challenges faced both by countries where the disease is endemic and by those where it is not—can play an important role in addressing the altered epidemiology of Chagas’ disease in the 21st century. REFERENCES 1. AABB Chagas Biovigilance Network. 2011, posting date. Reports through 04/18/2011. http://www.aabb.org/programs/biovigilance/Pages/chagas.aspx. 2. Abad-Franch, F., and F. A. Monteiro. 2007. Biogeography and evolution of Amazonian triatomines (Heteroptera: Reduviidae): implications for Chagas disease surveillance in humid forest ecoregions. Mem. Inst. Oswaldo Cruz 102(Suppl. 1):57–70. 3. Acquatella, H. 2007. Echocardiography in Chagas heart disease. Circulation 115:1124–1131. 4. Aguilar, H. M., F. Abad-Franch, J. C. Dias, A. C. Junqueira, and J. R. Coura. 2007. Chagas disease in the Amazon region. Mem. Inst. Oswaldo Cruz 102(Suppl. 1):47–56. 5. Altclas, J., et al. 2005. Chagas disease in bone marrow transplantation: an approach to preemptive therapy. Bone Marrow Transplant. 36:123–129. 6. Andrade, A. L., et al. 2004. Benznidazole efficacy among Trypanosoma cruzi-infected adolescents after a six-year follow-up. Am. J. Trop. Med. Hyg. 71:594–597. 7. Andrade, A. L., et al. 1996. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet 348:1407–1413. 8. Andrade, M. C., et al. 2009. Nonspecific lymphocytic myocarditis in ba-
9. 10. 11.
12. 13.
14.
15.
16.
17.
18. 19.
20.
21.
22. 23. 24.
25.
26. 27.
28.
29. 30. 31.
32. 33.
34. 35.
36.
37.
38.
boons is associated with Trypanosoma cruzi infection. Am. J. Trop. Med. Hyg. 81:235–239. Andrade, S. G. 1982. The influence of the strain of Trypanosoma cruzi in placental infections in mice. Trans. R. Soc. Trop. Med. Hyg. 76:123–128. Anonymous. 1956. Found: two cases of Chagas disease. Texas Health Bull. 9:11–13. Arganaraz, E. R., et al. 2001. Blood-sucking lice may disseminate Trypanosoma cruzi infection in baboons. Rev. Inst. Med. Trop. Sao Paulo 43:271– 276. Arnold, H. L., and D. B. Bell. 1944. Kissing bug bites. J. Allergy Clin. Immunol. 74:436–442. Atias, A. 1994. A case of congenital chagasic megaesophagus: evolution until death caused by esophageal neoplasm, at 27 years of age. Rev. Med. Chil. 122:319–322. Azogue, E., and C. Darras. 1991. Prospective study of Chagas disease in newborn children with placental infection caused by Trypanosoma cruzi (Santa Cruz-Bolivia). Rev. Soc. Bras. Med. Trop. 24:105–109. Badra, E. S., et al. 2008. Histopathological changes in the placentas and fetuses of mice infected with Trypanosoma cruzi isolated from the Myotis nigricans nigricans bat. J. Comp. Pathol. 139:108–112. Barcan, L., et al. 2005. Transmission of T. cruzi infection via liver transplantation to a nonreactive recipient for Chagas’ disease. Liver Transplant. 11:1112–1116. Barnabe, C., R. Yaeger, O. Pung, and M. Tibayrenc. 2001. Trypanosoma cruzi: a considerable phylogenetic divergence indicates that the agent of Chagas disease is indigenous to the native fauna of the United States. Exp. Parasitol. 99:73–79. Barr, S., D. Baker, and J. Markovits. 1986. Trypanosomiasis and laryngeal paralysis in a dog. J. Am. Vet. Med. Assoc. 188:1307–1309. Barr, S. C., C. C. Brown, V. A. Dennis, and T. R. Klei. 1991. The lesions and prevalence of Trypanosoma cruzi in opossums and armadillos from southern Louisiana. J. Parasitol. 77:624–627. Barr, S. C., V. A. Dennis, and T. R. Klei. 1991. Serologic and blood culture survey of Trypanosoma cruzi infection in four canine populations of southern Louisiana. Am. J. Vet. Res. 52:570–573. Barr, S. C., K. A. Gossett, and T. R. Klei. 1991. Clinical, clinicopathologic, and parasitologic observations of trypanosomiasis in dogs infected with North American Trypanosoma cruzi isolates. Am. J. Vet. Res. 52:954–960. Barr, S. C., et al. 1989. Chronic dilatative myocarditis caused by Trypanosoma cruzi in two dogs. J. Am. Vet. Med. Assoc. 195:1237–1241. Barr, S. C., et al. 1995. Trypanosoma cruzi infection in Walker hounds from Virginia. Am. J. Vet. Res. 56:1037–1044. Basombrio, M. A., et al. 1999. The transmission de Chagas disease in Salta and the detection of congenital cases. Medicina (Buenos Aires) 59(Suppl. 2):143–146. Basquiera, A. L., et al. 2003. Risk progression to chronic Chagas cardiomyopathy: influence of male sex and of parasitaemia detected by PCR. Heart 89:1186–1190. Beard, C. B., et al. 2003. Chagas disease in a domestic transmission cycle, southern Texas, USA. Emerg. Infect. Dis. 9:103–105. Beard, C. B., D. G. Young, J. F. Butler, and D. A. Evans. 1988. First isolation of Trypanosoma cruzi from a wild-caught Triatoma sanguisuga (LeConte) (Hemiptera: Triatominae) in Florida, USA. J. Parasitol. 74:343– 344. Beltrao, B., et al. 2009. Investigation of two outbreaks of suspected oral transmission of acute Chagas disease in the Amazon region, Para State, Brazil, in 2007. Trop. Doct. 39:231–232. Bern, C., and S. P. Montgomery. 2009. An estimate of the burden of Chagas disease in the United States. Clin. Infect. Dis. 49:e52–54. Bern, C., et al. 2007. Evaluation and treatment of Chagas disease in the United States: a systematic review. JAMA 298:2171–2181. Bern, C., S. P. Montgomery, L. Katz, S. Caglioti, and S. L. Stramer. 2008. Chagas disease and the US blood supply. Curr. Opin. Infect. Dis. 21:476– 482. Bern, C., et al. 2009. Congenital Trypanosoma cruzi transmission in Santa Cruz, Bolivia. Clin. Infect. Dis. 49:1667–1674. Bestetti, R. B., and T. A. Theodoropoulos. 2009. A systematic review of studies on heart transplantation for patients with end-stage Chagas’ heart disease. J. Card. Fail. 15:249–255. Bittencourt, A. L. 1992. Possible risk factors for vertical transmission of Chagas’ disease. Rev. Inst. Med. Trop. Sao Paulo 34:403–408. Bittencourt, A. L., L. A. Rodrigues de Freitas, M. O. Galvao de Araujo, and K. Jacomo. 1981. Pneumonitis in congenital Chagas’ disease. A study of ten cases. Am. J. Trop. Med. Hyg. 30:38–42. Bittencourt, A. L., M. Sadigursky, and H. S. Barbosa. 1975. Congenital Chagas’ disease. Study of 29 cases. Rev. Inst. Med. Trop. Sao Paulo 17: 146–159. Bittencourt, A. L., G. O. Vieira, H. C. Tavares, E. Mota, and J. Maguire. 1984. Esophageal involvement in congenital Chagas’ disease. Report of a case with megaesophagus. Am. J. Trop. Med. Hyg. 33:30–33. Bocchi, E. A., and A. Fiorelli. 2001. The Brazilian experience with heart
VOL. 24, 2011
39.
40. 41.
42.
43.
44.
45.
46.
47.
48.
49.
50. 51.
52. 53.
54.
55.
56.
57. 58.
59.
60.
61.
62.
63. 64.
T. CRUZI AND CHAGAS’ DISEASE IN THE UNITED STATES
transplantation: a multicenter report. J. Heart Lung Transplant. 20:637– 645. Bocchi, E. A., and A. Fiorelli. 2001. The paradox of survival results after heart transplantation for cardiomyopathy caused by Trypanosoma cruzi. First Guidelines Group for Heart Transplantation of the Brazilian Society of Cardiology. Ann. Thorac. Surg. 71:1833–1838. Bosseno, M. F., et al. 2002. Predominance of Trypanosoma cruzi lineage I in Mexico. J. Clin. Microbiol. 40:627–632. Bradley, K. K., D. K. Bergman, J. P. Woods, J. M. Crutcher, and L. V. Kirchhoff. 2000. Prevalence of American trypanosomiasis (Chagas disease) among dogs in Oklahoma. J. Am. Vet. Med. Assoc. 217:1853–1857. Brashear, R. J., et al. 1995. Detection of antibodies to Trypanosoma cruzi among